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ABSTRACT
Bone elongation disorders can lead to painful musculoskeletal disabilities in adulthood.
Existing treatment options to correct left-right asymmetry in limb length include invasive
surgeries and/or drug regimens. These are often only partially effective. Previous
studies in weanling mice have shown that a daily application of mild heat (40°C) to limbs
on one side of the body could be used to noninvasively enhance bone elongation.
However, the impact of heat-treatment on bone at the cellular level remains elusive. The
epiphyseal growth plate, the band of cartilage located at each end of long bones, is the
main site of longitudinal growth and is regulated by local and systemic growth factors.
Insulin-like growth factor 1 (IGF1) is the major regulator of growth and controls bone
elongation by promoting chondrocyte proliferation and hypertrophy. The objective of this
study was to build upon an established method of targeted limb heating to determine
how heat-treatment influences IGF1 action in the growth plate. This study tests the
hypothesis that exposure to warm temperature augments the actions of IGF1 in
the growth plate and permanently increases length of the extremities. This
dissertation demonstrates that differences of less than 1.5% are functionally significant
measured by a nearly 20% increase in hindlimb weight bearing on heat-treated sides.
Heat-enhanced bone elongation is documented in female C57BL/6 mice after 7 days of
heat-treatment during the most active period of growth from 3-4 weeks of age. This
increase in bone elongation is accompanied by increased chondrocyte proliferation and
hypertrophy in the proximal tibial growth plate. Moreover, this study is the first to show
that targeted limb-heating impacts local action of IGF1 in growth plate chondrocytes.
Results suggest that heat-induced limb length is IGF1 dependent since the growth

xvii

effects are attenuated when IGF1 activity is blocked. Administration of a low dose of
IGF1 (2.5mg/kg) was found to augment heat enhanced bone elongation and effects
were sustained to skeletal maturity (12 weeks of age). These studies help contribute to
the ultimate goal of developing a noninvasive method for lengthening bones that may
translate in a clinical setting to treat linear growth disorders in children.

xviii

CHAPTER I: IN DEPTH REVIEW INTO LONGITUDINAL BONE GROWTH

1.1 POSTNATAL LONGITUDINAL BONE GROWTH THROUGH ENDOCHONDRAL
OSSIFICATION
1.1.1 Endochondral Ossification and Growth Plate Morphology
The skeleton develops by means of two different mechanisms: (1)
Intramembranous ossification, involving direct differentiation of mesenchyme cells to
bone as with the development of the flat bones of the skull and (2) Endochondral
ossification, occurring when mesenchyme cells condense and differentiate into cartilage
tissue, which then is replaced by bone forming the vertebrae, ribs and limbs (Gilbert,
2014). Endochondral ossification is initiated during fetal life but continues from infancy
through adolescence (transitional period from childhood to adulthood). Cartilaginous
growth plates found at each end of developing long bones are responsible for
longitudinal bone growth (or linear growth). Longitudinal bone growth increases the
length of long bones during postnatal development and is mediated by the growth plate.
Growth plate cartilage is composed of cells known as chondrocytes that secrete
extracellular matrix and are organized into functional zones (Fig. 1).
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Figure 1. Diagram of a Growth Plate
Illustration represents the different cellular zones of the cartilaginous growth plate (dark
gray). Arrows indicate the different zones within the growth plate. The vertical yellow
line denotes the proliferative zone (PZ) and the green line denotes the hypertrophic
zone (HZ). The PZ is a region of actively dividing chondrocytes stacked and flattened in
multicellular columns. The HZ is a region of enlarged chondrocytes. Epiphyseal and
metaphyseal bone on each end of the growth plate contain blood vessels (red lines) that
supply each region of bone. Illustration based on Mackie, Ahmed, Tatarczuch, Chen,
and Mirams (2008).
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The cartilaginous growth plate functions as the command center of longitudinal bone
growth. Understanding the general morphology of the growth plate is beneficial for
appreciating its overall function. The end portion of the long bone is referred to as the
epiphysis and the shaft of each long bone is termed the diaphysis. Directly between the
epiphysis and the diaphysis is metaphysis, which contains the growth plate. The region
adjacent to the epiphysis is the first zone of the growth plate, or the reserve zone (RZ).
The RZ consists of round quiescent chondrocytes. The role of the RZ has been debated
but is most commonly reported to act as the coordinator for the organization and
orientation of the neighboring proliferative zone (PZ) (Abad et al., 2002). It has been
suggested that the RZ contains stem-like cells that promote the production of
proliferative chondrocytes and that this proliferative capacity decreases with age aiding
to the closure of the growth plate associated with skeletal maturity (Abad et al., 2002;
Hunziker, 1994b; Raimann, Javanmardi, Egerbacher, & Haeusler, 2017; Schrier et al.,
2006). Adjacent to the RZ is the PZ containing rapidly dividing chondrocytes stacked
and flattened in multicellular columns. The PZ is a region of actively dividing cells that
directs longitudinal growth along the long axis by which the cells line up in their
arranged columns.
The proliferating chondrocytes at the base of the columns make the transition from
the PZ to the hypertrophic zone (HZ) where chondrocytes behave as terminally
differentiated cells that begin to enlarge, secrete extracellular matrix and ultimately
undergo physiological death (Kronenberg, 2003; Mackie et al., 2008; Shapiro, Adams,
Freeman, & Srinivas, 2005; Ulici, Hoenselaar, Gillespie & Beier, 2008). Hypertrophic
chondrocytes induce vascular invasion and recruit osteogenic cells in the process of
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endochondral ossification and the replacement of cartilage with bone at the chondroosseous junction (region of growth cartilage between the growth plate and the newly
mineralized bone). A majority of the bone-forming osteoblasts are said to be
differentiated from bone marrow stromal cells. However, current research in the
mammalian growth plate suggests that not all hypertrophic chondrocytes undergo
apoptosis but instead transdifferentiate into osteoblasts during both bone development
and repair (Bahney et al., 2014; Enishi et al., 2014; Hu et al., 2017; Zhou et al., 2014).
Studies by Bahney et al. (2014) used cartilage grafts to promote bone regeneration
through endochondral ossification (analogous to long bone development), and results
from lineage tracing experiments showed chondrocytes differentiated into osteoblasts
during bone repair. It is suggested that transdifferentiation occurs adjacent to the
vasculature at the chondro-osseous junction and that the vasculature may have a
signaling role in the transformation of chondrocytes to osteoblasts (Hu et al., 2017). It is
not yet known if these chondrocytes undergo the same process of transdifferentiation
during development as they do during repair.

1.1.2 Differential Growth of Long Bones
While the anatomical structure of the cartilaginous growth plate is comparable
between the developing long bones, the rate at which these growth plates contribute to
longitudinal bone growth differs from bone to bone, and from proximal end to distal end.
This phenomenon is referred to as differential growth (Digby, 1916; Payton, 1932). The
humerus, radius and ulna are the major long bones of the upper limb (excluding the
hand and foot), and the lower limb includes the femur and tibia. When comparing
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proximal to distal ends of these bones, the faster-growing sites are located at the
proximal humerus (shoulder), distal radius and ulna (wrist), and distal femur and
proximal tibia (knee) (J. Bisgard & M. Bisgard, 1935; Farnum, 2007; Kember, 1972;
Pritchett, 1992; Raimann et al., 2017; Serrat, Lovejoy, & King, 2007; Wilsman, Farnum,
Green, Leiferman, & Clayton, 1996a; Wilsman, Farnum, Leiferman, Fry, & Barreto,
1996b; Wilsman, Bernardini, Leiferman, Noonan, & Farnum, 2008). Based on peak
growth rates, the most rapid developing growth plate in humans and rodents is at the
proximal end of the tibia followed by the distal femur (knee), distal radius (wrist), and
proximal humerus (shoulder) (Rolian, 2008). Wilsman et al. (2008) have shown in rats
that the proximal tibial growth plate (growth rate of 396 μM/day) is nearly nine times
faster than the much slower proximal radial growth plate (growth rate of 47μM/day).
The main factors contributing to increasing length of long bones and differential
growth are the number of columnar cells in the PZ, the rate of proliferation, and the size
of expanded cells in the hypertrophic zone (Hunziker, Schenk, & Cruz-Orive, 1987;
Hunziker, 1994b; Kember, 1993; Lupu, Terwilliger, Lee, Segre, & Efstratiadis, 2001;
Walker & Kember, 1972). Investigators have observed increased numbers of
proliferative chondrocytes, increased rates of proliferation, and hypertrophic
chondrocyte expansion in the faster-growing sites (Cooper et al., 2013; Farnum, 2007;
Hunziker & Schenk, 1989; Kember, 1972; Raimann et al., 2017; Rolian, 2008; Serrat et
al., 2007; Wilsman et al., 1996a, 1996b, 2008). Therefore, the cellular components of
the growth plate are involved in regulating the process of endochondral bone
development and linear growth.
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1.1.3 Age Comparison of Mouse and Man
A common model organism in the study of bone growth is the rodent, particularly
the house mouse (Mus musculus). The murine model is beneficial because the mouse
is small in size, cost-effective, easily available, and shares physiological similarities to
humans making the mouse the most widely used animal (~59% of total animals used) in
biomedical research (Dutta & Sengupta, 2016). However, mice have a shorter lifespan
(~24 months) compared to humans (~80 years) (Dutta & Sengupta, 2016). While there
may be a momentous difference in lifespan between mice and humans, it allows for
accelerated projects when following the mouse throughout stages of development.
Mouse age during different phases of postnatal growth is comparable to human
age (Fig. 2). At birth, until approximately 2-3 weeks of age, mice rely completely on their
mother for temperature regulation and food. At 3-4 weeks of age, pups will wean and
become independent (Dutta & Sengupta, 2016; Latham & Mason, 2004). This phase of
natural weaning that is the transition from exclusive nursing to nourishment by other
food, is comparable to a 6-month-old infant (Dutta & Sengupta, 2016; Sengupta, 2013;
Vail et al., 2015). While longitudinal growth is rapid during early postnatal stages of
development, there is a progressive decline in this rate of active growth with
approaching maturity. In mice, the accelerated rate of post weaning bone growth is from
3-4 weeks of age, then gradually decelerates from 4-8 weeks of age, and significantly
slows between 8-12 weeks of age (Callewaert et al., 2010; Li et al., 2017; Lui, Nilsson,
& Baron, 2011) (Fig. 2). In humans, rapid linear growth is observed from infancy to
childhood (6 months-3 years), decelerates from childhood through adolescence (3-16
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years), and stops at adulthood (18-20 years) (Armstrong, 2007; Dutta & Sengupta,
2016; Sengupta, 2013) (Fig. 2).

7

Cessation of longitudinal
bone growth

Slowed longitudinal
bone growth
Slowed longitudinal
bone growth

Early puberty
growth spurt

Rapid longitudinal
bone growth
11-16 years

epiphyseal
fusion

18-20 years

8-12 weeks

3-11 years
6-8 weeks
6 months-3 years
4-6 weeks

NO epiphyseal
fusion

3-4 weeks

Weaning/
Infancy

Puberty

Childhood

Skeletal Maturity/
Adulthood

Stage of Linear Growth

Figure 2. Developmental Stages During Postnatal Linear Bone Growth Compared
Between Mouse and Man
Diagram follows the appropriate age ranges of a human with the comparative ages of a
mouse during stages of linear growth. Rates of longitudinal bone growth are also noted
during each developmental stage. Both human and mouse follow similar trends in linear
growth with the exception of epiphyseal closure (indicated by the blue boxes). At the
end of puberty, cessation of growth at the human growth plate is accompanied by
epiphyseal fusion. No epiphyseal fusion is observed in the mouse. There is also an
early pubertal growth spurt specific to humans that interrupts the decline in linear growth
(gray). Mouse and human silhouettes provided by GetDrawings.com.
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Puberty, when reproduction becomes possible, is reached in mice at 6-8 weeks
(Jilka, 2013; Latham & Mason, 2004; Dutta & Sengupta, 2016) and 11-16 years in
humans on average (Chirwa, Griffiths, Maleta, & Cameron, 2014; Dutta & Sengupta,
2016; Lee, 1980; Kelly & Diméglio, 2008). Although linear bone growth progressively
slows with age, this decline in growth rate is interrupted by an early pubertal growth
spurt in humans (Li et al., 2017; Lui et al., 2011; Nilsson & Baron, 2004; Shim, 2015).
During this time, increased rates of chondrocyte proliferation and hypertrophy within the
growth plate are observed. This growth spurt is one reason why there is concern for
childhood sport related physeal injuries, which are most common between 10-16 years
of age (Grimmer, Jones, & Williams, 2000; Schwab, 1977) and account for 6-15% of
youth fractures (Hunt & Amato, 2003). Disturbances during this period of developing
growth cartilage can result in growth deformities (Caine, DiFiori, & Maffaulli, 2006; Mirtz,
Chadler, & Eyers, 2011).
Eventually a cessation of growth plate activity occurs as final adult height is
reached. The cessation of longitudinal bone growth, also referred to as growth plate
senescence, involves decreased rates of chondrocyte proliferation and hypertrophy
(Forcinito et al., 2011; Lui et al., 2011; Nilsson & Baron, 2004; Nilsson et al., 2014;
Walker & Kember, 1972). There is variation in time of closure between bones, but
faster-growing sites such as in the proximal tibia close later (16-18 years of age in a
human) than slower growing sites such as in the proximal radius (14-16 years of age in
a human) (Schwab, 1977; Zoetis, Tassinari, Bagi, Walthall, & Hurtt, 2003). The process
of growth plate senescence varies from species to species (Geiger, Forasiepi, Koyabu,
& Sánchez-Villagra, 2014; Kilborn, Trudel, & Uhthoff, 2002). In humans, growth plate
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cessation at the end of puberty is accompanied by epiphyseal fusion and the formation
of a bony union (Geiger et al., 2014; Nilsson & Baron, 2004; Parfitt, 2002). In mice,
there is not a complete closure of the growth plate (Dawson, 1925, 1935; Geiger et al.,
2014). The lack of complete epiphyseal fusion in mice contributes to complications in
forming a direct comparison to humans. However, research has shown that even
without complete closure, growth plate senescence still occurs at comparable
developmental periods with similar cellular kinetics (Dawson, 1925, 1935; Geiger et al.,
2014; Walker & Kember, 1972). Skeletal maturity, not to be confused with sexual
maturity, is similar between mice (8-12 weeks of age) (Kilborn et al., 2002; Li et al.,
2017; Serrat et al., 2007; Stempel, Fritsch, Pfaller, & Blumer, 2011; Zoetis et al., 2003)
and humans (18-20 years of age) (Duren, Seselj, Froehle, Nahhas, & Sherwood, 2013;
Dutta & Sengupta, 2016; Schwab, 1977) in regard to the proportion of their lifespan
(Kilborn et al., 2002). When skeletal maturity is reached, chondrocyte proliferation,
hypertrophy and longitudinal growth essentially stops despite the presence of a
previously active growth plate.

1.1.4 Limb Length Discrepancy
An orthopedic condition that is characterized by asymmetric length of lower
extremity pairs is referred to as anisomelia, or limb length discrepancy (LLD) (Baker,
Liu, Robertson, & Efstratiadis, 1993; Gurney, 2002). LLD usually emerges during
childhood but the etiology varies and may be congenital, acquired or idiopathic. Prior to
the development of the polio vaccine in the 1960s, the most common cause of LLD in
children was poliomyelitis (viral infection causing paralysis) that resulted in leg
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shortening (Morscher, 1977; Wilson & Thompson, 1939). While polio has been
eliminated from the United States, treatment options are still studied for middle-aged
patients suffering from long-term LLD as a result of poliomyelitis developed during their
childhood (Kirienko et al., 2011; Sonekatsu, Sonohata, Kitajima, Kawano, & Mawatari,
2018). Aside from paralysis, other acquired causes of LLD include infection, tumors,
and trauma (Morscher, 1977; Shapiro, 1982; Wilson & Thompson, 1939). LLDs caused
by trauma most commonly involve epiphyseal fractures (shortening on the fractured
side) and meta- and diaphyseal fractures (lengthening on the fractured side) (Hansson,
Stenström, & Thorngren, 1976; Morscher, 1977; Shapiro, 1982; Togrul, Bayram,
Gulsen, Kalaci, & Ozabarlas, 2005; Truesdell, 1921; Wilson & Thompson, 1939; Wray &
Goodman, 1961). Regardless of the cause of the LLD, untreated inequalities into
adulthood have been associated with painful musculoskeletal disorders (Campbell,
Ghaedi, Ghongomu, & Welch, 2018; Gurney, 2002) including lower back pain (Friberg,
1983; Defrin, Ben Benyamin, Aldubi, & Pick, 2005), gait abnormalities (Aiona, Do,
Emara, Dorociak, & Pierce, 2015; Kaufman, Miller, & Sutherland, 1996; Khamis &
Carmeli, 2017; Mahmood, Huffman, & Harris, 2010; Song, Halliday, & Little, 1997),
scoliosis (abnormal curvature of the spine) (Papaioannou, Stokes, & Kenwright, 1982),
and osteoarthritis of the hip and knee (Golightly, Tate, Burns, & Gross, 2007a; Golightly
et al., 2007b; Harvey et al., 2010; Resende, Kirkwood, Deluzio, Morton, & Fonseca,
2016).
The severity of limb length discrepancy varies depending on the condition, as
well as the onset of acquired cases. Limb length inequalities of 2 cm or more involve
surgical methods of treatment with intentions of permanently correcting unequal length
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of limbs (Gurney, 2002; Stevens, 2016; Vitale et al., 2006; Zhang, Hamamura, Turner, &
Yokota, 2010). Limb shortening is recommended for limb length inequalities of 2-5 cm
using epiphysiodesis procedures (Stevens, 2016). This method involves shortening the
longer limb by either permanently halting growth from a surgically formed bony bridge
(Phemister, 1933) or temporarily slowing of growth using guided growth techniques
(Pendleton, Stevens, & Hung, 2013; Sabharwal, Nelson, & Sontich, 2015; Stevens,
2016). Limb lengthening is recommended for those with limb length inequalities over 5
cm (Stevens, 2016) and includes methods based off the traditional Ilizarov technique
using external fixators (Ilizarov, 1988) or by mechanical bone guidance (Hasler & Krieg,
2012). The aforementioned surgical interventions involve a variation of percutaneous
drilling and use of external and internal fixation devices (including a cortical screw
surgically placed through the epiphysis, across the growth plate, and into the
metaphysis). In addition to the high cost of these invasive procedures, they are also
often associated with complications including pain, implant failure, angular deformities
and infection (Hasler & Krieg, 2012; Wilson & Thompson, 1939).
For relative comparison, a 2 cm discrepancy is roughly equivalent to a 2.8-2.4%
difference using a reference limb length of 72-82.5 cm (total height minus sitting height
averaged from mean male and female reference data) corresponding to a 10-16 year
old adolescent (Fredricks et al., 2005; McDowell, Fryar, & Ogden, 2009) during the
period of sexual maturity/puberty (Fig. 2) when still growing but approaching final height.
A 5 cm discrepancy is therefore roughly equivalent to a 6.9-6.1% difference. It is
important to note that these percent differences based on total limb length vary through
development until final height is reached. At final height (reference limb length of 85 cm
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for a young adult), a 2 cm discrepancy is a difference of 2.4%, while a 5 cm discrepancy
is a difference of 5.9% (Fredricks et al., 2005; McDowell et al., 2009; Racine, Meadows,
Ion, & Serrat, 2018).
The projected limb length discrepancy at the point of maturity varies between
congenital cases (based on a fixed limb length inequality) and acquired cases (based
on how much limb growth remains) (Kelly & Diméglio, 2008). There have been
numerous methods of predicting final limb length including the Green-Anderson method
(Anderson, Green, & Messner, 1963), Menelaus method (Menelaus, 1966), Moseley
method (Moseley, 1977), and Paley method (Paley, Bhave, Herzenberg, & Bowen,
2000). The predicated final limb length discrepancy varies vastly between these
methods (Monier, Aronsson, & Sun, 2015) and thus there is not one method that is
more accurate than another. Therefore, determining the most effective timing to start
treatment is difficult and can lead to possible over- or under-compensation for the
observed unequal limb length. When the correction is not successful, either because of
surgical failure or miscalculated predictions of final limb length discrepancy, surgical
interventions have to be repeated (Stevens, 2016) and therefore increase the risk of
post-surgical complications.
While surgical intervention is typically recommended only for discrepancies of 2
cm or more (Gross, 1978; Gurney 2002; Knutson, 2005), some studies have shown that
discrepancies of 0.5-1 cm (0.6-1.2% limb length difference based on young adult height)
may impact everyday walking (White, Gilchrist, & Wilk, 2004) leading to problems into
adulthood including knee osteoarthritis (Harvey et al., 2010; Resende et al., 2016).
Conservative methods of correction are typically recommended for those with these
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minor limb length inequalities such as shoe lifts or prosthetics (Campbell et al., 2018;
Hasler & Kreig, 2012; Wilson & Thompson, 1939). While inexpensive and less invasive,
these methods do not permanently change the length of the bone. An alternative noninvasive method for permanently lengthening limbs would therefore be ideal. A study by
Zhang et al. (2010) showed that applying intermittent 0.5 N lateral loads to the knee
joints of mice (~8-weeks old) increased femoral (2.3%) and tibial length (3.7%). This
increase in limb length is noteworthy because treatment occurred during slower rates of
longitudinal bone growth when mice were close to reaching skeletal maturity. Long-term
effects of these studies have also not yet been done. Serrat et al. (2015) demonstrated
that using once daily targeted limb heating (40°C for 40mins/day) to unilaterally increase
femoral (1.3%) and tibial (1.5%) length of growing mice (3-5 weeks of age) is another
non-invasive alternative to treating limb length discrepancies. At skeletal maturity (12
weeks of age), femoral (1.0%) and tibial (1.0%) lengths remained significantly increased
on the heat-treated sides (Serrat et al., 2015).

1.2 REGULATION OF GROWTH PLATE DURING POSTNATAL LINEAR GROWTH
1.2.1 Endocrine Regulation of Linear Growth
The process of postnatal longitudinal growth is tightly controlled by 1) endocrine
actions by molecules, such as hormones, distributed in the blood that act on target cells
of the growth plate, and 2) paracrine/autocrine actions by locally produced factors
expressed in epiphyseal chondrocytes or surrounding perichondrium. Mutations in
genes encoding any of these regulators result in dysfunctional chondrocytes, abnormal
longitudinal growth, and skeletal dysplasia including short-limbed dwarfism. By
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endocrine action, systemic factors shown to regulate longitudinal growth include growth
hormone (GH), insulin-like growth factor 1 (IGF1), thyroid hormone, estrogen, androgen,
glucocorticoids, and vitamin D (Börjesson et al., 2010; van der Eerden, Karperien, &
Wit, 2003; Lui, Nilsson, & Baron, 2014; Ohlsson et al., 1993; Simpson, Asling, & Evans,
1950; Tryfonidou et al., 2010; Wang, Shao, & Ballock, 2010). For example, while
circulating thyroid hormone has been shown to increase longitudinal bone growth
indirectly by increasing systemic GH secretion (Ohlsson et al., 1993), it also has been
shown to directly interact with the epiphyseal chondrocytes and initiate terminal
differentiation (Ohlsson, Nilsson, Isaksson, Bentham, & Lindahl, 1992a; Stevens et al.,
2000).

1.2.2 Autocrine/Paracrine Regulation of Linear Growth
In regards to autocrine/paracrine regulation within growth plate cartilage, locally
acting factors reported include Indian hedgehog (Ihh), parathyroid hormone-related
protein (PTHrP), fibroblast growth factors (FGFs) (including FGF1, -2, -9 and -18), bone
morphogenic proteins (BMPs) (including BMP2-7), vascular endothelial growth factor
(VEGF), IGF1, and Wnt (van der Eerden et al., 2003; Karimian, Chagin, & Sävendahl,
2012; Kronenberg, 2003; Lui et al., 2014; Maeda, Schipani, Densmore, & Lanske, 2010;
Tryfonidou et al., 2010; Wang et al., 2010). Different regional zones of growth plate
chondrocytes are regulated by particular factors. For instance, regulation of
prehypertrophic chondrocytes (chondrocytes at maturation that no longer proliferate) in
the region between the proliferative zone and hypertrophic zone, have been
characterized by the expression of signaling molecules responsible for the successful
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and timely transition from proliferative to hypertrophic chondrocytes. These include FGF
receptors (Lazarus, Hedge, Andrade, Nilsson, & Baron, 2007; Su, Jin, & Chen, 2014),
BMPs (Garrison, Yue, Hanson, Baron, & Lui, 2017; Nilsson et al., 2007), and Ihh/PTHrP
receptors (Vortkamp et al., 1996).
Often, it has been shown that longitudinal bone growth is controlled by the
collaboration of both endocrine and paracrine/autocrine actions when systemic factors
interact with locally expressed factors of the growth plate cartilage to promote
chondrocyte proliferation and hypertrophy. Among these interactions, estrogen
(endocrine) has been shown to regulate expression of IGF1 (autocrine/paracrine) in
growth plate chondrocytes (Börjesson et al., 2010). Thus, in addition to the independent
influences of systemic and local factors on the growth plate, there are important
interactions between regulators to maintain growth. While the impact of some factors
(such as IGF1) act predominantly over others, there is no evidence supporting that one
is mutually exclusive from the rest in regulating longitudinal bone growth. There is still
much to be understood regarding the molecular mechanisms involved in linear growth
and further research will lead to a greater depth of comprehension.

1.3 GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR REGULATE
LINEAR GROWTH
1.3.1 Evolution of the Somatomedin Hypothesis
GH and IGFs have an integral role in maintaining normal growth and
development. The original understanding of the means by which GH and IGFs regulate
growth was set into motion after experiments conducted in 1957 by Salmon and
Daughaday (Salmon & Daughaday, 1957). In the early 1970s, the same group in
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addition to other investigators referred to their findings as the somatomedin hypothesis,
which described pituitary-gland derived GH to act upon the liver to secrete an
intermediate hormone stimulating somatic growth (Daugaday et al., 1972). The
intermediates were termed insulin-like growth factor 1 (IGF1) and insulin-like growth
factor 2 (IGF2) (also referred to as somatomedin C and A) later in the decade
(Rinderknecht & Humbel, 1978a,b). Both factors are important for growth and
development and when disrupted display abnormal phenotypes (Table 1).
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Table 1. Mouse Models with Disrupted IGF1 Regulation
Model
Phenotype
Citation
Igf1 null mice (global
95% mice died prenatally;
Baker et al., 1993
IGF1 disruption)
undetectable levels of IGF1 in Bikle et al., 2001
serum and tissues; significant Powell-Braxton et al., 1993
decrease in tibial length
Wang et al., 2006
(70%); abnormal chondrocyte
proliferation and differentiation
Igf2 null mice (global
Mice are viable; reduced body DeChiara, Efstratiadis, &
IGF2 disruption)
growth (60%) at birth; normal
Robertson, 1990
postnatal growth
Yakar et al., 1999
LID mice (systemic
disruption of liverderived IGF1)

75% reduction in serum IGF1;
no significant change in body
length; no significant change
in tibial length; slight decrease
in femoral length (6%)
ALS knockout mice
65% reduction in serum IGF1;
(systemic disruption
no significant change in body
ternary complexes
length; slight decrease in
(IGF1/ALS/IGFBP-3)
femoral length (7.5%)
LID+ALSKO mice
85-90% reduction in serum
(systemic disruption of IGF1; significant reduction in
liver-derived IGF1 and body length (30%); significant
ternary complexes
decrease in femoral length
(IGF1/ALS/IGFBP-3))
(20%)
(Col2a1)-driven Cre
40% reduction in chondrocyte
mice (local disruption
IGF1; Significant decrease in
of chondrocyte-derived postnatal body length; no
IGF1)
morphological differences in
proliferative and hypertrophic
regions
CartIgf1r-/- mice (local
Mice died shortly after birth
disruption of cartilagespecific IGF1R)

Sjögren et al., 1999
Yakar et al., 1999

TamCartIgf1r-/- mice

Tahimic, Wang, & Bikle, 2013
Wang et al., 2011
Wu, Yang, & De Luca, 2015

(local disruption of
cartilage-specific
IGF1R induced by
tamoxifen injections)

Significant decrease in body
length (40%); disorganized
growth plates associated with
reduced chondrocyte
proliferation and differentiation
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Ueki et al., 2000

Yakar et al., 2002

Govoni et al., 2007a

Wang et al., 2011

The introduction of the dual effector theory in 1985 disputed the original
somatomedin hypothesis and proposed an additional IGF1-independent role of GH
(Green, Morikawa, & Nixon, 1985). This revision came with reports of local IGF1
production in nonhepatic tissues, including bone (Tahimic et al., 2013) demonstrating
that IGF1 acts as both an endocrine and autocrine/paracrine factor. In the growth plate,
investigators found that GH directly stimulated cell differentiation in the RZ of precursor
cells, while local IGF1 production mediated clonal expansion of the resulting PZ
chondrocytes (Isaksson, Jansson, & Gause, 1982, Isaksson, Eden, & Jansson, 1985;
Ohlsson et al., 1992a; Ohlsson, Nilsson, Isaksson, & Lindahl, 1992b; Ohlsson,
Bengtsson, Isaksson, Andreassen, & Slootweg 1998; Schlechter, Russell, Greenberg,
Spencer, & Nicoll, 1986). Recent research also supports the direct contribution of GH
acting on the growth plate independent of IGF1 (Dobie et al., 2015; Wu et al., 2015).
The evolution of the somatomedin hypothesis incorporates an adaptation of previous
theories to describe a more complex interplay between GH and IGF1, including
negative feedback mechanisms where IGF1 inhibits further GH production (Moody et
al., 2014). The interaction between IGF1 and GH is commonly referred to as the
GH/IGF1 axis (Fig. 3).
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Figure 3. GH/IGF1 Axis in Postnatal Limb Elongation
Flow diagram illustrates the complex interplay between GH and IGF1 in promoting
longitudinal bone growth. In addition to stimulating IGF1 production in the liver as
originally proposed in the somatomedin hypothesis, GH also stimulates longitudinal
growth (1) by promoting local production of IGF1 in growth plate chondrocytes and (2)
independent of IGF1 as explained by the dual effector theory. IGF1 also has
autocrine/paracrine effects independent of GH promoting longitudinal growth locally in
growth plate chondrocytes. The red arrow demonstrates the negative feedback
mechanism of IGF1 inhibiting further GH synthesis and release. Tibia illustration
provided with permission by Amsel S on Exploring Nature Educational Resources
(2018).
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1.3.2 IGF Induced Signaling Pathway
IGF binding protein-3 (IGFBP-3) is the major carrier of IGFs. In serum, majority of
IGFs (~75%) exist in a ternary complex of one molecule each of IGF1, IGFBP-3, and
the acid labile subunit (ALS) (Holman & Baxter, 1996; Yakar et al., 2002). The ternary
complex prolongs the half-life of serum IGFs and regulates transport from the circulation
to the target tissue (Baxter, 2000; Holman & Baxter, 1996; Le Roith, Bondy, Yakar, Liu,
& Butler, 2001). Similar to IGF1, IGF2 binds to IGFBPs (Baxter, 2000; Le Roith et al.,
2001). Upon release at the surface of the target tissue, both IGFs are capable of binding
to the receptor tyrosine kinase type 1 IGF receptor (IGF1R) (Le Roith et al., 2001)
expressed in all regions of the growth plate (Parker et al., 2007; E. Wang, J. Wang,
Chin, Zhou, & Bondy, 1995). The activation of the IGF1R leads to a signaling cascade
involving the phosphatidylinositide 3-kinase (P13K) and mitogen-activated protein
kinase (MAPK) pathways ultimately leading to cell survival and proliferation, which
contributes to longitudinal growth rate (Fig. 4). IGF2 is classically described to be
essential only during prenatal growth (DeChiara et al., 1990; Lund et al., 1986; Yakar et
al., 1999), whereas IGF1 is expressed at low levels during embryonic development and
is important for postnatal growth (Baker et al., 1993; Liu, Baker, Perkins, Robertson, &
Efstratiadias, 1993; Powell-Braxton et al., 1993). Evidence supports that IGF1 is more
critical to postnatal longitudinal bone growth compared to IGF2 because the postnatal
phenotype of the Igf1 null is more severe than the Igf2 null mice (see Table 1) (Baker et
al., 1993; DeChiara et al., 1990; Liu et al., 1993; Yakar et al., 1999).
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Figure 4. IGF1 Induced Intracellular Signaling Pathway
Model demonstrates how IGF1 functions as a ligand and binds to its receptor (IGF1R)
triggering two downstream signaling cascades including the phosphatidyl inositol-3
kinase (P13K) and mitogen-activated protein kinase (MAPK) pathways and ultimately
leading to cell survival and proliferation. Illustration based on Crudden, Girnita, A, and
Girnita, L (2015).
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1.3.3 GH and IGF1 Distinct and Overlapping Functions on Linear Growth
One example of a mouse model that demonstrates the importance of the
GH/IGF1 axis is the growth hormone receptor knockout (GHR-/-) mouse. The GHR-/mouse is a model of human Laron Syndrome, a recessively inherited inactivating
mutation(s) in the GHR. The disease is characterized by GH resistance, high serum
GH, and low serum IGF1 (Laron, 2015a; List et al., 2011; Sims et al., 2000; Zhou et al.,
1997). While at birth these mice are similar in size to their wild-type littermates
(suggesting prenatal growth not dependent on GH), the significant size difference
becomes apparent during postnatal development (Zhou et al., 1997). GHR-/- mice have
a 30-40% reduction in body size (List et al., 2011; Sims et al., 2000; Yakar & Isaksson,
2016; Zhou et al., 1997) as well as a 65% reduction in tibial growth rate (Davies et al.,
2007; Wang, Zhou, Cheng, Kopchick, & Bondy, 2004) and decreased chondrocyte
proliferation and hypertrophy (List et al., 2011). Studies by Lupu et al. (2001)
determined that GH and IGF1 have distinct, yet overlapping, functions during
mammalian linear growth. When comparing mutant mouse models of Igf1 mutant mice,
GHR-/- (lacking GH action), and double-mutants (Ghr/Igf1), it was determined that the
observed growth retardation of the double Ghr/Igf1 nullizygotes was more severe than
that of either single mutant model (Lupu et al., 2001). With advancements in the field of
endocrinology, investigators continue to refine the original somatomedin hypothesis and
study how GH and IGF1 interact to regulate linear growth.
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1.3.4 GH and IGF1 Treatment of Hormonal Deficiencies
As described, normal longitudinal bone growth requires functional hormonal
regulation. Hormonal disorders involving the deficient or excessive production of the
important hormones of growth (GH, IGF1, thyroid hormones, glucocorticoids, and sex
steroids), can lead to abnormally short or tall stature. Short stature characterized by
stunted linear growth may result from GH deficiency (Lupu et al., 2001; Ohlsson et al.,
1998; Tritos & Klibanski, 2016), IGF1 deficiency (Liu et al., 1993; Mohan et al., 2003;
Powell-Braxton et al., 1993; Wang, Zhou, & Bondy, 1999; Wang et al., 2006; Yakar &
Isaksson, 2016), hypothyroidism (Bassett & Williams, 2016), or hypercortisolism (Bello
& Garrett, 1999; Silvestrini et al., 2000). Thyroid hormone (T3) deficiency in children is
associated with growth retardation (Rivkees, Bode, & Crawford, 1988) and studies in
mice using knockout models have shown that linear growth is impaired in thyroid
hormone deficient mice (Basset et al., 2008; Friedrichsen et al., 2003) when levels are
normal but the thyroid receptor (TRα1 and TRβ) is mutated (Göthe et al., 1999;
Kindblom et al., 2005).
One of the main problems associated with short stature in children is the
development of behavioral and emotional problems (van der Eerden et al., 2003;
Gordon, Crouthamel, Post, & Richman, 1982; Sandberg, 2000). The most common
treatment option for children with stunted linear growth involves frequent subcutaneous
injections of recombinant human GH until adult height is reached (Ohlsson et al., 1998;
Pfäffle, 2015; Wit & Oostdijk, 2015). In addition to treatment of short stature as a result
of hormonal disorders, GH has also been used to treat short stature resulting from
chromosomal disorders and genetic syndromes including Turner syndrome (Pfäffle,
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2015; Ranke, 1995a, Tritos & Klibanski, 2016; Wit & Oostdijk, 2015), Achondroplasia
(Harada et al., 2017), Prader-Willi syndrome (Moix, Gimébez-Palop, & Caixàs, 2018;
Pfäffle, 2015), and Noonan syndrome (Noonan & Kappelgaard, 2015; Pfäffle, 2015).
Other therapies including oxandrolone (man-made steroid similar to testosterone),
estrogens, gonadotropin-releasing hormone (GnRH) and IGF1 have also been used to
increase linear bone growth (Wit & Oostdijk, 2015). While GH therapy is more
commonly used in clinical settings, IGF1 has also been shown to effectively reverse
skeletal growth discrepancies (Azcona et al., 1999; Backeljauw, Kuntze, Frane,
Calikoglu, & Chernausek, 2013; Chernausek et al., 2007; Laron & Klinger, 2000; Laron,
2001; Laron & Kauli, 2015b; Lupu et al., 2001; Midyett et al., 2010; Ranke et al., 1995b,
1999; Sims et al., 2000). However, there are more adverse effects associated with IGF1
treatment including hypoglycemia (abnormally low levels of glucose in the bloodstream)
(Clemmons, 2004; Guevara-Aguirre et al., 1997; Laron & Klinger, 2000; Lindsey &
Mohan, 2016; Ross, Lee, Gut, & Germak, 2015). In patients that already show
symptoms of hypoglycemia, such as those with Laron’s Syndrome (GH insensitive),
IGF1 therapy can intensify these symptoms and can lead to loss of consciousness or
seizures (Chernausek et al., 2007; Cohen et al., 2014; Kovacs et al., 1999). Other risks
with IGF1 treatment include headaches, intracranial hypertension, growth of the
nasopharyngeal lymphoid tissues, hearing loss, and injection site lipohypertrophy
(Backeljauw et al., 2013; Chernausek et al., 2007; Midyett et al., 2010; Ranke et al.,
1995b). Therefore, it would be favorable to develop a successful drug treatment
regimen using a lower dose of IGF1 to avoid the adverse effects of increased systemic
levels.
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1.4 IGF1 AS A PRIMARY MEDIATOR OF LONGITUDINAL BONE GROWTH
1.4.1 Function of Locally Expressed IGF1
Numerous studies have supported the importance of both GH and IGF1 in
mediating linear bone growth; however, IGF1 appears to be the most critical regulator of
postnatal growth. In mutant animal models where GH action is impaired (Laron, 2015a;
List et al., 2011; Lupu et al., 2001; Sims et al., 2000; Wang et al., 2004; Zhou et al.,
1997), animals thrived despite being significantly smaller than the wild-type
counterparts. In contrast, in mutant animals where local IGF1 action is impaired, most
animals died shortly after birth and those that did survive had severe growth defects
(Tahimic et al., 2013; Wang et al., 2011; Wu et al., 2015) supporting the importance of
local chondrocyte-produced IGF1. The observed growth defects suggest that while a
degree of circulating IGF1 is necessary (Yakar et al., 2002), local action of IGF1 may be
more critical for longitudinal bone growth than serum IGF1 (see Table 1).
The role of local IGF1 in the proliferation of chondrocytes in mice and rats has
been debated. Investigators have detected the expression of IGF1 in the PZ of the
epiphyseal growth plate measured by in situ hybridization (Lazowski et al., 1994; Lupu
et al., 2001; Nilsson, Carlsson, Isgaard, Isaksson, & Rymo, 1990; Ohlsson et al.,
1992a). However, these results were not in agreement with the findings of two different
groups from the early to mid-1990s that were both unable to detect IGF1 mRNA in
proliferating chondrocytes by in situ hybridization methods, and instead found IGF2
mRNA (Shinar, Endo, Halperin, Rodan, & Weinreb, 1993; Wang et al., 1995). Additional
investigators also identified the expression of IGF2 in the PZ (Parker et al., 2007;
Reinecke, Schmid, Heyberger-Meyer, Hunziker, & Zapf, 2000). In all cases, it was
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consistently reported that the level of IGF2 expression in the PZ decreased with age.
Overall IGF1 expression levels increase after birth, including those in proliferating
chondrocytes (Parker et al., 2007). The absence of IGF1 mRNA in proliferating
chondrocytes by Shinar et al. (1993) and Wang et al. (1995) was reported using rodents
during the earliest stages of postnatal development. Therefore, it is possible that these
rodents had not yet reached the postnatal age by which an increase in IGF1 expression
in the PZ can be detected, such as that reported by Parker et al. (2007).
The significance of IGF2 in early postnatal chondrocyte development, secondary
to IGF1, has begun to emerge. IGF2 is not included in the GH-IGF1 axis (Humbel,
1990; Pierce, Dickey, Felli, Swanson, & Dickhoff, 2010) but recent studies are now
investigating the role of IGF2 in postnatal bone growth after a group discovered that
human postnatal growth restriction was associated with nonsense IGF2 mutations
(Begemann et al., 2015). Uchimura et al. (2017) have shown significant reductions in
bone length in IGF2-null mice at postnatal periods prior to weaning (1-3 weeks of age)
and their histological analysis suggests IGF2 has a role in regulating chondrocyte
development by controlling the progression from proliferation to hypertrophy. The
mechanism and extent by which IGF2 regulates longitudinal bone growth through
cartilage development remains unclear and its evaluation will be important in future
experiments.
Regardless of its local versus systemic roles, IGF1 is undisputedly a significant
factor in epiphyseal cartilage development. Local regulation of IGF1 has been studied in
other regions of the growth plate aside from the PZ. Cell kinetic studies using
hypophysectomized rats (pituitary gland removed reducing systemic levels of GH and
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IGF1) determined that IGF1 regulated all phases of chondrocyte differentiation in the
growth plate including the RZ of chondrocyte precursors (Hunziker, Wagner, & Zapf,
1994a). IGF1 expression has also been observed in the HZ of epiphyseal growth plates
(Lazowski et al., 1994; Nilsson et al., 1990) and local regulation by IGF1 has been
shown to augment chondrocyte hypertrophy (Abbaspour et al., 2008; Mushtaq, Bijman,
Ahmed, & Farquharson, 2004; J. Wang et al., 1999; Y. Wang et al., 2006). An observed
35% reduction in HZ height was reported in an IGF1 null mouse model (Wang et al.,
1999). IGF1 has also been shown to induce collagen X production (made in the HZ)
(Repudi, Patra, & Sen, 2013; Wang et al., 1999). When local expression of IGF1 was
blocked by the binding of Wnt induced secreted protein 3 (WISP3), a protein involved in
cell differentiation, IGF1-induced collagen X expression was reduced (Repudi et al.,
2013).

1.4.2 IGF1 Antagonists
Mouse models designed to control the expression of IGF1 through genetic
manipulation are a useful method for studying IGF1 regulation. Another approach for
studying IGF1 action and its role in regulating linear bone growth is by blocking IGF1
action. The major target of an IGF1 antagonist is the IGF1R, which serves as the
gateway for IGF1 action (see Fig. 3). When activation of the IGF1R is inhibited, the
growth promoting effects of IGF1 are blocked (Fig. 4). Multiple types of antagonists of
IGF1 have been studied including small-molecule tyrosine kinase inhibitors (TKIs) and
competitive antagonists such as monoclonal antibodies directed against the IGF1R or
the use of IGF1 peptide analogs (Table 2). Since hormones and growth factors,
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including IGF1, function to promote growth by inducing cell proliferation and survival,
hormone antagonists are often investigated as means for treating abnormal cell growth
such as carcinogenesis. However, many of these antagonists face scrutiny because of
the reports of failure in clinical trials (Guha, 2013). Therefore, investigators are
continuing to seek a better understanding of these antagonists using animal models
(Moody et al., 2014) and continue to research alternatives for IGF1 antagonists to
improve targeted therapies (Guha, 2013).
Apart from clinical studies using IGF1 antagonists as anti-cancer drugs, testing
antagonists for their ability to block IGF1 action in various tissues, including bone,
should be done. Since many of these drugs are administered systemically, the smaller
sized antagonists (<0.9 kDa) are more soluble and better for transport out of the
vasculature and into the tissue (Hadacek & Bachmann, 2015; Macielag, 2012). As
highlighted in Table 2, IGF1 peptide analogs are effective because of their specificity,
small molecular size (0.6-1.2 kDa) and low toxicity (Haylor et al., 2000; Huang, Golden,
Tarjan, Madison, & Stern, 2000; Kleinridders, 2016; Pietrzkowski, Wernicke, Porcu,
Jameson, & Baserga, 1992; Smith et al., 1999). Multiple IGF1 peptide analogs have
been used to inhibit cellular proliferation including JB1, JB2 and JB3 (Pietrzkowski et al.,
1992). Presently, JB1 is the analog commercially available to researchers that
competitively binds to IGF1R and blocks downstream IGF1 activity (Brock et al., 2011;
Huang et al., 2000; Kleinridders, 2016; Todd, Fraley, Peck, Schwartz, & Etgen, 2007;
Wen et al., 2012) (Fig. 5). As with many antagonists, resistance is possible. Haylor et al.
(2000) reported a bell-shaped curve with the dose response of JB3 and its successful
inhibition of kidney growth in rats. In addition to determining an effective range of
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treatment, challenges still arise in eliciting a tissue specific response without affecting
other systems dependent on IGF1 for normal growth. Therefore, further investigation
into methods of targeting small molecules will be beneficial in optimizing application of
IGF1 antagonists.
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Table 2. Summary of IGF1 Antagonists in Inhibiting Overall Growth
Antagonist
Advantage
Disadvantage
Citation
Anti-IGF1R
Highly specific for
Activates the insulin Huang et al., 2000
antibodies (i.e.
the IGF1R
receptor and
Moody et al., 2014
ganitumab and
promotes unwanted
αIR3)
growth; Large
molecular weight
(145-155kDa); Drug
resistance
Small-molecule
Targets both
Less specific;
Li, Pourpak, & Morris,
TKIs (i.e.
IGF1R and insulin Reported toxicity
2009
Linsitinib and
receptor; Small
(i.e. diarrhea and
Pillai & Ramalingam,
BMS-754807)
molecular weight
myelosuppression); 2013
(0.42-0.46kDa)
Drug resistance
Refolo et al., 2017
IGF1 peptide
Highly specific for
Drug resistance
Haylor et al., 2000
analogs (i.e. JB1, the IGF1R; Small
Huang et al., 2000
JB2 and JB3)
molecular weight
Kleinridders, 2016
(0.6-1.2kDa); Low
Pietrzkowski et al., 1992
toxicity
Smith et al., 1999
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IGF1
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Akt
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ERK1/2

Kinase
Signaling
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BCL-2

mTOR

p27
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Cell survival and proliferation
Figure 5. JB1 Blocks IGF1R Signaling
Model demonstrates how IGF1 peptide analog, JB1, competitively binds to the IGF1R.
JB1 thus inhibits IGF1 binding preventing IGF1R activation and ultimately blocking
kinase signaling that would otherwise lead to cell survival and proliferation (repressed
downstream effects indicated by the red “X”). Illustration based on Crudden et al.
(2015).
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1.5 REGULATION OF LINEAR GROWTH BY TEMPERATURE
1.5.1 Temperature Regulates Linear Growth in Nature
For over 50 years, several environmental factors have been shown to influence
bone growth and development. As reviewed by Schell, Gallo, & Ravenscroft (2009),
environmental factors include nutrition, altitude, climate and temperature. Temperature
has classically been described to influence extremity length as described by Allen’s rule
that warm-blooded animals living in cold climates display decreased length of
extremities and appendages (Allen, 1877). Temperature regulated limb length is thought
to be an adaptation to the cold climate by reducing the body mass to surface area ratio
(Newman, 1953).

1.5.2 Temperature Regulates Linear Growth in Laboratory Setting
Allen’s rule is often still applied to a variety of different species in present day
studies. In humans, Allen’s rule was demonstrated in a study suggesting that shorter
limbs (including those of Neanderthals, a group of archaic humans) are advantageous
for survival in cold climates by reducing the metabolic cost of maintaining body
temperature (Tilkens, Wall-Scheffler, Weaver, & Steudel-Numbers, 2007). In reptiles,
studies have shown that increased incubation temperature (32°C) of embryonic
crocodiles led to increased tibial length (Pollard et al., 2017). Serrat (2014b) thoroughly
reviewed the impact of temperature on extremity growth in various species. For
instance, mice from 3.5-12 weeks of age housed at warm ambient temperature (27°C)
displayed longer limbs than cold-reared mice (7°C) (Serrat, Williams, & Farnum, 2010).
Overall results of Allen’s rule replicated in laboratory settings (mainly in rodents) appear
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to be most profound when experimentation occurs during the active period of postnatal
growth. Al-Hilli and Wright (1983) studied effects of warm ambient temperature (33°C)
on tail growth in young mice (3 weeks of age) and showed heat enhanced tail growth
occurred during the first 3-4 weeks of exposure. Serrat (2013) reanalyzed this
temperature sensitive period of postnatal growth in young mice (3 weeks of age) and
found that the “critical phase” of temperature sensitive growth occurs between 3-5
weeks of age, followed by a later “maintenance phase,” whereby limb length differences
are simply maintained.

1.5.3 Unilateral Heating Model Enhances Bone Lengthening
Serrat et al. (2015) later showed that targeted unilateral limb heating (40°C) in
growing mice (3-5 weeks of age) increased limb length on heat-treated sides. However,
the mechanism of action is unclear. It can be difficult to narrow down a single
mechanism responsible for temperature-altered physiology, as there are numerous
possibilities, both direct and indirect, and include altered cellular gene expression,
vascularization, transport of nutrients and growth factors (Serrat, 2014b), and systemic
hormone concentrations. It is likely that multiple mechanisms are involved in
temperature-enhanced limb growth. Since the cartilaginous growth plate drives linear
bone growth and the observed temperature induced changes in limb length occur
concurrently with periods of elevated growth plate activity (3-5 weeks of age in the
mouse), it is likely that temperature elicits direct and indirect effects on the growth plate.
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1.5.4 Potential Function of IGF1 in Heat-Enhanced Linear Growth
As previously discussed, IGF1 is the main regulator of linear growth since normal
skeletal development does not occur without functional IGF1 activity (see Table 1) (Liu
et al., 1993; Mohan et al., 2003; Powell-Braxton et al., 1993; Wang et al., 2006). In
addition to liver-derived serum IGF1 (endocrine), it has also been suggested by rodent
studies that locally expressed IGF1 (autocrine/paracrine) regulates cellular mechanisms
of longitudinal bone growth in the growth plate (Isaksson et al., 1982, 1985; Isaksson,
Ohlsson, Nilsson, Isgaard, & Lindahl, 1991; Ohlsson et al. 1992a, 1992b, 1998;
Schlechter et al., 1986). Therefore, a working hypothesis for heat-enhanced linear
growth is that temperature increases activity of IGF1, which increases rates of
chondrocyte proliferation and hypertrophy to subsequently enhance limb growth. Heatenhanced linear growth may occur by: (1) indirectly increasing IGF1 access to the
growth plate with temperature-enhanced blood flow (endocrine actions), (2) directly
increasing IGF1 activity within the growth plate (autocrine/paracrine actions) with
temperature-enhanced expression of regulators, or (3) a combination of both.
While supporting evidence of temperature-enhanced blood flow and vascular
transport are discussed in later sections, literature also supports that IGF1 expression
increases with higher temperature. A recent study showed that during early
development in a population of eels (endoskeleton is entirely made of bone), those
reared in warmer temperatures (22°C) compared to colder temperatures (16°C), were
significantly longer in length and had increased gene expression of IGF1 (Politis et al.,
2017). Other studies comparing the effect of thermal manipulation on IGF1 expression
in skeletal muscles of growing broiler chicks showed increased expression associated
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with increased temperature (Al-Zghoul et al., 2016; Halevy, Krispin, Leshem, McMurtry,
& Yahav, 2001). In addition to the suggested relationship between temperature and
IGF1 expression in developing tissues, temperature has also been shown to weaken
the affinity of IGF1 binding to ALS in its ternary complex (ALS-IGF1-IGFBP3)
accounting for increased free IGF1 in the circulation (Holman & Baxter, 1996). Further
research is required to determine if temperature impacts IGF1 action in bone and
cartilage tissue in mammals during development.

1.6 ROLE OF VASCULATURE IN PROMOTING LONGITUDINAL BONE GROWTH
1.6.1 Vascular Supply of the Growth Plate
In addition to local and systemic factors that regulate the well-controlled process
of endochondral ossification, vascular systems are also crucial because they transport
regulators that are essential for longitudinal bone growth. Therefore, it is important to
understand the blood supply of growth plate cartilage. Although bone is a highly
vascularized tissue, signaling molecules involved in bone elongation must overcome a
challenge that is unique to the growth plate. Cartilage does not have a penetrating blood
supply. Systemic factors essential for bone elongation are delivered from surrounding
blood vessels (Brodin, 1955; Maes, 2013; Trueta, 1968). These vascular routes include:
1) epiphyseal vessels, 2) metaphyseal vessels, and 3) perichondral vessels (Brookes &
Revell, 1998; Brighton, 1978; Spira & Farin, 1967; Wirth et al., 2002). Perichondral
vessels arise from a ring vessel found in the encircling fibrochondrosseous structure in
the perichondrium known as the groove of Ranvier (Brookes & Revell, 1998; Walzer et
al., 2014). The epiphyseal vessels have been reported to provide the means for normal
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chondrocyte proliferation, while chondrocyte hypertrophy is dependent on the
metaphyseal vessels (Trueta & Amato, 1960; Zoetis et al., 2003). Studies have shown
that the epiphyseal vasculature is essential for normal growth plate cartilage
development (Maes et al. 2004; Maes, 2013; Trueta, 1968; Williams, Zipfel, Tinsley, &
Farnum, 2007). While the viability of chondrocytes may be dependent on epiphyseal
vasculature as opposed to metaphyseal vasculature (Trueta, 1968), metaphyseal
vessels are essential for providing osteogenic factors that replace cartilage with bone
during the process of endochondral ossification.
Studies have recently emerged using novel techniques to investigate the not fully
elucidated mechanism of molecular transport into the growth plate through the
surrounding vasculature. Multiphoton microscopy (MPM) as described by Zipfel,
Williams, & Webb (2003) is an attractive, noninvasive method of in vivo fluorescent
imaging in living anesthetized animals. Investigators have used MPM imaging as a
means of tracking systemic fluorescent tracers through the vasculature into the growth
plate (Farnum, Lenox, Zipfel, Horton, & Williams, 2006; Serrat, Williams, & Farnum,
2009; Serrat et al., 2010; Serrat, Efaw, & Williams 2014a; Williams et al., 2007). For
biological significance, the size of the fluorescent tracers was selected based on the
range of endogenous molecules that diffuse into the growth plate. The comprehension
of how signaling molecules enter the growth plate through the surrounding vasculature
is helpful in understanding regulation of growth plate chondrocytes. For example, very
small amounts of molecules larger than 40kDa enter the growth plate (Serrat et al.,
2014a), but molecules less than 10kDa were found to enter the growth plate through all
three vascular routes (Farnum et al., 2006). Larger sized molecules (10kDa and
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greater) appear to enter the growth plate from the surrounding perichondral vessels
(Williams et al., 2007). Transport of molecules into the growth plate is relevant to
understanding how larger signaling molecules such as FGFs (FGF2, 18kDA; FGF18,
23kDa), PTHrP (9-23kDa), and BMPs (BMP-2, 26kDa) expressed in the perichondrium
regulate growth plate chondrogenesis (Kronenberg, 2003).

1.6.2 Transport of Systemic IGF1 into the Growth Plate
IGF1 is the major circulating hormone of growth. At a molecular weight of
7.6kDa, IGF1 falls within the range of molecules that readily enter the growth plate
through the surrounding vasculature (less than 10kDa). Therefore, it is beneficial to
study IGF1 transport and improve our understanding of its role in regulating growth
plate chondrocytes. In an attempt to develop the means to facilitate this expansion in
knowledge, Serrat and Ion (2017) developed a methodology for fluorescently labeling
IGF1 in order to track its transport into the growth plate using MPM. They showed that
biologically active IGF-488 (IGF1 conjugated with Alexa Fluor 488) entered the growth
plate and localized to chondrocytes (Serrat & Ion, 2017). In addition to the general
comprehension of growth plate chondrocyte regulation, vascular transport studies also
are important in the development of therapies for growth plate disorders. IGF1 is used
as a drug to treat impaired growth in growth hormone insensitive children, i.e Laron
Syndrome patients (Azcona et al., 1999; Backeljauw et al., 2013; Chernausek et al.,
2007; Laron & Klinger, 2000; Laron, 2001, 2015a; Laron & Kauli, 2015b; Lupu et al.,
2001; Midyett et al., 2010; Ranke, 1995a; Ranke et al., 1995b, 1999; Sims et al., 2000).
It is therefore essential to understand how IGF1 can be modulated to improve effective
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treatment. Modulation may include methods for increasing IGF1 activity within the
growth plate, or better targeting its delivery to the growth plate.
Environmental factors, such as temperature, can affect vascular systems in bone
and affect their growth (Reviewed by Serrat (2014b)). In vivo imaging studies using
MPM have shown that warm temperature increases molecular uptake into the growth
plate (Serrat et al., 2009, 2010, 2014a). Temperature enhanced solute delivery is sizedependent as the transport of smaller molecules (less than 10kDa) is increased by over
150%, while larger molecules (40kDa and larger) are increased by less than 50%
(Serrat et al., 2014a).

1.6.3 Chondrocyte Expression of Angiogenic Factors
Angiogenesis (development of new blood vessels) is essential for normal linear
bone growth. During endochondral ossification, hypertrophic chondrocytes secrete
angiogenic factors that initiate vascular invasion and recruit bone absorbing and forming
cells to replace mineralized cartilage with bone. The key regulator of angiogenesis
during both prenatal and postnatal growth and development is vascular endothelial
growth factor (VEGF). Survival is dependent on functional VEGF during both embryonic
(Carmeliet et al., 1996; Ferrara et al., 1996) and early postnatal life (Gerber et al.,
1999a). Different VEGF isoforms exist but only VEGF-A is expressed in growth plate
cartilage and therefore is the most important for regulating longitudinal bone growth
(Emons et al., 2010). There are also additional splice isoforms of VEGF-A that vary
between species. Hypertrophic chondrocytes in both human and murine growth plates
secrete VEGF (Filipowska, Tomaszewski, Niedźwiedzki Ł, Walocha, Niedźwiedzki T,
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2017; Gerber et al., 1999b; Horner et al., 1999; Hunziker, 1994b; Maes et al., 2004; van
der Eerden et al., 2003; Zelzer & Olsen, 2005) to promote vascular invasion from the
metaphyseal bone throughout postnatal limb elongation. In human growth plates, the
most common splice isoforms are VEGF121, VEGF165 and VEGF189 (Emons et al., 2010;
Maes et al., 2004). The analogous isoforms in mice are VEGF120, VEGF164 and VEGF188
(Maes et al., 2002, 2004). Interestingly, Maes et al. (2004) discovered that different
processes of vascularization require specific isoforms of VEGF-A and that the combined
action of VEGF120 and VEGF188 is required for both epiphyseal and metaphyseal
vascularization. Other local factors expressed by hypertrophic chondrocytes that
promote angiogenesis include FGFs (Baron et al., 1994; Hung, Yu, Lavine, & Ornitz,
2007; Liu, Lavine, Hung, & Ornitz, 2007) and matrix metalloproteinase 9 (MMP-9)
(Engsig et al., 2000; Gerber et al., 1999b; Maes et al., 2002; van der Eerden et al.,
2003; Vu et al., 1998). Systemic factors including estrogen (Emons et al., 2010) and
IGF1 (Ahmed & Farquharson, 2010; Álvarez-García et al., 2010) have also been shown
to induce vascular invasion by stimulation of VEGF in growth plate chondrocytes.
Normal longitudinal bone growth is dependent on VEGF expression in growth
plate chondrocytes. Inhibition of VEGF in young mice (24 days old) suppressed blood
vessel invasion, lengthened the hypertrophic zone and reduced bone growth, all of
which was corrected after anti-VEGF treatment ended (Gerber et al., 1999b). These
results are clinically relevant to actively growing children that may require therapeutic
intervention using angiogenesis inhibitors to prevent unwanted formation of new blood
vessels such as in pediatric cancers. A monoclonal antibody against VEGF,
bevacizumab (Avastin®; Genentech, Inc), has been used in adults as a FDA approved
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anti-cancer agent (Ferrara, 2004) and is considered a promising treatment option for
children (Barone & Rubin, 2013; Han et al., 2016). It is especially important to improve
chemotherapy in pediatric patients since children are undergoing an essential stage of
bone development requiring growth factors, including IGF1 and VEGF, for bone
elongation. Therefore, as with IGF1 antagonists, the development of non-invasive
methods for targeting drugs directly to a tissue is beneficial for preserving linear growth
in children.

1.7 SCOPE OF CURRENT WORK
The goal of the current studies in this dissertation is to build upon an established
method of targeted limb heating as a potential non-invasive alternative to enhance bone
lengthening. This study tests the overall hypothesis that exposure to warm
temperature augments the actions of IGF1 in the growth plate and permanently
increases length of the extremities. The central aims of this study are 1) to determine
if IGF1 enhances bone elongation in heat-treated extremities and 2) determine the longterm extent of left-right limb length asymmetries and potential vasculature modifications
resulting from unilateral heat-treatment.
The application of the model for targeted limb heating (unilateral heating model)
and its functional impact is described in Chapter 2. This chapter sets the foundation for
following experiments using the unilateral heating model as a means to test the overall
hypothesis. As discussed above, the epiphyseal growth plate is the primary site of
longitudinal bone growth, and regulated by IGF1 (Börjesson et al., 2010; Lui et al.,
2014; Ohlsson et al., 1993; Tryfonidou et al., 2010; van der Eerden, 2003; Wang et al.,
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2010). Chapter 3 tests the hypothesis that there will be a unilateral increase in bone
length associated with increased chondrocyte proliferation and hypertrophic zone
expansion in the growth plate with heat-treatment. Observation of morphological
changes in the growth plate is a means to assess heat-enhanced bone elongation. In
Chapter 4, a study administering a low dose of IGF1 (2.5 mg/kg, once daily) coupled
with targeted limb heating tests the hypothesis that IGF1 administered with heattreatment will further enhance limb length than with heat alone. To further test the
overall hypothesis of this thesis, Chapter 5 describes the outcome of linear growth with
heat-treatment when IGF1 activity is blocked. The hypothesis is that with diminished
IGF1 activity, heat-enhanced limb length is attenuated. The goal shared by both
Chapter 4 and 5 is to demonstrate that unilateral exposure to warm temperature
augments actions of IGF1 in the growth plate to enhance bone length.
The long-term impact of targeted limb heating after the end of treatment is
elucidated in Chapter 6. This study tests the hypothesis that differential limb length will
be maintained throughout skeletal development after treatments have ended. The goal
of this chapter was also to demonstrate that persistent limb length differences will be
prominent in mice administered IGF1 following heat-treatment. The final chapter of this
thesis (Chapter 7) describes a pilot study measuring limb surface temperature following
heating and tests the hypothesis that skin temperature of heat-treated limbs will remain
elevated for an extended time following treatment. This chapter prefaces future studies
into possible mechanisms of the targeted heating-model as it suggests a heat-induced
increase in blood flow that accelerates bone lengthening. Together, current studies
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within the chapters of this thesis will use the unilateral heating model to test the overall
hypothesis (as stated above).
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CHAPTER II: FUNCTIONAL IMPACT OF TARGETED LIMB HEATING IN MICE
2.1 INTRODUCTION
Both congenital and acquired bone elongation disorders arise during early stages
of development. Without childhood medical intervention, problems associated with
these disorders can persist into adulthood and often are accompanied by painful health
conditions. Limb length discrepancy (LLD) of the lower limbs is characterized by the
asymmetric length of the lower extremities and can result from trauma or disease
(Morscher, 1977; Shapiro, 1982; Wilson & Thompson, 1939). Untreated LLD can lead to
chronic and painful musculoskeletal disabilities (Campbell et al., 2018; Gurney, 2002).
While the options for intervention vary based on the severity of the discrepancy,
research has addressed possible treatment options that typically involve more
permanent, invasive procedures (Gurney, 2002; Hasler & Krieg, 2012; Niedzielski,
Flont, Domżalski, Lipczyk, & Malecki, 2016; Pendleton et al., 2013; Sabharwal et al.,
2015; Stevens, 2016). Traditionally, intervention is recommended for what has been
considered an important functional discrepancy of 2 cm or more (Gross, 1978; Gurney
2002; Knutson, 2005). However, studies within the last two decades have shown that a
left-right asymmetry in limb length of less than 2 cm (0.5-1 cm) is functionally significant
(Harvey et al., 2010; Resende et al., 2016; White et al., 2004). Smaller left-right
asymmetries involve more conservative methods for correction such as shoe lifts or
prosthetics (Campbell et al., 2018; Golightly et al., 2007a; Hasler & Krieg, 2012; Wilson
& Thompson, 1939), but these methods do not permanently change the length of the
bone. It is important to explore alternative, noninvasive methods for correcting LLD,
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including even small discrepancies, during critical stages of postnatal longitudinal bone
growth.
A promising noninvasive alternative involves using targeted heat (40°C) to
increase bone length on one side of the body (Serrat et al., 2015). After two weeks of
localized unilateral heating, Serrat et al. (2015) demonstrated increases in tibial
elongation rate (>12%), femoral length (1.3%) and tibial length (1.5%). The ultimate goal
of these studies is to use heat-based therapy to correct a range of bone growth
impairments such as LLD in children. However, one fundamental question is whether
these heat-induced limb length differences are functionally significant.
One functional outcome of LLD includes gait disturbances (Aiona et al., 2015;
Kaufman et al., 1996; Khamis & Carmeli, 2017; Mahmood et al., 2010; Song et al.,
1997) resulting from a pelvic tilt toward the shorter side (Kerr, Grant, & MacBain, 1943;
Rush & Steiner, 1946). Therefore, this study aimed to determine if the small
discrepancies after one week of daily intermittent targeted limb-heating result in
changes in weight bearing. Longitudinal x-ray imaging and weight bearing distribution
analyses were used to test the hypothesis that heat-induced limb length asymmetry
has a functional impact on weight bearing in mouse hindlimbs.

2.2 MATERIAL AND METHODS
2.2.1 Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=12) mice were
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 days weaning age.
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Previous studies have shown that heat-enhanced bone elongation occurs in both male
and female mice with unilateral heat-treatment (Serrat et al., 2015). These studies
focused only on female mice since there were no reported differences between the
sexes and because other related studies in our laboratory required females. Mice were
singly housed at 21°C in standard plastic caging, exposed to a 12 hour light/dark cycle
and provided with food and water ad libitum.
Mice post-weaning were treated with 40 minutes of daily unilateral heat (40°C)
for 7 days beginning when mice were 3-weeks old following methods described by
Serrat et al. (2015). This period of postnatal growth was chosen because it has
previously been shown as a period of rapid, temperature sensitive growth (Serrat,
2013). Relative to human development, this pre-pubertal age range is comparable to
the period between toddler age and elementary school (as shown in Fig. 2). Mice were
anesthetized under 1.5% isoflurane and positioned right lateral recumbent on a 40°C
gel heating pad each day (Fig. 6). Heat-treatment was deliberately scheduled to begin
at the same time each day at the beginning of the light cycle (~7 a.m.) when growth
plate height and growth rate are maximal (Noonan et al., 2004; Stevenson, Hunziker,
Hermann, & Schenk, 1990). For each day of treatment, placement of each individual
mouse was rotated along the anesthesia manifold to account for any positioning effects
(the end positions for example are closer to the edge of the gel heating pad and
closer/further from the source of isoflurane). Limbs on the heat-treated side were fitted
in custom made insulating booties to warrant uniform heat distribution. Foam separators
were placed between the limbs as a thermal shield preventing heat transfer to the nonheated limb (30°C). Ear and hindlimb temperatures were taken throughout heating and
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core temperature and respirations were recorded as means of physiological monitoring.
The procedural room temperature remained at 19°C throughout the duration of
treatment.
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Figure 6. Diagram of the Unilateral Heating Method
Labeled photograph shows the unilateral heating method during the 40 minutes of
treatment (40°C). Temperature of heating pad topped with custom gel packs (colored
yellow) is manually controlled by a thermostat (not shown in image) and maintained at
40°C. Mice are positioned right lateral recumbent along the anesthesia manifold and
anesthetized with 1.5% isoflurane. Isoflurane flows through the plastic tubing controlled
for each individual mouse. Limbs on the heat-treated side are fitted in custom made
insulating booties. Foam separators are placed between the limbs (temporarily removed
from position 4 to reveal the insulating booties underneath).
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2.2.2 Tibial Radiographs
Radiographs were collected from mice (N=6) at the start (3 weeks of age) and
end (4 weeks of age) of the limb-heating experiments using an IVIS Lumina XRMS live
animal imaging system (Perkin Elmer, Waltham, MA, USA). Mice were anesthetized
individually under 1.5% isoflurane and positioned in ventral recumbency on a heated
platform. Each mouse was secured to the platform with adhesive tape with its hindlimbs
extended and taped down following published methods to ensure reproducible limb
positioning and a true projection of the tibia (Fig. 7) (Hughes & Tanner, 1970). Highresolution x-ray images were taken following methods described in the literature
(McManus & Grill, 2011) using modified settings (animal energy, 35 Kv 100μA, filtered
x-rays) at 5 cm X 5 cm field of view with f/stop set at 4 and subject height at 1.5 cm. The
mouse was then returned to its individual cage and observed during anesthesia
recovery (1-2 minutes). Methodology adapted from Racine et al. (2018).
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BEFORE

AFTER

Figure 7. Radiographs Collected Before and After Unilateral Heat-Treatment
Digital radiographs (29 X 45mm area) of the same mouse taken with an IVIS Lumina
XRMS live animal imaging system before (3-weeks of age) and after (4-weeks of age)
heating. Individual mouse represents one of the experimental group (N=6) used to
measure tibial length before and after targeted limb heating.
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2.2.3 Hindlimb Weight Bearing
Starting and ending weight-bearing data were collected from mice (N=12)
following x-ray procedures (~2 hours after anesthesia recovery). Weight bearing was
measured using an incapacitance meter (Stoelting Company, Wood Dale, IL, USA), a
device for measuring weight distribution of the two hindlimbs of a small rodent or bird.
The incapacitance meter records hindlimb weight bearing of each side of the mouse.
The mouse is placed in an angled plexiglass chamber positioned in a rearing posture so
that each hindlimb is placed over a separate force plate. Prior to collection, mice were
acclimated (2-5 minutes) to the chamber following published methods (TenBroek,
Yunker, Nies, & Bendele, 2016). Measurements were collected during 3-second
intervals and mean weight distribution was calculated during that period, thus
accounting for possible shifts in weight from one side to another during testing. A total of
3-5 recordings were taken per mouse at each time point and mean weight distribution
from each hindlimb was used in data analyses. Methodology adapted from Racine et al.
(2018).

2.2.4 Tissue Collection
All experimental mice (N=12) were euthanized for tissue collection 1 day after the
last day of heat-treatment when final x-ray and weight bearing analyses were performed
at the 4 weeks of postnatal age endpoint. Long bones (femora) from each side were
dissected, cleaned, dried, and scanned on a flatbed scanner. It has previously been
found that the intact femur can be dissected and cleaned most consistently for reliable
bone length data. Proximal tibiae from each hindlimb were dissected, cleaned and
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bisected. One unfixed half was arranged on a glass slide and cover-slipped with
glycerol in PBS prepared for tibial elongation rate analysis. Methodology adapted from
Racine et al. (2018).

2.2.5 Tibial Elongation Rate Analysis and Long Bone Measurements
A single intraperitoneal injection of oxytetracycline (OTC) (7.5 mg/kg, Norbrook
200 mg/mL) was administered to mice at the experimental start, 8 days prior to
euthanization and tissue collection. OTC is a calcium chelator that integrates into
mineralizing tissue and leaves a band of fluorescence that can be visualized using a UV
filter. Fluorescence was visualized in unfixed slab sections of tibiae using Ocular Image
Acquision Software (version 1.05.211) under 2.5X magnification with a Leica DM2500
epifluorescence microscope (Leica Microsystems, Wetzlar, Germany) coupled with a
QImaging Retiga R6 6.0 megapixel monochrome camera (Surrey, BC, Canada) and
using a UV filter. Tibial elongation rate (μM/day) was quantified by measuring the
distance between the metaphyseal chondro-osseous junction, where calcification
begins, and the proximal edge of the OTC band in metaphyseal bone, where the
fluorescent label is visualized after the 8-day period of growth.
Images of scanned femora were calibrated in ImageJ (version 1.48, National
Institutes of Health, USA) using a metric ruler and measurements were taken by
drawing a line between proximal and distal landmarks on the articular ends. Femoral
length was measured as the distance between the proximal-most point on the greater
trochanter and the distal-most point on the medial condyle. These methods of
quantifying tibial elongation rate and limb length have been described as reliable
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techniques in past experiments (Lee et al., 2016; Rolian, 2008; Serrat et al., 2015;
Wilsman et al., 2008).
Tibial length was measured from digital x-rays at the start and end of the study
(Fig. 7). Radiographs were calibrated in ImageJ using a razor blade for scale. The tibia
was selected for analysis because its landmarks could be most consistently identified in
both left and right hindlimbs of the same animal over time. Tibial length was measured
as the distance from the middle of the proximal articular surface to the distal-most
projection of the medial malleolus. Methodology adapted from Racine et al. (2018).

2.2.6 Statistical Analysis and Sample Size
Statistical analyses were performed using SPSS 25.0 software (IBM Corporation,
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side
comparisons for femoral length, tibial length, and tibial elongation rate were made using
one-tailed paired t-tests. Linear regression, with asymmetry in tibial elongation rate as
the regressor and weight bearing as the dependent variable, was used to assess the
relationship between weight bearing of hindlimbs and tibial elongation rate. Data were
reported as mean ± standard deviation (SD) in tabular format and as mean ± standard
error (SE) in graphical format. Study included a total of N=12 mice to account for
potential loss of samples and missing cases were excluded from statistical analysis on
an analysis-by-analysis basis. Sample sizes for measurements that are documented as
less than the size of the experimental sample set was a result of either sample loss due
to damage during dissection, poor acclimation to the incapacitance meter, and/or
improper limb position in the x-ray imager (Racine et al., 2018).
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2.3 RESULTS
2.3.1 Unilateral Heating Parameters
After 7 days of unilateral heating, mice gained an average of 5 g between the
start and the end of the study, consistent with the weight gain of age-matched nontreated control mice (Serrat et al., 2015). The core temperature averaged 36°C during
heat-treatment, which is analogous to the core temperature of a healthy C57BL/6
mouse (Gordon, 2012, 2017). While anesthetized the average surface temperature of
non-treated hindlimbs was 30°C and the heat-treated hindlimbs were 40°C. The
average time to anesthesia recovery after limb heating was 1 minute.

2.3.2 Bone Length and Tibial Elongation Rate
At the beginning of the study, prior to unilateral heating, there were no significant
left-right differences in tibial length (paired t=0.65, p=0.55) measured on x-rays (Fig. 7,
Table 3). At the experimental end when mice were 4 weeks of age following 7 days of
targeted limb heating, tibial length (paired t=11.5, p<0.001) measured on x-rays
increased by 0.9% on heat-treated sides (Fig. 7, Table 3) and femoral length (paired
t=7.7, p<0.001) measured from the digital scans increased by 1.4% on the heat-treated
side (Fig. 8A). Tibial elongation rate measured by OTC labeling averaged
160±14μM/day on the non-treated side and 170±13μM/day on the heat-treated side with
an increase of 6.5% on the heat-treated side over the 8-day labeling period (Fig. 8B).
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Figure 8. Extremities are Lengthened on the Heat-Treated Side
(A) Error bar plot comparing femoral length of non-treated and heat-treated limbs, show
femoral length increased on the heat-treated side by 1.4% after 7 days of heating. (B)
Tibial elongation rate increased on the heat-treated side by 6.5%. Mean ± 1 standard
error plotted. ***p<0.001, significance in left-right comparisons.
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Table 3. Comparison of Hindlimb Weight Bearing and Tibial Length Measured by
X-Rays.
Parameter

Non-Treated
(30°C)

Heat-Treated
(40°C)

Percent
Increase

N

Before

12.93 (0.27)

12.94 (0.26)ns

0.1

6

After

14.19 (0.14)

14.32 (0.12)***

0.9

5

Before

3.36 (0.38)

3.23 (0.25)ns

-2.9

7

After

5.44 (0.58)

6.51 (0.80)***

19.6

8

Tibial Length (mm)
measured from x-rays

Hindlimb Weight Bearing (g)
measured using incapacitance meter

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01;
***p<0.001; ns, non-significant.
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2.3.3 Hindlimb Weight Bearing
As with starting tibial length, there were no significant left-right differences in
hindlimb weight bearing (paired t=0.94, p=0.38) at the start of the study (Table 3).
Although not statistically significant, hindlimb bearing was about 3% greater on the
intended non-treated side prior to unilateral heating. After 7 days of targeted limb
heating, hindlimb weight bearing (paired t=11.9, p<0.001) was nearly 20% greater on
the heat-treated side (Table 3). There was also a significant positive linear relationship
between the increase in weight bearing and increase in tibial elongation rate (R2=0.82,
p<0.01) on the heat-treated side (Fig. 9).
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Figure 9. Increase in Weight Bearing and Tibial Elongation Rate are Correlated
After 7 Days of Unilateral Heat-Treatment
Scatter plot of individual mice shows a significant positive linear relationship between
the increase in weight bearing and increase in tibial elongation rate after 7 days of
targeted limb heating (y= 14.23 + 0.9x).

58

2.4 DISCUSSION
The goal of this study was to determine if the heat-induced differences in limb
length are functionally significant as assessed by changes in hindlimb weight bearing.
Our data support the hypothesis that heat-induced limb length asymmetry has a
functional impact on weight bearing in mouse hindlimbs.
After 7 days of targeted limb heating, there was a nearly 1% increase in tibial
length on the heat-treated side determined by measurements from x-ray images of live
anesthetized mice (Table 3). This increase in tibial length is comparable to the 1.4%
increase in femoral length measured by postmortem femoral scans (Fig. 8). While the
femoral length increase was slightly greater, this may be due to a larger sample size, or
because the dried femoral landmarks were more distinct than those of the tibia in the
radiographs. The femur was not measured in radiographs because its proximal and
distal ends were more prone to distortion. Endpoint tibial length measured from whole
tibia postmortem was also not accomplished since tibiae were reserved for tibial
elongation rate analyses.
The heat-enhanced bone length and tibial elongation rate measured after 7 days
of heating was associated with a nearly 20% increase in hindlimb weight bearing on the
heat-treated side (Table 3). This increase in hindlimb weight bearing positively
correlates to tibial elongation rate indicating that gait asymmetry increases along with
bone elongation (Fig. 9). The positive correlation between hindlimb weight bearing and
tibial elongation rate is consistent with similar findings in human studies (Kaufman et al.,
1996; Khamis & Carmeli, 2017). One limitation to this study was the difficulty to obtain
longitudinal weight bearing data (before and after measurements from the same mouse)
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using the incapacitance meter since data could only be used when the mice were calm,
immobile, and properly positioned within the plexiglass chamber. Using a dynamic gait
analysis would be beneficial because it would enable the collection of data in
unrestrained mice in their natural posture. An additional study to further support the
functional significance of heat-induced limb length asymmetry may include a balance
beam test with mice. Assessment of motor coordination and balance response to heattreatment would be relevant since poor balance is associated with human limb length
discrepancies (Azizan et al., 2018; Bonnet, Cherraf, Szaffarczyk, & Rougier, 2014).
Radiography and weight bearing analyses were useful methods for acquiring
before and after bone length and hindlimb weight bearing measurements from the same
mouse. Measurements collected at the start of the experiment are useful for evaluating
the functional importance of targeted limb heating because they demonstrate the natural
differences in both bone length and weight bearing prior to experimental manipulation.
In humans, many individuals have a degree of normal left-right asymmetry in the
lengths of their lower limbs (Green & Anderson, 1955; Knutson, 2005). Serrat et al.
(2015) showed that there was no inherent side asymmetry in non-treated control
animals. The current study further supported that left-right asymmetry is heat-induced
and not a natural variation by comparing the before and after measurements of both
tibial length and weight bearing.

2.5 CONCLUSION
In conclusion, even small discrepancies in limb length (nearly 1% to 1.4%) have
a functional impact on hindlimb weight distribution (nearly 20%) in young mice. These
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results suggest that heat-based therapies should continue to be pursued as a noninvasive alternative to surgical correction of limb length discrepancy. Chapter 6 tests the
hypothesis that heat-induced limb length asymmetry is maintained to skeletal maturity
(12 weeks of age). However, future studies will determine if left-right limb length
asymmetry in skeletally mature mice has a functional impact on weight bearing. This
would be translatable to the orthopedic problems described to accompany LLD and gait
disturbances in adulthood. The functional significance of the heat-induced difference in
limb length sets the foundation to further experimentation using the unilateral heating
model to gain a better understanding of heat-enhanced limb growth.
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CHAPTER III: CHONDROCYTE PROLIFERATION AND HYPERTROPHY IN TIBIAL
GROWTH PLATES INCREASES AFTER 7 DAYS OF TARGETED LIMB HEATING

3.1 INTRODUCTION
During longitudinal bone growth via endochondral ossification, cartilaginous
growth plates undergo a process of proliferation, expansion and apoptosis. Bone growth
rate is largely dependent on the dynamics of cartilage growth. It is therefore likely that
heat enhanced bone elongation involves modifications to growth plate cartilage. Others
have determined the main contributing factors to longitudinal growth include: the
amount of columnar cells in the proliferative zone of the growth plate, the rate of
proliferation, and the size of expanded cells in the hypertrophic zone (Cooper et al.,
2013; Farnum, 2007; Hunziker et al., 1987; Hunziker & Schenk, 1989; Hunziker, 1994b;
Kember, 1993; Rolian, 2008; Walker & Kember, 1972; Wilsman et al., 1996a, 1996b,
2008).
The growth period from 3-5 weeks of age in mice post weaning is the most rapid,
temperature sensitive period of longitudinal bone growth (Al-Hilli & Wright, 1983;
Callewaert et al., 2010; Li et al., 2017; Serrat, King, & Lovejoy, 2008). Temperature as a
therapeutic intervention therefore should be most effective during this stage of early
postnatal linear growth in mice. Treatment with 40°C unilateral heat for 40 minutes/day
over a period of 14 days in mice starting at 3 weeks of age resulted in extremity
lengthening and enhanced tibial elongation rate in both male and female mice (Serrat et
al., 2015). This phase of growth is an ideal period to focus therapeutics for optimum
limb lengthening results.
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The objective of this study was to determine how localized heating impacts bone
growth at the site of the cartilage growth plate after one and two weeks of limb heating.
The one week duration of heating was selected in addition to two weeks since the mice
have the largest gain in body mass from 3-4 weeks of age as shown by growth curves
provided by Hilltop Lab Animals, Inc (“Growth Chart C57BL/6,” 2018) and The Jackson
Laboratory (“Body Weight Information for C57BL/6J,” 2018). This study tested the
hypothesis that increased bone length in heat-treated limbs will be associated
with increased chondrocyte proliferation and hypertrophic zone expansion
compared to the non-treated contralateral limbs.

3.2 MATERIAL AND METHODS
3.2.1 Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=24) mice were
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 (N=18) or 28 (N=6)
days weaning age. Mice were singly housed at 20°C in standard plastic caging,
exposed to a 12 hour light/dark cycle and provided with food and water ad libitum.
As indicated by the unilateral heating methods schematic (Fig. 10) mice postweaning were treated with daily unilateral heat (40°C). Unilateral heat-treatment for 7
days began when mice were 3 weeks (N=6) and 4 weeks old (N=6), and treatment for
14 days started when mice were 3 weeks old (N=6). The procedural room temperature
remained at 19°C while mice were anesthetized under 1.5% isoflurane and positioned
right lateral recumbent on a 40°C heating pad each day for 40 minutes.
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Mice were weighed and given subcutaneous injections of a saline solution (3:1,
1xPBS:dH2O) at a volume of 0.01mL/g daily at the beginning of the light cycle. Mice
were injected with saline because they serve as a control group to compare with their
weight-matched littermates injected with drug treatments discussed in Chapters 4 and
5. Previous studies in our laboratory have shown that there are no significant
differences in heat-treatment outcome variables between non-injected and salineinjected mice (unpublished data). Localized heating occurred one hour following
injections.
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from 3-4 weeks of age
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Figure 10. Unilateral Heating Schematic
Mice were injected subcutaneously (SQ) with saline one hour prior to treatment of 40°C
unilateral heat for 40 minutes daily for: (1) 7 days from 3-4 weeks of age, (2) 7 days
from 4-5 weeks of age or (3) 14 days from 3-5 weeks of age. Euthanasia and tissue
collection occurred 1 day after the last day of heat-treatment. Mouse illustration based
on “mouse clip art black and white” from clipartstockphotos.com.
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3.2.2 Tissue Collection
All experimental mice (N=24) were euthanized for tissue collection 1 day after the
last day of heat-treatment. Mice that were subjected to unilateral heating from 3-4
weeks of postnatal age (N=6) were euthanized at the 4 weeks of age endpoint and
those treated from 3-5 weeks of postnatal age (N=18) were euthanized at the 5 weeks
of age endpoint (Fig. 10). It is important to note that although tissues were collected
from mice treated for 7 days from 4-5 weeks of age, only weight gain comparisons are
made from these mice in this study since mice from 3-4 weeks of age grew more rapidly
in comparison. Therefore, mice treated for 7 days from 3-4 weeks of age were
preferable for analysis.
Long bones (femora and humeri) from each side were dissected, cleaned, dried,
and scanned on a flatbed scanner. Proximal tibiae from each hindlimb were dissected,
cleaned and bisected. One unfixed half was arranged on a glass slide and cover-slipped
with glycerol in PBS prepared for tibial elongation rate analysis. The other tibial half was
fixed in 10% neutral buffered formalin for 24 hours, decalcified in 19% EDTA (pH 7.4)
for 1 week, rinsed in PBS, dehydrated in a series of ethanol, cleared in xylene, and
embedded in paraffin. Sagittal sections 6μM thick were cut with a microtome (Leica
RM2125) and mounted on Diamond™ White Glass slides (Globe Scientific) for
histological analysis.

3.2.3 Tibial Elongation Rate Analysis and Long Bone Measurements
A single intraperitoneal injection of oxytetracycline (OTC) (7.5 mg/kg, Norbrook
200 mg/mL) was administered to mice 7 days prior to euthanization and tissue
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collection. Fluorescence was visualized in unfixed slab sections of tibiae using the UV
filter on a fluorescence stereoscope. Measurements collected from scans of femora,
and quantification of tibial elongation rate, were done as described in Chapter 2
(Material and Methods 2.2.5). Images of scanned humeri were also calibrated and
measured in ImageJ, but humeral length was measured as the distance between the
proximal- and distal-most articular ends.

3.2.4 Growth Plate Morphometry
Serial sections of proximal tibiae were deparaffinized in xylene, rehydrated in a
graded series of ethanol, and incubated in Weigert’s hematoxylin for 6 minutes prior to
Safranin-O (0.1%, Sigma)/ fast green (0.01%, Fisher) staining. Stained sections were
dehydrated in graded series of ethanol and xylenes and cover slipped with DPX
(Sigma). Sections were then imaged using Ocular Image Acquisition Software (version
1.05.211) under 20X magnification with a Leica DM2500 optical microscope (Leica
Microsystems, Wetzlar, Germany) fitted with a QImaging Retiga R6 color camera
(QImaging Corporation).
The heights of individual growth plate zones (reserve, proliferative and
hypertrophic) were measured from calibrated images in ImageJ. Measurements were
taken at five different points across the width of the growth plate and the mean was
calculated to represent the height for each zone. Total growth plate height was
determined by the sum of the individual zones. Each individual zone was then
normalized to the total growth plate height to allow comparisons among ages. It is
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important to note that tibiae from mice (N=6) treated for two weeks (N=12) were not
used for histological analysis due to sample loss during tissue processing.

3.2.5 Immunohistochemistry
Serial sections of proximal tibiae from mice treated from 3-4 weeks of age were
stained using a rabbit polyclonal antibody against PCNA (Santa Cruz, sc-7907) at a
dilution of 1:200 (Table 4). Serial sections of proximal tibiae from mice treated 3-5
weeks of age were stained using a monoclonal rabbit antibody against PCNA (Cell
Signalling, #13110) at a dilution of 1:200 after the previously used antibody against
PCNA was discontinued. In both cases, antigen unmasking was accomplished by
incubating slides at 40°C with a pre-warmed sodium citrate buffer (pH 3.5) for 30
minutes followed by a rinse cycle and another incubation at 40°C in a 1:100 dilution of
chondroitinase ABC (Sigma, C2905) for 10 minutes. Endogenous peroxidase activity
was quenched with 3% hydrogen peroxide (H2O2) at room temperature (21°C) for 10
minutes followed by a 1-hour incubation in normal blocking serum. Incubation with the
primary antibody occurred in the humidified chamber at room temperature overnight.
The avidin-biotin complex (ABC) horseradish peroxidase method was then used to
detect positive immunostaining either with the ImmunoCruz rabbit ABC staining system
(Santa Cruz Biotechnology, sc-2018) or the VECTASTAIN Elite ABC-HRP kit (Vector,
Rabbit IgG, PK-6101). Both methods used DAB as the chromagen (Vector, SK-4100)
and all were counterstained with 0.1% methyl green (Sigma), dehydrated and cover
slipped with DPX before allowing to dry overnight prior to imaging.
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Stained sections were imaged using the Leica DM2500 optical microscope as
previously described above. Chondrocytes within the proliferative zone of the proximal
tibial growth plate visualized as dark brown nuclei were manually counted as positively
stained cells for PCNA. Chondrocytes were counted in a 130μM wide sample area (two
per section). This size was chosen because it consistently contained an area of the
growth plate encompassing all zones of chondrocytes to allow comparisons among
samples. The percent of positively stained cells was quantified by dividing the number
of counted positive cells by the total number of chondrocytes within the proliferative
zone.
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Table 4. List of Primary Antibodies and Secondary Antibody Kits Used in the
Study
Length of
Heat-Treatment

1° Ab / 2° Ab Detection Kit

Company

Catalog No.

Dilution

PCNA

Santa Cruz

sc-7907

1:200

IGF1R

Santa Cruz

sc-712

1:200

Phospho-IGF1R

abcam

ab39396

1:100

ImmunoCruz ABC

Santa Cruz

sc-2018

as instructed

PCNA

Cell Signalling

#13110

1:200

IGF1R

abcam

ab131476

1:100

Phospho-IGF1R

abcam

ab39398

1:100

Vectastain Elite ABC

Vector Laboratories

PK-6101

as instructed

7 days
(3-4 weeks of age)

14 days
(3-5 weeks of age)
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3.2.6 Statistical Analysis and Sample Size
Statistical analyses were performed using SPSS 25.0 software (IBM Corporation,
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side
comparisons for humeral length, femoral length, tibial elongation rate, growth plate zone
heights and percent cells positive for PCNA expression were made using one-tailed
paired t-tests. Multiple comparisons made between durations of heat-treatment were
made using a one-way ANOVA with the Tukey post hoc test. Data were reported as
mean ± standard deviation (SD) in tabular format and as mean ± standard error (SE) in
graphical format.
Sample sizes for measurements that are documented as less than the size of the
experimental sample set was a result of either sample loss during dissection or sample
processing. Since left-right comparisons are made, if one side is damaged during
dissection, sample preparation, tissue processing, sectioning or staining, the entire leftright pair is lost. Samples and missing cases were excluded from statistical analysis on
an analysis-by-analysis basis.

3.3 RESULTS
3.3.1 Unilateral Heating Parameters
Mice treated for 7 days from 3-4 weeks of age gained 4.7±0.7g, and mice treated
for 7 days from 4-5 weeks of age gained 1.6±1.0g in mass (Fig. 11). Thus, the largest
growth spurt of experimental mice occurred from 3-4 weeks of age. This growth spurt is
as shown by Hilltop Lab Animals, Inc (“Growth Chart C57BL/6,” 2018) and The Jackson
Laboratory (“Body Weight Information for C57BL/6J,” 2018). Change in mass

71

significantly differed between each experimental group as determined by multiple
comparison analysis using one-way ANOVA and Tukey post hoc test (F(2,21)=53.3,
p<0.01). Therefore, the mice treated for 7 days from 3-4 weeks of age were selected for
analysis instead of the slower growing mice from 4-5 weeks of age.
Mice treated for 14 days from 3-5 weeks of age gained 6.0±0.9g in mass (Fig.
11). This total gain is nearly equivalent to the sum of the mass gained after 7 days of
heating from mice 3-4 weeks and 4-5 weeks of age. The core temperature averaged
36°C during all extents of unilateral heating, consistent with the other limb heating
studies in the previous chapter and those to follow. While anesthetized the average
surface temperature of non-treated hindlimbs was 30°C and the heat-treated hindlimbs
were 40°C for all durations of unilateral heating.
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Figure 11. Majority of Body Mass Gained During 14 Days of Unilateral HeatTreatment Occurs During the First 7 Days
Scatter plots show the change in mass of individual mice treated for (1) 7 days from 3-4
weeks of age (open circles), (2) 7 days from 4-5 weeks of age (gray circles) and (3) 14
days from 3-5 weeks of age (dark gray circles). Significance (p<0.05) in the mean
change in mass between heat-treatment durations is denoted as: a, 3-4 weeks and 4-5
weeks of age; b, 3-4 weeks and 3-5 weeks of age; c, 4-5 weeks and 3-5 weeks of age.
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3.3.2 Bone Length and Tibial Elongation Rate
At experimental end, mice treated for 14 days from 3-5 weeks of age had an
increase in femoral length (paired t=10.1, p<0.001) of 1.1% on the heat-treated side
(Fig. 12A; Table 5). Humeral length did not differ (paired t=1.0, p=0.34) (Table 5). Mice
treated for 7 days from 3-4 weeks of age, femoral length (paired t=4.4, p<0.01)
increased by 1.7% (Fig. 12A, Table 5). Humeral length did not differ (paired t=0.74,
p=0.50) (Table 5). Multiple comparisons by one-way ANOVA with Tukey post hoc tests
showed no significant differences in heat-enhanced femoral length between durations of
treatment (F(1,14)=2.7, ns, p=0.12).
Mice treated for 14 days had a tibial elongation rate of 110±11μM/day on the
non-treated side and 121±11μM/day on the heat-treated side with an increase on the
heat-treated side (paired t=7.8, p<0.001) of nearly 11% (Fig. 12B; Table 5). Mice treated
for 7 days of treatment had a tibial elongation rate of 157±11μM/day on the non-treated
side and 169±13μM/day on the heated side with an increase on the heat-treated side
(paired t=4.6, p<0.01) of nearly 8% (Fig. 12B; Table 5). Multiple comparison analysis by
one-way ANOVA determined no significant differences in heat-enhanced tibial
elongation rate between durations of treatment (F(2,17)=4.74, p<0.05).
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Table 5. Comparison of Non-Treated and Heat-Treated Sides of Saline-Injected
Experimental Mice Bone Parameters.
Parameter

Length of
Heat-Treatment

Non-Treated
(30°C)

Heat-Treated
(40°C)

Percent
Increase

N

7 days

9.27 (0.14)

9.23 (0.20)ns

-0.4

6

10.14 (0.11)

10.15 (0.13)ns

0.1ns

9

10.44 (0.19)

10.62 (0.26)**

1.7

6

12.86 (0.18)

13.00 (0.17)***

1.1ns

9

156.88 (11.24)

168.94 (12.85)**

7.7

5

109.57 (11.18)

121.22 (10.70)***

10.8ns

8

Humeral Length (mm)
(3-4 weeks)

14 days
(3-5 weeks)

Femoral Length (mm)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Tibial Elongation Rate (µM/day)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Values are mean (standard deviation). Length of heat-treatment is in days (age of mice
during treatment). Sample size (N) is number of left-right pairs. Significantly larger on
heat-treated side by one-tailed paired t-test: **p<0.01; ***p<0.001; ns, not significant.
Significant differences in percent increase between durations of heat-treatment by oneway ANOVA: ns, not significant.
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Figure 12. Extremities are Lengthened on the Heat-Treated Side
(A) Error bar plots show percent change in heat-treated limb compared to non-treated
limb. Femoral length increased on the heat-treated side by 1.7% and 1.1% for mice
treated for 7 days (3-4 weeks of age) and 14 days (3-5 weeks of age) respectively. (B)
Tibial elongation rate increased on the heat-treated side by 7.7% and 10.8% after 7
days of heating and 14 days of heating respectively. Mean ± 1 standard error plotted.
**p<0.01; ***p<0.001, significance in left-right comparisons.
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(N=8)(N=8)

3.3.3 Growth Plate Morphometry
Normalized proliferative zone (PZ) height was reduced by 9.0% on the heattreated sides of mice treated for 7 days from 3-4 weeks of age (paired t=10.2, p<0.001),
and 7.3% on the heat-treated sides of mice treated for 14 days from 3-5 weeks of age
(paired t=3.5, p<0.05) (Fig. 13A, C; Table 6). The normalized hypertrophic zone (HZ)
height increased by 8.6% on the heat-treated sides of mice treated for 7 days (paired
t=9.0, p<0.001) and 8.8% on the heat-treated sides of mice treated for 14 days (paired
t=4.2, p<0.05) (Fig. 13B, C; Table 6). There were no significant changes in reserve zone
height (zone of quiescent chondrocytes) at any duration of heat-treatment (paired t=0.0
and 0.6; p=1.00 and 0.59 respective to as reported above). Multiple comparison
analysis by one-way ANOVA determined no significant differences in heat-enhanced PZ
height (F(2,14)=0.84, ns, p=0.46) and HZ height (F(2,14)=0.94, ns, p=0.42) between
durations of heat-treatment.
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Table 6. Comparison of Growth Plate Morphometry between Non-Treated and
Heat-Treated Sides of Saline-Injected Experimental Mice.
Parameter

Length of
Heat-Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

7 days

0.104 (0.015)

0.104 (0.011)ns

0.9

5

0.118 (0.008)

0.114 (0.015)ns

-0.4ns

5

0.450 (0.023)

0.412 (0.019)**

-9.0

5

0.466 (0.039)

0.430 (0.027)*

-7.3ns

5

0.448 (0.026)

0.484 (0.025)**

8.6

5

0.420 (0.032)

0.454 (0.021)*

8.8ns

5

Reserve Zone Height
(Normalized)
(3-4 weeks)

14 days
(3-5 weeks)

Proliferative Zone Height
(Normalized)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Hypertrophic Zone Height
(Normalized)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Values are mean (standard deviation). Length of heat-treatment is in days (age of mice
during treatment). Sample size (N) is number of left-right pairs. Significantly larger on
heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; ***p<0.001; ns, nonsignificant. Significant differences in percent increase between durations of heattreatment by one-way ANOVA: ns, not significant.
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Figure 13. When Normalized to Total Proximal Tibial Growth Plate Height, PZ is
Reduced on the Heat-Treated Side and HZ is Enlarged
(A) Error bar plot shows percent change in heat-treated limb compared to non-treated
limb. Normalized proliferative zone (PZ) height is reduced on the heat-treated side by
9.0% in mice treated for 7 days from 3-4 weeks of age and 7.3% in mice treated for 14
days from 3-5 weeks of age. (B) Normalized hypertrophic zone (HZ) height is enlarged
by 8.6% in mice treated for 7 days from 3-4 weeks of age and 8.8% in mice treated for
14 days from 3-5 weeks of age. (C) Non-treated and heat-treated tibial growth plates
from the same mouse treated from 3-4 weeks of age, stained with Safranin-O/fast green
to distinguish cartilage (red) from bone (green/blue). Arrows indicate the different zones
within the growth plate. The vertical yellow line denotes the PZ while the green line
denotes the HZ. Mean ± 1 standard error plotted.
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3.3.4 PCNA Expression
PCNA expression in chondrocytes of the PZ was increased on the heat-treated
side of mice treated for both 7 days (3-4 weeks of age) and 14 days (3-5 weeks of age)
(Fig. 14). Expression of PCNA increased by 8.6% on the heat-treated side of mice
treated for 7 days from 3-4 weeks of age (paired t=2.7, p<0.05) and 16.7% on the heattreated side when mice were treated for 7 days from 3-5 weeks of age (paired t=2.9,
p<0.05)(Fig. 14A). Multiple comparisons by one-way ANOVA determined no significant
differences between durations of treatment (F(2,16)=2.16, ns, p=0.15).
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Figure 14. Expression of PCNA, Marker for Cell Proliferation, Increased with HeatTreatment in the PZ of the Proximal Tibial Growth Plate
(A) Error bar plot shows percent of chondrocytes positive for PCNA expression on nontreated (open circles) and heat-treated (gray circles) sides. PCNA expression increased
by 8.6% on the heat-treated sides of mice treated for 7 days from 3-4 weeks of age and
increased by 16.7% on the heat-treated sides of mice treated for 14 days from 3-5
weeks of age. (B) Immunoreactivity of PCNA in non-treated and heat-treated proximal
tibial growth plates from the same mouse treated from 3-4 weeks of age. Positive
staining, shown by dark brown nuclei, within the PZ of the growth plate (region between
the double arrows) increases on the heat-treated side by >10%. Mean ± 1 standard
error plotted. *p< 0.05, significance in left-right comparisons.
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3.4 DISCUSSION

The goal of this study was to determine how unilateral heating enhances
longitudinal bone growth at the cellular level. Femoral length (1.7%) and tibial
elongation rate (7.7%) increased on the heat-treated sides of mice treated for 7 days
from 3-4 weeks of age (Fig. 12, Table 5). Chondrocyte proliferation (8.6%) and size of
the hypertrophic zone (8.6%) also increased in these mice (Fig. 13B, 12; Table 6). After
14 days of treatment, femoral length (1.1%) and tibial elongation rate (10.8%) increased
on the heat-treated sides of mice treated 3-5 weeks of age (Fig. 12, Table 5).
Chondrocyte proliferation (16.7%) and size of the hypertrophic zone (8.8%) also
increased in these mice (Fig. 13B, 12; Table 6).
The data supported the hypothesis that there will be a unilateral increase in bone
length associated with increased chondrocyte proliferation and hypertrophic zone
expansion in the growth plate with heat-treatment. Humeral length did not differ
between non-treated and heat-treated sides (Table 5), consistent with previous studies
from our laboratory. The likely explanation is the similarity of humeral skin temperature
to body core temperature accounting for a marginal temperature differential during
treatment (Serrat et al., 2015). Results from Chapter 2 (mice were treated from 3-4
weeks of age) suggest that one week of unilateral heat-treatment can effectively
increase bone length (Fig. 8, Table 3). In this study, two separate age groups (3-4
weeks and 4-5 weeks of age) were chosen for one week of unilateral heat-treatment.
Mice from 3-4 weeks of age gained more mass after 7 days of treatment than the mice
treated from 4-5 weeks (Fig. 11). The growth spurt that occurred when mice were
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treated from 3-4 weeks of age supported the rationale for choosing that age group for
data analysis.
Although the impact of temperature on postnatal longitudinal bone growth has
been documented (Serrat, 2014b), there had been a gap in our understanding of the
kinetics of the growth plate cartilage with heating. This study demonstrated that
longitudinal bone growth is accompanied by increased proliferation and hypertrophic
zone expansion. Increased proliferation may be due to either an increase in
chondrocyte number (not measured in this study), or rate of proliferation (Kember, 1993;
Rolian, 2008). Here we measured proliferation as (PCNA) expression within the
proliferative zone of the growth plate. PCNA immunohistochemistry was chosen over
other methods for analyzing cell proliferation such as bromodeoxyuridine (BrdU),
because PCNA is a less invasive technique and both methods have shown similar
results (Wildemann et al., 2003).
PCNA expression increased on the heat-treated sides at all durations of heattreatment, but trends indicate that proliferation was increased to a larger extent with two
weeks of treatment (Fig. 14). While PCNA expression was exclusively measured in the
proliferative zone of the growth plate, there was observed positive staining in the
hypertrophic zone as well. Other studies have also reported positive staining of PCNA in
the hypertrophic zone of rabbit growth plates (Enishi et al., 2014) and suggest
hypertrophic chondrocytes (more commonly described to undergo programmed cell
death) survive, proliferate and transdifferentiate into bone forming cells (Bahney et al.,
2014; Enishi et al., 2014; Hu et al., 2017; Zhou et al., 2014).
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In addition to hypertrophic zone height, the height of the reserve and proliferative
zones were also analyzed (Table 6). Reserve zone height was unaffected as expected
since chondrocytes in this zone are quiescent and do not participate in bone growth.
Minor differences in total height of the growth plate were seen on heat-treated sides
(data not shown), which is similar to what was observed in a study comparing control(21°C) and warm-housed (27°C) mice (Serrat, 2014b).
Interestingly, the height of the proliferative zone decreased on heat-treated sides
after 7 days (9.0%) and 14 days (7.3%) of unilateral heating (Fig 13A; Table 6). A cause
for the reduced proliferative zone height after heat-treatment may be explained by the
mechanical properties of proliferating chondrocytes. Periods of rapid bone growth are
often accompanied by increased matrix synthesis exerting pressure on the
chondrocytes causing them to flatten (Prein et al., 2016; Walker & Kember, 1972).
Compressed columns of chondrocytes may also be a consequence of the expanding
hypertrophic zone. Therefore, a shortened proliferative zone height does not necessarily
reflect decreased proliferation, but a more compressed region of cells. However, to
show the cells are compressed would involve comparing numbers of chondrocytes in
the proliferative zone between growth plates of non-treated and heat-treated limbs (not
done in this study). Another possibility for a shortened proliferative zone height may be
due to heat-induced changes to Indian hedgehog (Ihh)/parathyroid hormone-related
protein (PTHrP) negative feedback mechanisms that control the transition from
proliferative, to hypertrophic chondrocytes. Downregulation of Ihh/PTHrP (maintains
chondrocyte proliferation, and delays chondrocyte hypertrophy) would promote cell
differentiation and leads to faster turnover to hypertrophic chondrocytes (van der
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Eerden et al., 2003; Kronenberg, 2003; Wang et al., 2011). As an example, IGF1 has an
important role in downregulating PTHrP to promote chondrocyte differentiation (Wang et
al., 2011).
Limitations of this study include the sample size for heat-treatment. While power
analysis indicates 6 animals to be a sufficient effect size, it can be difficult to attain this
number because of the laborious nature of the experiments. Our studies focus on leftright differences after unilateral heat-treatment, and thus consistent collection of
samples from both sides of the animal is necessary. If one side is damaged during
dissection, sample preparation, tissue processing, sectioning or staining, the entire leftright pair is lost. Left-right comparisons also limit the ability to collect the same samples
for a variety of analyses. For example, since both left and right femora are needed to
make left-right length comparisons, they cannot also be used for histological analysis.
The rationale for selecting the proximal tibia for growth rate and histological analysis is
because the proximal tibia contributes most to tibial lengthening compared to the distal
end (as discussed in Chapter 1, Section 1.1.2) (J. Bisgard & M. Bisgard, 1935; Farnum,
2007; Kember, 1972; Pritchett, 1992; Raimann et al., 2017; Rolian, 2008; Serrat et al.,
2007; Wilsman et al., 1996a, 1996b, 2008). The growth plate of the proximal tibia also
has been shown to have a higher rate of cell division and hypertrophy compared to sites
of other long bones including that of the distal femur (Rolian, 2008).

3.5 CONCLUSION
In conclusion, evidence supports the hypothesis that there will be a unilateral
increase in bone length associated with increased chondrocyte proliferation and
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hypertrophic zone expansion in the growth plate with heat-treatment. The hypothesis
was supported by results from mice treated for 7 days (3-4 weeks of age) and 14 days
(3-5 weeks of age). This study demonstrated that investigating morphological changes
in the growth plate is a means to assess heat-enhanced bone elongation. Future
studies will determine how targeted limb heating affects the activity of insulin-like growth
factor I (IGF1), the major growth factor that regulates longitudinal bone growth.
Improving and understanding the methods for using targeted limb heating to enhance
bone elongation is important for developing a noninvasive alternative for treatment of
limb lengthening disorders in children.
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CHAPTER IV: SUBCUTANEOUS INJECTIONS OF LOW DOSE IGF1 IN
CONJUNCTION WITH TARGETED LIMB HEATING CAN AUGMENT HEATENHANCED BONE GROWTH

4.1 INTRODUCTION
The GH/IGF1 axis has been extensively studied and is often described as the
major control system of postnatal growth and development (Le Roith et al., 2001;
Woodall, Breier, O’Sullivan, & Gluckman, 1991) particularly of skeletal growth (Isgaard,
Nilsson, Lindahl, Jansson, & Isaksson, 1986; Hunziker et al., 1994a; Lindsey & Mohan,
2016; Lupu et al., 2001; Mohan et al., 2003; Oberbauer & Peng, 1995; Yakar &
Isaksson, 2016; Wu et al., 2015). This anabolic axis involves the dependent and
independent relationship between GH and IGF1 and their associated factors in
regulating linear growth in both an endocrine and paracrine/autocrine manner. Severe
growth retardation observed in double Ghr/Igf1 mutant mice supports that both GH and
IGF1 are essential for linear growth (Lupu et al., 2001). However, IGF1 is a critical part
of this axis because there is greater linear growth defects without the action of IGF1
(Baker et al., 1993; Bikle et al., 2001; Liu et al., 1993; Mohan et al., 2003; PowellBraxton et al., 1993; Wang et al., 2006) compared to when GH action is impaired
(Kasukawa, Baylink, Guo, & Mohan, 2003; Mohan et al., 2003). It has been reported
that 83% of postnatal growth is dependent on the GH/IGF1 system and 69% of that
dependent on IGF1 (Ciarmatori, Kiepe, Haarmann, Huegel, & Tönshoff, 2007). While
studies have shown that postnatal growth can occur absent circulating levels of IGF1
(Fan et al., 2009; Sjögren et al., 1999; Ueki et al., 2000; Yakar et al., 1999, 2002; Yakar
& Isaksson, 2016), disruptions in local IGF1 impair longitudinal bone growth (Govoni et
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al., 2007a,b; Sheng, Zhou, Bonewald, Baylink, & Lau, 2013; Wang et al., 2011; Yakar,
Courthland, & Clemmons, 2010; Yakar & Isaksson, 2016).
Administration of GH and IGF1 has been used for treatment of stunted linear
growth. GH therapy is more commonly used in clinical settings to treat short stature
(Ohlsson et al., 1998; Pfäffle, 2015; Wit & Oostdijk, 2015) such as those resulting from
GH deficiency or other chromosomal and genetic syndromes (Harada et al., 2017; Moix
et al., 2018; Noonan & Kappelgaard, 2015; Pfäffle, 2015; Ranke, 1995a, Tritos &
Klibanski, 2016; Wit & Oostdijk, 2015). IGF1 is not as commonly used because of the
adverse effects associated with increased serum IGF1 (such as hypoglycemia) during
treatment (Clemmons, 2004; Guevara-Aguirre et al., 1997; Laron & Klinger, 2000;
Lindsey & Mohan, 2016; Ross et al., 2015). However, long-term treatment with IGF1
has been shown to effectively reverse skeletal growth discrepancies (Azcona et al.,
1999; Backeljauw et al., 2013; Chernausek et al., 2007; Laron & Klinger, 2000; Laron,
2001; Laron & Kauli, 2015b; Lupu et al., 2001; Midyett et al., 2010; Ranke et al., 1995b,
1999; Sims et al., 2000).
It is clear that IGF1 has an essential role in longitudinal growth. Without the
action of IGF1, if survived past birth, there is a reported 70% reduction in body size and
40% reduction in linear bone growth (Liu et al., 1993; Mohan et al., 2003; PowellBraxton et al., 1993; J. Wang et al., 1999; Y. Wang et al., 2006; Yakar & Isaksson,
2016). Studies have used IGF1 to enhance linear growth in various animal models. It
has been shown that IGF1 administered through local administration directly into the
growth plate has significantly increased bone length (Isgaard et al., 1986). Since
targeted heat can increase vascular supply to the growth plate (Chapter 1, Section
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1.6.2), the goal of this study was to use unilateral limb heating as a method to target a
low dose of IGF1 administered subcutaneously once daily to the growth plate on the
heat-treated side. This study tests the hypothesis that IGF1 administration with
heat-treatment will further enhance limb length than with heat alone. Published
studies are still ongoing to optimize IGF1 therapy in children without complications
(Hansen-Pupp et al., 2017). Using limb heating to target once daily, low doses of IGF1
only to sites of longitudinal bone growth would improve current IGF-based therapies for
children by enhancing limb elongation without the negative side effects.

4.2 MATERIAL AND METHODS
4.2.1 Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=32) mice were
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 (N=12) and 28
(N=24) days weaning age. Mice were singly housed at 21°C in standard plastic caging,
exposed to a 12 hour light/dark cycle and provided with food and water ad libitum.
As described in the previous chapters and as indicated by the unilateral heating
methods schematic (Fig. 15), mice were subjected to same procedural conditions. Mice
were treated for 7 days from 3-4 weeks of age and for 14 days 3-5 weeks of age. Mice
were weighed each day and given subcutaneous injections of IGF1 (2.5mg/kg;
Peptrotech). IGF1 injections were administered daily at the start of the light cycle one
hour prior to heat-treatment for 7 days (N=6) and 14 days (N=12). IGF1 has been
administered subcutaneously anywhere from once daily, to continuously, in other animal
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studies at a dosage range of 2-6 mg/kg (Ding, List, Bower, & Kopchick, 2011; Lynch,
Cuffe, Plant, & Gregorevic, 2001; Sims et al., 2000; Woodall et al., 1991). Therefore, the
selected dose of 2.5 mg/kg administered once daily is considered low in comparison.
While IGF1-injected twice a day may be more effective at promoting overall growth, this
study aimed to target a small dose of IGF1 unilaterally using warm temperature without
subsequent systemic effects. The timing of injections was also deliberate because peak
IGF1 in circulation is approximately one hour after subcutaneous injections (Woodall et
al., 1991) and study intended to time the peak of IGF1 with heat-treatment. Left-right
comparisons in IGF1-injected mice were made to the saline-injected control mice
treated for 7 days from 3-4 weeks of age (N=6) and 14 days from 3-5 weeks of age
(N=12) as discussed in Chapter 3.
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Figure 15. Unilateral Heating Schematic
Mice were injected subcutaneously (SQ) with IGF1 (2.5mg/kg) one hour prior to
treatment of 40°C unilateral heat for 40 minutes daily for 7 days from 3-4 weeks of age
or 14 days from 3-5 weeks of age. Euthanasia and tissue collection occurred 1 day after
the last day of heat-treatment. Mouse illustration based on “mouse clip art black and
white” from clipartstockphotos.com.
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4.2.2 Tissue Collection and Sample Analysis
Long bones (femora and humeri) were collected and measured as described in
Chapter 3 (Sections 3.2.2 and 3.2.3). Proximal tibial halves from each hindlimb were
collected (Section 3.2.2) for tibial elongation rate analysis (Section 3.2.3) and growth
plate morphometry (Sections 3.2.4) following methods described in Chapter 3.

4.2.3 Immunohistochemistry
Serial sections of proximal tibiae from mice subjected to 7 days (N=12, 6 per
saline control and IGF1) and 14 days (N=12, 6 per saline control and IGF1) of unilateral
heating were stained using rabbit polyclonal antibodies against PCNA following
methods as described in Chapter 3 (Section 3.2.5). Rabbit polyclonal antibodies against
IGF1R and phospho-IGF1R (phospho-Y1161) were also used to assess IGF1 activity in
the PZ of growth plates following the same methods. Analysis focused on the
proliferative zone (PZ) specifically as the site of actively proliferating chondrocytes to
determine the heat-enhanced effect in conjunction with IGF1 administration.

4.2.4 Statistical Analysis and Sample Size
Statistical analyses were performed using SPSS 25.0 software (IBM
Corporation, Armonk, NY) with p<0.05 as accepted significance. Non-treated and heattreated side comparisons for humeral length, femoral length, tibial elongation rate,
growth plate zone heights, and percent cells positive for protein expression were made
using one-tailed paired t-tests. Multiple comparisons made between saline controls and
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IGF1-injected mice were made using a one-way ANOVA. Data were reported as mean
± standard deviation (SD) in tabular format and as mean ± standard error (SE) in
graphical format.
Sample sizes for measurements that are documented as less than the size of the
experimental sample set was a result of either sample loss during dissection or sample
processing. Since left-right comparisons are made, if one side is damaged during
dissection, sample preparation, tissue processing, sectioning or staining, the entire leftright pair is lost. Samples and missing cases were excluded from statistical analysis on
an analysis-by-analysis basis.

4.3 RESULTS
4.3.1 Unilateral Heating Parameters
IGF1-injected mice treated for 7 days from 3-4 weeks of age gained 5.1±0.5g
while saline control mice (established in Chapter 3) gained 4.7±0.7g (Fig. 16A). IGF1injected mice treated for 14 days from 3-5 weeks of age gained 6.4±0.8g while saline
control mice (also established in Chapter 3) gained 6.0±0.9g (Fig. 16B). There was no
significant difference in the amount of mass gained between saline and IGF1-injected
mice after 7 days (F(1,11)=1.4, ns, p=0.27) or 14 days (F(1,23)=0.9, ns, p=0.35) of limb
heating. The core temperature averaged 36°C during all extents of unilateral heating.
During the duration mice were anesthetized, the average surface temperature of nontreated hindlimbs was 30°C and the heat-treated hindlimbs were 40°C, consistent with
parameters during the daily limb heating reported in previous chapters. At the end of
each daily heat-treatment (40mins), the average time for saline control mice to recover
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from anesthesia after 7 days and 14 days of heating was 1.6±0.33mins and
1.5±0.37mins respectively. The average time for IGF1-injected mice to recover from
anesthesia was 3.3±0.79mins and 3.0±0.80mins, which was significantly longer than the
saline controls after both 7 days (F(1,11)=22.35, p<0.001) and 14 days (F(1,23)=31.5,
p<0.001) of unilateral heating.
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Figure 16. Overall Change in Mass was not Impacted by IGF1 Injections at Either
Length of Heat-Treatment
(A) Scatter plots show the change in mass of individual mice after 7 days of heattreatment from 3-4 weeks of age. Saline control mice (open circles) gained an average
of 4.7g and IGF1-injected mice (gray circles) gained an average of 5.1g. (B) Scatter
plots show the change in mass of individual mice after 14 days of heat-treatment from
3-5 weeks of age. Saline control mice gained 6.0g and IGF1-injected mice gained 6.4g.
Significance (p<0.05) is the mean change in mass between injections. One-way ANOVA
indicated no significant difference in overall gain in mass between saline control and
IGF1-injected mice with either length of heat-treatment.
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4.3.2 Length of Long Bones and Tibial Elongation Rate
Femoral length of IGF1-injected mice treated for 7 days increased on the heattreated sides by 1.7% (paired t=3.8, p<0.05) (Fig. 17A(a), Table 7). Femoral length of
IGF1-injected mice treated for 14 days increased by 1.9% (paired t=7.6, p<0.001) on
the heat-treated sides (Fig. 17B(a); Table 7). Compared to saline controls (Chapter 3;
Fig. 12A, Table 5), the heat-induced increase in femoral length of IGF1-injected mice
(1.7%) treated for 7 days was equivalent to that of the controls. However, femoral length
of IGF1-injected mice (1.9%) treated for 14 days was significantly greater (F(1,20)=6.3,
p<0.05) than that of the saline controls (1.1%) as determined by one-way ANOVA.
Humeral length did not differ between non-treated and heat-treated sides in
saline control mice as shown in Chapter 3 (Table 5). Humeral length of IGF1-injected
mice treated for 7 days also did not differ (paired t=1.4, ns, p=0.23). However, there was
a slight 0.7% increase in humeral length on the heat-treated side of IGF1-injected mice
treated for 14 days (paired t=3.6, p<0.05), which was significantly greater (F(1,20)=6.5,
p<0.05) than saline mice as determined by one-way ANOVA.
Tibial elongation rate of IGF1-injected mice treated for 7 days increased on the
heat-treated side by 7.3% (paired t=2.9, p<0.05) (Fig. 17A(b), Table 7). Tibial elongation
rate of IGF1-injected mice treated for 14 days increased by 18.7% (paired t=7.2,
p<0.001) on the heat-treated side (Fig. 17B(b), Table 7). Compared to saline controls
(Chapter 3; Fig. 12B, Table 5), the heat-induced increase in tibial elongation rate of
IGF1-injected mice (7.3%) treated for 7 days was not greater than the controls (7.7%)
as determined by one-way ANOVA (F(1,9)=0.02, ns, p=0.89). However, tibial elongation
rate of IGF1-injected mice (18.7%) treated for 14 days was significantly greater
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(F(1,18)=5.3, p<0.05) than that of the saline controls (10.8%) as determined by one-way
ANOVA. Together, left-right comparisons of femoral and humeral length, as well as
tibial elongation rate, indicate that injections of low dose IGF1 further enhances heat
induced limb elongation only after mice are treated for 14 days from 3-5 weeks of age.
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Table 7. Comparison of Non-Treated and Heat-Treated Sides of IGF1-Injected
Experimental Mice Bone Parameters.
Parameter

Length of
Heat-Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

7 days

9.31 (0.23)

9.27 (0.19)ns

-0.4

6

10.29 (0.15)

10.36 (0.16)***

0.7

12

10.51 (0.20)

10.68 (0.28)*

1.7

6

12.86 (0.18)

13.10 (0.22)***

1.9

12

157.51 (6.16)

168.85 (8.93)*

7.3

5

103.38 (9.43)

122.32 (11.61)***

18.7

11

Humeral Length (mm)
(3-4 weeks)

14 days
(3-5 weeks)

Femoral Length (mm)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Tibial Elongation Rate (µM/day)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; ***p<0.001;
ns, non-significant.
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Figure 17. Extremities are Lengthened on the Heat-Treated Sides when Injected
with Saline and IGF1
(A) Error bar plots compare saline- and IGF1-injected mice treated for 7 days (3-4
weeks of age) and shows percent change in heat-treated limb compared to non-treated
limb. (a) Femoral length increased by 1.7% on the heat-treated sides of both saline and
IGF1-injected mice (b) Tibial elongation rate increased by 7.7% and 7.3% on the heattreated sides of saline and IGF1-injected mice. (B) Error bar plots compare saline- and
IGF1-injected mice treated for 14 days (3-5 weeks of age). (a) Femoral length increased
by 1.1% and 1.9% on the heat-treated side of saline and IGF1-injected mice. (b) Tibial
elongation rate increased by 10.8% and 18.7% on the heat-treated side of saline and
IGF1-injected mice. Mean ± 1 standard error plotted. *p< 0.05; **p<0.01; ***p<0.001,
significance in left-right comparisons; #p<0.05 comparing % change in saline control and
IGF1-injected mice.
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4.3.3 Growth Plate Morphometry
The height of the PZ normalized to total growth plate height was significantly
reduced by 9.0% on the heat-treated sides of saline control mice (Chapter 3; Fig. 13A,
C; Table 6) and by 5.9% on the heat-treated sides of IGF1-injected mice (paired t=2.6,
ns, p=0.059) treated for 7 days (Fig. 18A(a), Table 8). The height of the PZ was reduced
by 7.3% on the heat-treated sides of saline mice (Chapter 3; Fig. 13A, C; Table 6) and
by 7.8% on heat-treated sides of IGF1-injected mice (paired t=3.7, p<0.05) treated for
14 days (Fig. 18B(a), Table 8).
The height of the hypertrophic zone (HZ) normalized to the total growth plate
height was significantly enlarged by 8.6% on the heat-treated sides of saline control
mice (Chapter 3; Fig. 13B, C; Table 6) and by 5.3% on the heat-treated sides of IGF1injected mice (paired t=5.1, p<0.01) treated for 7 days (Fig. 18A(b), Table 8). The
expansion in the HZ height observed in IGF1-injected mice (5.3%) was significantly less
than that of the controls (8.6%) as determined by one-way ANOVA (F(1,9)=7.8, p<0.05).
The height of the HZ expanded by 8.8% on the heat-treated sides of saline mice
(Chapter 3; Fig. 13B, C; Table 6) and by 9.4% of IGF1-injected mice (paired t=4.4,
p<0.05) treated for 14 days (Fig. 18B(b), Table 8). Overall, PZ and HZ height was
comparable between saline and IGF1-injected mice. However, the left-right differences
in zonal height were greater in saline mice treated for 7 days.
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Table 8. Comparison of Growth Plate Morphometry Between Non-Treated and
Heat-Treated Sides of IGF1-Injected Experimental Mice.
Parameter

Length of
Heat-Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

7 days

0.104 (0.019)

0.106 (0.011)ns

5.7

5

0.138 (0.011)

0.134 (0.011)ns

-1.0

5

0.450 (0.029)

0.422 (0.028)ns

-5.9

5

0.460 (0.010)

0.426 (0.023)*

-7.8

5

0.448 (0.023)

0.474 (0.031)**

5.3

5

0.404 (0.022)

0.442 (0.031)*

9.4

5

Resting Zone Height
(Normalized)
(3-4 weeks)

14 days
(3-5 weeks)

Proliferative Zone Height
(Normalized)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Hypertrophic Zone Height
(Normalized)
7 days
(3-4 weeks)

14 days
(3-5 weeks)

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01;
***p<0.001; ns, non-significant.
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Figure 18. Proximal Tibial Growth Plate Morphometry After Administration of Low
Dose IGF1 with Targeted Heating
(A) Error bar plots compare growth plate (GP) morphometry of mice treated for 7 days
and shows percent change in heat-treated limb compared to non-treated limb. (a)
Proliferative zone (PZ) height decreased by 9.0% and 5.9% on heat-treated sides of
saline control and IGF1-injected mice respectively. (b) Hypertrophic zone (HZ) height
increased by 8.6% and 5.3% in saline and IGF1-injected mice. (B) Error bar plots
compare GP morphometry of mice after 14 days of treatment. (a) PZ height decreased
by 7.3% and 7.8% in saline and IGF1-injected mice (b) HZ height increased by 8.8%
and 9.4% in saline and IGF1-injected mice. Mean ± 1 standard error plotted. *p< 0.05;
**p<0.01; ***p<0.001, significance in left-right comparisons; #p<0.05 comparing %
change in IGF1-injected mice with saline controls.
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4.3.4 PCNA Expression
In saline control mice treated for 7 days, the percent of chondrocytes positive for
PCNA in the PZ was 85.1± 6.9% on the non-treated sides, and 91.9±2.0% on the heattreated sides for an 8.6% increase in expression (Chapter 3; Fig. 14). Chondrocytes in
the PZ of IGF1-injected mice were positive for a lesser 79.3±4.6% on non-treated sides
and 83.3±4.4% on the heat-treated sides for a 5.0% increase in PCNA expression
(paired t=3.5, p<0.05) on the heat-treated side (Fig. 19A). In saline mice treated for 14
days, chondrocytes were positive for PCNA in 77.6±11.5% and 89.3±4.5% on the nontreated and heat-treated sides respectively for an increase of 16.7% (Chapter 3; Fig.
14). Chondrocytes in the PZ of IGF1-injected mice were positive for 84.9±4.5% and
93.2±3.9% PCNA on the non-treated and heat-treated sides respectively for an increase
of 9.9% (paired t=5.1, p<0.01) on the heat-treated side (Fig. 19B). There were no
significant differences in the heat-induced increase in PCNA expression between saline
and IGF1-injected mice treated for 7 day days (F(1,10)=0.7, ns, p=0.43) and 14 days
(F(1,9)=1.0, ns, p=0.34).

103

0.4

**

p<0.01

0.3

(b)

0.2

PCNA
100

*

90

*

p<0.05

80

p<0.05

70
60

Non-Treated
0.5
Heat-Treated

50
40

*

SALINE

p<0.05(N=5)

*
p<0.05

Injection

Non-Treated

0.0

1 Week
2 Weeks
1 Week
(3-4wks of age) (4-5wks of age) (3-5wks of age)
(N=5)

IGF1

(N=5)

**

0.4

p<0.01

0.3

(N=6)

Length of Heat-Treatment

100

PCNA
**

*

90

p<0.01

p<0.05

80
70
60

Non-Treated
Heat-Treated

50
40

*

SALINE

p<0.05 (N=5)

*

IGF1

p<0.05

Injection

(N=5)

(b)
Heat-Treated

Non-Treated

Heat-Treated
0.2

0.1

(N=5)

14 days of heat-treatment

(a)

PZ height normalized to total height

% positive cells in the PZ

PZ height normalized to total height

(a)

0.5

B

7 days of heat-treatment

% positive cells in the PZ

A

0.1
0.0

<<

1 Week
2 Weeks
1 Week
(3-4wks of age) (4-5wks of age) (3-5wks of age)
(N=5)

(N=5)

<<

(N=6)

Length of Heat-Treatment

<<

<<

Figure 19. Expression of PCNA in the PZ of Proximal Tibial Growth Plates After
Administration of Low Dose IGF1 with Targeted Heating
(A) PCNA expression in mice treated for 7 days (a) Error bar plots show percent of
chondrocytes positive for PCNA expression on non-treated (open circles) and heattreated (gray circles) sides. PCNA expression increased by 8.6% and 5.0% on the heattreated sides of saline and IGF1-injected mice respectively. (b) Left-right comparison of
proximal tibial growth plates from an IGF1-injected mouse immunostained for PCNA. A
larger quantity of PCNA staining was counted on heat-treated sides. Positive staining is
shown by dark brown nuclei within the PZ of the growth plate (region between the
double arrows). (B) PCNA expression in mice treated for 14 days (a) Error bar plot
shows a 16.7% and 9.9% increase in saline and IGF1-injected mice. (b) Left-right
comparison of proximal tibial growth plate from an IGF1-injected mouse immunostained
for PCNA. There was more PCNA staining on heat-treated sides.
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4.3.5 IGF1R and pIGF1R Expression in Proliferating Chondrocytes
IGF1R expression in the PZ of mice treated for 7 days increased by 14.5%
(paired t=3.2, p<0.05) and 7.7% (paired t=2.39, ns, p=0.076) on the heat-treated sides
of saline control and IGF1-injected mice respectively (Fig. 20A(a), Table 9). This
increase of IGF1R expression on the heat-treated sides of IGF1-injected mice was 2fold less compared to the saline mice (F(2,15)=26.6, p<0.001). Activation of the IGF1R,
assessed by pIGF1R expression in the PZ, increased by 7.7% (paired t=5.3, p<0.01)
and 28.2% (paired t=3.5, p<0.05) on the heat-treated sides of saline and IGF1-injected
mice respectively (Fig. 20A(b), Table 9). This increase of pIGF1R expression on the
heat-treated sides of IGF1-injected mice was over 3-fold more compared to the saline
(F(2,15)=16.8, p<0.001). Therefore, even though IGF1-injected mice had less of a heatinduced increase in IGF1R expression, there was a greater increase in activation of
these receptors compared to saline controls.
IGF1R expression in the PZ of mice treated for 14 days increased by 37.6%
(paired t=6.1, p<0.01) and 30.8% (paired t=3.5, p<0.05) on the heat-treated side of
saline and IGF1-injected mice respectively (Fig. 20B(a), Table 9). Differences were
comparable between saline and IGF1-injected mice (F(1,7)=0.16, ns, p=0.70).
Expression of pIGF1R increased by 23.9% (paired t=5.2, p<0.01) and 25.4% (paired t=
6.3, p<0.01) on the heat-treated sides of saline and IGF1-injected mice respectively
(Fig. 20B(b), Table 9). Differences were comparable between the injection groups
(F(1,7)=0.03, ns, p=0.86).
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Table 9. Comparison of Non-Treated and Heat-Treated Expression of Markers for
IGF1 Activation in Proliferative Zone of Tibial Growth Plates in Saline and IGF1Injected Mice.
Length of
Heat-Treatment

Antibody in
Proliferative Zone

Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

7 days
(3-4 weeks)

IGF1R expression
Saline

69.68 (6.36)

79.52 (7.61)*

14.5

5

IGF1

72.10 (11.87)

75.70 (11.63)ns

7.7#

5

Saline

84.85 (10.36)

90.97 (7.90)**

7.7

6

IGF1

62.44 (8.74)

78.72 (4.09)*

28.2#

5

Saline

37.98 (11.24)

51.03 (11.44)**

37.6

4

IGF1

47.40 (22.22)

57.93 (17.43)*

30.8ns

4

Saline

59.28 (9.40)

72.48 (4.84)*

23.9

4

IGF1

47.70 (4.13)

59.85 (6.94)**

25.4ns

4

pIGF1R expression

14 days
(3-5 weeks)

IGF1R expression

pIGF1R expression

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01;
ns, non-significant. Significant differences in percent increase between saline controls
and IGF1-injected mice by one-way ANOVA: #p<0.05; ns, non-significant.
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Figure 20. Heat-Induced Effect on IGF1 Activity in the PZ of the Tibial Growth
Plate with IGF1 Administration
(A) Expression in saline control and IGF1-injected mice with 7 days of unilateral heating.
(a) Error bar plot shows percent change in heat-treated limb compared to non-treated
limb. IGF1R expression increased by 14.5% and 7.7% in the PZ on the heat-treated
side of saline and IGF1-injected mice. (b) pIGF1R expression in the PZ increased by
7.7% and 28.2% of saline and IGF1-injected mice. (B) Expression in saline and IGF1injected mice with 14 days of heating. (a) IGF1R expression in the PZ increased by
37.6% and 30.5% in saline and IGF1-injected mice. (b) pIGF1R expression in the PZ
increased by 23.9% and 25.4% in saline and IGF1-injected mice. Mean ± 1 standard
error plotted. *p< 0.05; **p<0.01; ns, significance in left-right comparisons; #p<0.05
comparing % change in IGF1-injected mice with saline controls.
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4.4 DISCUSSION
Previous chapters have established that in a group of saline control mice,
targeted limb heating can enhance longitudinal growth on the heat-treated sides after
both 7 days (shown in Chapters 2 and 3) and 14 days of heating (Chapter 3). Heatenhanced limb elongation was shown with unilateral increases in femoral length, tibial
elongation rate, chondrocyte proliferation and hypertrophic expansion in proximal tibial
growth plates. The goal of this study was to determine if targeted limb heating in
conjunction with the administration of a low dose of the growth-promoting drug IGF1
would further enhance bone elongation without impacting overall physiology. Results of
the current study show that there was an additional heat-enhanced increase in femoral
length and tibial elongation rate in IGF1-injected mice. There was also a greater rate of
proliferation and hypertrophic zone expansion on heat-treated sides compared to saline
controls. Data supported the hypothesis that IGF1 administration with heat-treatment
will further enhance limb length than with heat alone.
Both saline and IGF1-injected mice had similar recorded core temperatures and
surface limb temperatures. While mice have been shown to demonstrate weight gain
with increased serum levels of IGF1 (D’Ercole,1993; Mathews et al., 1988; Woodall et
al., 1991; Yakar & Isaksson, 2016), overall gain in mass did not differ between saline
and IGF1-injected mice (Fig. 16). Livers collected and weighed from both saline and
IGF1-injected mice (data not shown) also were comparable between saline and IGF1injected mice treated for 7 days (p=0.49) and 14 days (p=0.68). Similar liver mass
between saline and IGF1-injected mice was not unexpected, as the stimulatory effect of
GH on the liver has been shown to be independent of IGF1 (Blutke et al., 2014).
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Comparable weights between treatment groups further supported the rationale to use a
low dose of IGF1.
An interesting observation during the unilateral heating regimen was the
differential anesthesia recovery time between the saline controls and IGF1 mice. The
mice injected with IGF1 took on average twice as long to wake up from the anesthesia
than the saline controls which was observed throughout the duration of both the 7 days
and 14 days of heating. Anesthesia recovery is a concern for patients with pituitary
disease (Menon, Murphy, & Lindley, 2011) including those with acromegaly (excess
GH, normal to high IGF1). Acromegaly presents a variety of challenges for general
anesthesia including prolonged awakening associated with obstructed airways (Chung
& Mokhlesi, 2014) common in these patients (Menon et al., 2011). While recovery time
with IGF1 has not been previously reported in the literature, other drugs including
caffeine (Fong et al., 2017; Wang, Fong, Mason, Fox, & Xie, 2014) have been shown to
accelerate recovery from anesthesia by facilitating neurotransmitter release. Since IGF1
has been shown to cross the blood-brain barrier (Pan & Kastin, 2000; Yan et al., 2011),
it is likely prolonged anesthesia recovery as an outcome of IGF1 administration could be
explained by IGF1 regulation in the brain. Since other tissues, including the brain, were
not examined in this study the cause of extended recover time with IGF1 remains
unknown. However, this finding aided to support if IGF1 administration was successful
throughout the duration of heat-treatment.
While not intended to be an indicator of effective IGF1 treatment, comparing
wake up times was a useful method throughout experimentation. These observations
were not supported by other means of confirming successful IGF1 administration, such
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as measuring levels of IGF1 or glucose in the blood following injections. Assays for
serum IGF1 require a considerable volume of blood that could not be collected daily
since mice are very small in size and to collect a sufficient volume of blood would
require animal sacrifice. A smaller volume of blood is needed to measure serum
glucose and lower levels of glucose would be indicative of increased serum IGF1
(Clemmons, 2004). However, to obtain even a small amount of blood from experimental
mice would cause a degree of stress to the animals, potentially interfering with the
results of heat-treatment. Since low levels of glucose, or hypoglycemia, is associated
with increased levels of IGF1, mice were monitored during the first couple days of
treatment. While uncommon, there were cases when mice required glucose injections
(15% glucose solution, 0.01mL per gram body weight) when demonstrating adverse
signs of IGF1 administration following heat-treatment (nonappearance of anesthesia
recovery and labored breathing). Hypoglycemia was another physiological response
indicative to increased levels of IGF1.
Outcome variables showed that with 7 days of unilateral heating, there was
almost a 2% increase in femoral length in both saline control and IGF1-injected mice
(Fig. 17A(a), Table 7). After 14 days of heating, femoral length increased by just over
1% on the heat-treated sides of saline controls but femora were almost 2% longer on
the heat-treated sides of IGF1-injected mice (Fig. 17B(a), Table 7). Tibial elongation
rate after 7 days of heating was also comparable between saline control and IGF1 mice
with a heat-induced increase of over 7% (Fig. 17A(b), Table 7). After 14 days of heating
the increase in tibial elongation rate on the heat-treated side was almost 19% with IGF1
administration, 2.5-fold greater than the over 7% increase observed in saline controls
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(Fig. 17B(b), Table 7). While both femoral length and tibial elongation rate significantly
increased with targeted limb heating, further enhancement with IGF1 was only apparent
with 14 days of heating.
In Chapter 3, longitudinal growth was assessed on the cellular level by amount of
proliferation and hypertrophy in proximal tibial growth plates. Increased femoral length
and tibial elongation rate were accompanied by increased PCNA expression in
proliferating chondrocytes and expanded heights of the hypertrophic zone. In this study,
when mice were administered IGF1, there was a significant 5.0% and 9.9% increase in
PCNA expression on the heat-treated sides after 7 days and 14 days of heating
respectively (Fig. 19). These increased levels of expression were not significantly
greater than that of saline controls. However, trends in overall PCNA expression
suggest an increased rate in proliferation when IGF1-injected mice were treated for 14
days. Longitudinal bone growth gradually slows with age and can be associated with a
decline in proliferation and hypertrophic zone height (Forcinito et al., 2011; Lui et al.,
2011; Nilsson & Baron, 2004; Nilsson et al. 2014; Walker & Kember, 1972). While
comparisons were not made between treatment durations in this study, marginal
differences can be seen. Overall PCNA expression in the PZ decreased in saline mice
treated for 14 days from 3-5 weeks of age (older) compared to expression in mice
treated for 7 days from 3-4 weeks of age (younger) (Fig. 19). However, overall PCNA
expression increased in IGF1-injected mice treated for 14 days compared to 7 days
which indicates that although the left-right comparisons in PCNA expression levels were
similar between saline and IGF1-injected mice at both durations, there was a higher rate
of proliferation when IGF1-injected mice were treated for 14 days. However, since
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observations are made from trends in overall PCNA expression (not between nontreated and heat-treated sides), further analysis is required to determine if the increased
rates in proliferation in IGF1-injected mice are results of targeted limb heating.
Hypertrophic zone expansion was significantly increased by 5% and 9% on the
heat-treated sides of IGF1-injected mice after 7 days and 14 days of unilateral heattreatment respectively (Fig. 18A(b), B(b); Table 8). Again, while there was still a heatinduced increase in expansion, the increase was not beyond that of saline controls. The
increase in hypertrophic height in IGF1-injected mice was a significant 3% less than the
saline mice after 7 days of heating, and comparable after 14 days of heating. Similar to
the trends observed when comparing heat-treatment duration of expression of PCNA,
IGF1-injected mice after 14 days of treatment displayed a greater difference in height of
the hypertrophic zone compared to those treated for 7 days (Fig. 18).
Multiple explanations are possible to rationalize why extremity lengthening is
similar between saline control and IGF1-injected mice with 7 days of heating, yet IGF1
further increases lengthening with 14 of heating. All possibilities require further
investigation before determining the contributing factor(s). In normal physiological
conditions, IGF1 levels decline after birth then increase during the early rapid stages of
postnatal growth (Daughaday, Parker, Borowsky, Trivedi, & Kapadia, 1982; Gluckman &
Butler, 1983; Hansen-Pupp et al., 2011), eventually dropping throughout childhood until
adolescence. If levels of IGF1 are elevated during the rapid 3-4 week period of growth,
than additional IGF1 in the system may not further heat-enhanced growth.
IGF-binding proteins (IGFBPs) regulate the bioavailability of IGF1 in the serum.
Studies have shown that mouse models created to lower IGF1s affinity for IGFBPs have
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increased bioavailability of IGF1 to tissues resulting in increased body length (Elis et al.,
2011). If the low dose of injected IGF1 is bound to IGFBPs, there may not be a enough
IGF1 available to the growth plates of long bones to further enhance limb elongation
with heat-treatment. In addition, temperature has been shown to weaken the affinity of
IGF1 binding to ALS in its ternary complex (ALS-IGF1-IGFBP3) accounting for
increased free IGF1 in the circulation (Holman & Baxter, 1996). A longer duration of
heat-treatment may be necessary to increase IGF1 bioavailability. Using a similar
mouse model allowing us to investigate the effects of IGF1 independent of IGFBPs
would be effective to determining if the binding proteins are the limiting factor.
Past studies have also shown that the genetic background of the mouse model
may contribute to variation in skeletal growth observed with increased serum IGF1
(Yakar & Isaksson, 2016). It is possible that increased serum IGF1 has minimal effects
on enhancing linear growth in C57BL/6 mice from 3-4 weeks of age as another possible
explanation of the similarity observed between saline control and IGF1-injected mice
with 7 days of heating. An extensive study would need to be conducted to quantify
linear growth with increased serum IGF1 in various mouse models.
IGF1 activity was assessed by measuring expression of IGF1R and pIGF1R in
the growth plate. IGF1R expression in the PZ on heat-treated sides of IGF1-injected
mice treated for 7 days (7.7%) was not significant and was significantly less than the
heat-induced increase in IGF1R expression in saline mice (14.5%). As rationalized
above, if IGF1 serum levels are further elevated from 3-4 weeks of age, there may be a
higher degree of receptor internalization (Chow, Condorelli, & Smith, 1998; Girnita,
Worrall, Takahashi, Seregard, & Girnita, 2014) as a result of an increased amount of
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IGF1 binding and activating the available receptors. Despite the similarity of IGF1R
expression in non-treated and heat-treated sides with IGF1 administration, there was a
significant increase in pIGF1R expression (28.2%) on the heat-treated sides, which was
20% greater than what was measured in saline controls (7.7%)(Fig. 20A, Table 9). Both
saline and IGF1-injected mice treated for 14 days had a significant increase in IGF1R
and pIGF1R expression on heat-treated sides but there was no difference between the
injection groups (Fig. 20B, Table 9). Therefore, it is possible that the outcome of
increased IGF1 signaling from 3-4 weeks of age is observed by the increased bone
elongation measured in heat-treated limbs from mice treated from 3-5 weeks of age.
Overall, results suggest that IGF1 activity was augmented with heat-treatment, and with
additional IGF1 administered in conjunction with unilateral limb heating IGF1 activity is
further increased when mice were treated for 7 days. Increased IGF1 activity after 7
days of treatment also indicates that despite the IGF1-driven increase shown in femoral
length and tibial elongation rate of mice treated for 14 days (Fig. 17B, Table 7), there
was a higher degree of IGF1 signaling detected in the PZ of mice treated for 7 days
(Fig. 20A, Table 9). Further investigation is required to better understand the
complicated IGF1 signaling cascade involved in growth plate chondrocytes in response
to additional IGF1 with targeted limb heating.
One shortcoming of this study is examining IGF1 activity within the limited scope
of growth plate chondrocytes. Studies have shown that with an increase in IGF1 activity
in osteoblasts via the Col1a1(3.6) promoter, there was increased femoral length
(Brennan-Speranza, Rizzoli, Kream, Rosen, & Ammann, 2011; Jiang et al., 2006).
While not examined in this study, IGF1 receptors are expressed in osteoblasts
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responsible for bone formation in the process of bone remodeling. With prolonged heattreatment, IGF1 may increase osteoblast activity to enhance longitudinal bone growth
independent of activity within the growth plate. Since osteoblasts also contribute to
radial growth, examining bone density would indicate if heat-treatment augments IGF1
activity in osteoblasts with IGF1 injections.

4.5 CONCLUSION
In conclusion, IGF1 activity is augmented with heat-treatment and low dose
IGF1-administration in conjunction with targeted limb heating can further enhance bone
elongation. IGF1-injected mice treated for 14 days had an additional heat-enhanced
increase in femoral length and tibial elongation rate compared to saline control mice
(heat alone). There was also more proliferation and an increased hypertrophic zone
height on heat-treated sides with IGF1 administration following 14 days of heating
despite the comparable left-right differential to saline mice. A heat-enhanced increase in
IGF1 activity was shown during both 7 days and 14 days of heating but was more
pronounced from mice heated for 7 days during the rapid period of growth. Further
studies are needed to better understand IGF1 signaling at the level of growth plate
cartilage when IGF1 administration is coupled to targeting limb heating. Chapter 5 will
test whether heat-enhanced limb length results in the absence of IGF1.
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CHAPTER V: IGF1 IS ESSENTIAL FOR HEAT-ENHANCED BONE ELONGATION
5.1 INTRODUCTION
As discussed in Chapter 1, there are a vast number of possible mechanisms,
both indirect and direct, by which localized heat enhances longitudinal growth. Although
multiple prospects create various avenues of study, this study focuses on a possible
direct effect of temperature on local regulation at the cellular level in the growth plate of
long bones. The process of chondrocyte proliferation and hypertrophy in the growth
plate is regulated by various contributing factors, none of which are mutually exclusive.
Many have reviewed local regulation of the growth plate during postnatal longitudinal
growth (Kronenberg, 2003; Lui et al., 2014; Mackie et al., 2008; van der Eerden et al.,
2003). Each functional zone of chondrocytes has a degree of local regulation by
numerous factors that play a role in maintaining efficient endochondral ossification. For
instance, Indian hedgehog (Ihh), parathyroid hormone-related protein (PTHrP), bone
morphogenic proteins (BMPs), fibroblast growth factors (FGFs), and insulin-like growth
factor-1 (IGF1) among others are expressed throughout distinctive regions of the growth
plate and interact to regulate the rate of proliferation and hypertrophy. When these
factors are inhibited, disturbances of longitudinal bone growth occur leading to
conditions such as short stature (Grunwald & De Luca, 2015; Lee et al., 2016; LuValle &
Beier, 2000; Maeda et al., 2010; Wang et al., 2004; Woods, Camacho-Hubner, Savage,
& Clark, 1996).
IGF1 produced by epiphyseal chondrocytes has been reported to regulate all
regions of growth plate cartilage (Tahimic et al., 2013; Ulici et al., 2008; J. Wang et al.,
1999; Y. Wang et al., 2006) despite the conflicting findings on its role in chondrocyte
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proliferation (Govoni et al., 2007a; Parker et al., 2007; Reinecke et al., 2000; Shinar et
al., 1993; Wang et al., 1995). Increased chondrocyte proliferation and hypertrophy have
also been shown following direct treatment with IGF1 as a resulting growth response
(Abbaspour et al., 2008; Mushtaq et al., 2004). IGF1 activity in the growth plate whether
locally or systemically derived, has a significant role in regulating longitudinal bone
growth.
IGF1 is a putative target of study in the process of heat-enhanced limb
elongation because of its essential role in longitudinal bone growth. Potential methods
for studying the action of IGF1 in the growth plate include (1) the administration of IGF1
blocking drugs such as IGF1 peptide analogues that specifically inhibit the downstream
action of the IGF1 receptor (IGF1R) (Pietrzkowski et al., 1992; Smith et al., 1999) and
(2) knockout mouse models with the absent or low levels of IGF1 (Yakar et al., 2010;
Yakar & Isaksson, 2016). This study uses both. Experiments here utilize a small peptide
analog of IGF1 known as JB1 that competitively binds to the receptor and blocks
downstream IGF1 activity (Chapter 1, Fig. 5) (Brock et al., 2011; Huang et al., 2000;
Kleinridders, 2016; Todd et al., 2007; Wen et al., 2012). This study also includes limited
data using the growth hormone receptor knockout mouse (GHR-/-) recognized for
having low levels of IGF1 and 30-40% reduction in body size (List et al., 2011; Sims et
al., 2000; Yakar & Isaksson, 2016; Zhou et al., 1997). This chapter tests the
hypothesis that with diminished IGF1 activity, heat-enhanced limb length is
attenuated.
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5.2 MATERIAL AND METHODS
5.2.1 Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=12) mice were
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 days weaning age.
Mice were singly housed at 21°C in standard plastic caging, exposed to a 12 hour
light/dark cycle and provided with food and water ad libitum.
As described in Chapter 2, and as indicated by the unilateral heating methods
schematic (Fig. 21), mice were subjected to the same procedural conditions. Mice (N=6)
were weighed each day and given subcutaneous injections of an IGF1 peptide analog
(JB1, Sigma) that blocks downstream activity of IGF1. Injections of the IGF1 blocking
drug JB1 (2.5 mg/kg) were administered daily at the start of the light cycle one hour
prior to heat-treatment. The rationale for the dose and time period of JB1 administration
was to be consistent with IGF1 drug treatment experiments described in Chapter 4.
Dose was accepted following pilot trials that mimicked experimental conditions and
tested the physiological response of the mice to the drug treatment. Saline-injected
control (N=6) mice described in Chapter 3 served as the controls.
An additional group of female (N=5) growth hormone receptor (GHR) knockout
(GHR-/-) mice on a C57BL/6 background was obtained from the Kopchick laboratory at
Ohio University (Athens, OH, USA) at 21 days weaning age. GHR-/- mice model
hereditary dwarfism in humans known as Laron Syndrome characterized by short
stature, low serum IGF1, and GH resistance (Laron, 2015a; Laron & Kauli, 2015b; List
et al., 2011; Sims et al., 2000; Zhou et al., 1997). These mice were housed under
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similar conditions previously described. GHR-/- mice were not drug injected and were
treated with unilateral heat (40°C for 40 mins/day) for 14 days. Although GHR-/- mice
were not injected with saline, previous studies have shown that there are no significant
differences between non-injected and saline-injected mice (unpublished data).
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Figure 21. Unilateral Heating Schematic
Mice were injected subcutaneously (SQ) with IGF1 blocking drug (JB1, 2.5 mg/kg) one
hour prior to treatment of 40°C unilateral heat for 40 minutes daily from 3-4 weeks of
age. Euthanasia and tissue collection occurred 1 day after the last day of heattreatment. Mouse illustration based on “mouse clip art black and white” from
clipartstockphotos.com.
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5.2.2 Tissue Collection and Sample Analysis
Long bones (femora and humeri) were collected and measured as described in
Chapter 3 (Sections 3.2.2 and 3.2.3). Proximal tibial halves from each hindlimb were
collected (Section 3.2.2) for tibial elongation rate analysis (Section 3.2.3) and growth
plate morphometry (Sections 3.2.4) following methods described in Chapter 3.

5.2.3 Immunohistochemistry
Serial sections of proximal tibiae from mice subjected to 7 days (N=12, 6 per
saline control and JB1) of unilateral heating were stained using rabbit polyclonal
antibodies against IGF1R, phospho-IGF1R (phospho-Y1161) and PCNA (as described
in Table 4) and rabbit polyclonal antibodies against pAkt, Thr308 (1:200, Santa Cruz,
sc-16646) following methods as described in Chapter 3 (Section 3.2.5). Analysis
focused on the proliferative zone (PZ) and the hypertrophic zone (HZ). PCNA was used
as a marker for rate of proliferation (PZ only) and IGF1R, pIGF1R and pAkt were
evaluated as markers of IGF1 activity (PZ and HZ). While an important part of the study,
bisected tibiae were not collected from the GHR-/- mice following techniques necessary
for immunohistochemistry analysis. Therefore, expression levels of PCNA, IGF1R,
pIGF1R, and pAkt could, unfortunately, not be done in the GHR-/- model.

5.2.4 Statistical Analysis
Statistical analyses were performed using SPSS 25.0 software (IBM Corporation,
Armonk, NY) with p<0.05 as accepted significance and comparisons as described in
Chapter 4 (Section 4.2.4).
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5.3 RESULTS
5.3.1 Unilateral Heating Parameters
There was no significant difference in the amount of mass gained between
controls and JB1-injected mice as determined by multiple comparison analysis using
one-way ANOVA (F(1,11)=1.1, ns, p=0.311). JB1-injected mice treated for 7 days from
3-4 weeks of age gained 4.3±0.5g while saline control mice (established in Chapter 3)
gained 4.7±0.7g (Fig. 22). Therefore, the JB1-inject mice exhibited normal body growth.
The core temperature averaged 36°C. While mice were anesthetized, the average
surface temperature of non-treated hindlimbs was 30°C and the heat-treated hindlimbs
were 40°C.
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Figure 22. Total Body Mass Gained in Mice Treated for 7 days from 3-4 weeks of
Age did not Differ Between Saline Controls and JB1-Injected Mice
Scatter plots show the change in mass of individual saline mice (open circles) and JB1
mice (dark gray circles). One-way ANOVA revealed no significant differences in overall
mass gain between saline and JB1 mice.
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5.3.2 Length of Long Bones and Tibial Elongation Rate
Femoral length was comparable on the non-treated sides of saline (10.44 mm)
and JB-1 injected mice (10.46 mm) (Table 10). However, femoral length (paired t=0.3,
ns, p=0.81) of JB1-injected mice did not differ between non-treated and heat-treated
sides (Fig. 23A; Table 10) while saline mice had a significant 1.7% increase on heattreated sides (Chapter 3; Fig. 12A, Table 5). This heat-induced increase in femoral
length was significantly greater (F(1,11)=6.2, p<0.05) than the JB1-injected mice.
Humeral length was not different between sides for saline (Chapter 3; Table 5) or JB1injected mice (paired t=0.1, ns, p=0.91).
Tibial elongation rate was also comparable on the non-treated sides of saline
mice (156.88 μM/day) and JB1-injected mice (153.31μM/day) (Table 10). However,
tibial elongation rate of JB1-injected mice decreased by nearly 3% (paired t=1.9, ns,
p=0.13) on the heat-treated side (Fig. 23B, Table 10), while saline mice had a significant
increase of nearly 8% on the heat-treated side (Chapter 3; Fig. 12B, Table 5). This
observed decrease was significantly less (F(1,9)=24.8, p<0.001) from the increase in
tibial elongation rate in saline mice. The potential of limb heating to target JB1 to the
heat-treated side was supported by data since unilateral differences in both femoral
length and tibial elongation rate between saline and JB1-injected mice were seen on the
heat-treated sides while the non-treated sides were similar between groups. Therefore,
these results along with the observed normal body growth (Fig. 22) indicate that JB1
blocked IGF1 locally in the growth plate on heat-treated sides.

124

Table 10. Comparison of Non-Treated and Heat-Treated Bone Parameters of 4Week Old Saline- and JB1-Injected Mice Following 7 Days of Heat-Treatment.
Parameter

Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

9.27 (0.14)

9.23 (0.20)ns

-0.4

6

JB1

9.09 (0.27)

9.10 (0.23)ns

0.1ns

6

Saline

10.44 (0.19)

10.62 (0.26)**

1.7

6

JB1

10.46 (0.27)

10.48 (0.33)ns

0.1#

6

Saline

156.88 (11.24)

168.94 (12.85)**

7.7

5

JB1

153.31 (25.72)

148.96 (22.13)ns

-2.6#

5

Humeral Length (mm)

Femoral Length (mm)

Tibial Elongation Rate (µM/day)

Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated
side by one-tailed paired t-test: **p<0.01; ns, non-significant. Significant differences in
percent increase between saline controls and JB1-injected mice by one-way ANOVA:
#p<0.05; ns, non-significant.
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Figure 23. Heat-Enhanced Growth Effects are Attenuated When IGF1 is Blocked
(A) Error bar plots shows percent change in heat-treated limb compared to non-treated
limb. Femoral length increased by 1.7% on the heat-treated side of saline control mice
and no increase when IGF1 is blocked in mice injected with JB1. (B) Tibial elongation
rate increased by 7.7% on the heat-treated side in saline mice and decreased by 2.6%
in JB1-injected mice. (C) The PZ of proximal tibial growth plates in saline mice
decreased by 9.0% on the heat-treated side but increased by 1.4% in JB1-injected
mice. (D) The HZ of proximal tibial growth plates increased by 9.0% on the heat-treated
side of saline mice but had a minimal increase of 0.4% in JB1 mice. Mean ± 1 standard
error plotted. *p< 0.05; **p<0.01; ***p<0.001, significance in left-right comparisons;
#p<0.05 comparing % change in JB1-injected mice with saline controls.
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5.3.3 Growth Plate Morphometry
The height of the PZ normalized to total growth plate height was significantly
reduced by 9.0% on the heat-treated sides of saline mice (Chapter 3; Fig. 13A, C; Table
6). JB1-injected mice displayed a 1.4% increase in PZ height (paired t=0.4, ns, p=0.68)
on the heat-treated side (Fig. 23C). The height of the HZ normalized to the total growth
plate height was significantly enlarged by 8.6% on the heat-treated sides of saline mice
(Chapter 3; Fig. 12B, C; Table 6). JB1-injected mice had a minimal decrease of 0.4% in
HZ height (paired t=0.0, ns, p=1.0) on the heat-treated side (Fig. 23D). The decrease in
height of the PZ (F(1,10)=17.9, p<0.01) and HZ (F(1,10)=14.4, p<0.01) on heat-treated
sides was significantly less when IGF1 is blocked than the increased heights reported in
saline mice as determined by one-way ANOVA. Overall, blocking IGF1 activity in tibial
growth plates attenuated the localized heat effect on growth plate morphometry.

5.3.4 PCNA Expression
PCNA expression (paired t=2.0, ns, p=0.12) decreased by 12.1% on the heattreated sides of JB1-injected mice (Fig. 24, Table 11). PCNA expression was
significantly less (F(1,10)=10.6, p<0.01) than the 8.8% increase in expression on the
heat-treated sides of saline control mice (Chapter 3; Fig. 14). Results indicate
decreased proliferation in tibial growth plates with localized heating when IGF1 is
blocked. However, while overall expression of PCNA was less in JB1-injected mice,
chondrocytes still demonstrated a level of proliferation suggesting mechanisms
regulated proliferation in the PZ independent of IGF1.
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Table 11. Comparison of Non-Treated and Heat-Treated Expression of PCNA in
Proliferative Zone of Tibial Growth Plates in Saline and JB1-Injected Mice.
Antibody in Proliferative Zone

Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

85.10 (6.90)

91.93 (1.98)*

8.6

6

JB1

71.08 (19.04)

62.20 (17.52)ns

-12.1#

5

PCNA expression

Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated
side by one-tailed paired t-test: *p< 0.05; ns, non-significant. Significant differences in
percent increase between saline controls and JB1-injected mice by one-way ANOVA:
#p<0.05.
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Figure 24. Expression of PCNA in the PZ of Proximal Tibial Growth Plates
Decreased when IGF1 is Blocked (Continued on the following page)
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Figure 24. (A) Error bar plots shows percent change in heat-treated limb compared to
non-treated limb. PCNA expression increased by 8.6% on the heat-treated side of
saline mice, and decreased by 12.1% in JB1-injected mice. (B) Comparison of heattreated proximal tibial growth plates from a saline and JB1-injected mouse
immunostained for PCNA. A larger quantity of PCNA staining was counted in saline
mice compared to JB1-injected mice. Positive staining is shown by dark brown nuclei
within the proliferative zone of the growth plate (region between the double arrows).
Mean ± 1 standard error plotted. *p< 0.05 significance in left-right comparisons; #p<0.05
comparing % change in JB1-injected mice with saline controls.
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5.3.5 IGF1R, pIGF1R and pAkt Expression
IGF1R expression in the PZ (paired t=5.0, p<0.01) of tibial growth plates
decreased by 28.0% on the heat-treated side of JB1-injected mice. This decrease was
significantly less (F(1,10)=39.4, p<0.001) than the 14.5% increase in IGF1R expression
(paired t=3.2, p<0.05) on the heat-treated side of saline control mice (Fig. 25A, 26A(a);
Table 12). Expression of activated IGF1R (pIGF1R) in the proliferative zone (paired
t=3.2, p<0.05) of tibial growth plates decreased by 23.6% on the heat-treated side of
JB1-injected mice. This decrease was significantly less (F(1,10)=24.0, p<0.001) than
the 7.7% increase in pIGF1R expression (paired t=5.3, p<0.01) on the heat-treated side
of saline mice (Fig. 25B, 26B(a); Table 12). The phosphatidylinositol-3 (PI-3) kinase
pathway is one of several signaling pathways activated by IGF1-IGF1R interaction (the
other is the mitogen-activated protein kinase (MAPK) pathway (Chapter 1, Fig. 4).
Downstream activation of IGF1R was therefore investigated by measuring
phosphorylated Akt (pAkt) expression as one of the key signaling molecules of the PI-3
kinase pathway in the tibial growth plate (Choukair, Hϋgel, Sander, Uhlmann, &
Tönshoff, 2014). Expression of pAkt decreased by 2.1% in the proliferative zone (paired
t=0.2, ns, p=0.87) of tibial growth plates on the heat-treated side of JB1-injected mice.
This decrease was significantly less (F(1,10)=6.4, p<0.05) than the 22.8% increase in
pAkt expression (paired t=4.4, p<0.01) on the heat-treated side of saline control mice
(Fig. 25C, Table 12). These data indicate that in the PZ, IGF1 activity is increased with
heat-treatment (as reported in Chapter 4), and when IGF1 is blocked, there is a
localized decrease in IGF1 activation.
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IGF1R expression in the HZ (paired t=2.7, p<0.05) of tibial growth plates
decreased by 19.2% on the heat-treated side of JB1-injected mice. This decrease was
significantly less (F(1,10)=11.0, p<0.01) than the 10.4% increase in IGF1R expression
(paired t=2.1, ns, p=0.11) on the heat-treated side of saline mice (Fig. 25A, 26A(b);
Table 13). Expression of pIGF1R in the HZ (paired t=1.7, ns, p=0.17) of tibial growth
plates decreased by 10.1% on the heat-treated side of JB1-injected mice. This
decrease was significantly less (F(1,10)=9.0, p<0.05) than the 10.2% increase in
pIGF1R expression (paired t=3.4, p<0.05) on the heat-treated side of saline mice (Fig.
25B, 26B(b); Table 13). Expression of pAkt decreased by 22.4% in the HZ (paired t=4,1,
p<0.05) of tibial growth plates on the heat-treated sides of JB1-injected mice. This
decrease was significantly less (F(1,10)=8.0, p<0.05) than the 13.5% increase in pAkt
expression on the heat-treated side of saline mice (paired t=1.7, ns, p=0.15) (Fig. 25C,
Table 13). These data indicate that in the HZ, there is increased IGF1 activity because
when IGF1 is blocked, there is a localized decrease in markers of IGF1 activation.
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Table 12. Comparison of Non-Treated and Heat-Treated Expression of Markers for
IGF1 Activation in Proliferative Zone of Tibial Growth Plates in Saline and JB1Injected Mice.
Antibody in Proliferative Zone

Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

69.68 (6.36)

79.52 (7.61)*

14.5

5

JB1

68.83 (18.80)

50.25 (18.71)**

-28.0#

6

Saline

84.85 (10.36)

90.97 (7.90)**

7.7

6

JB1

72.80 (15.38)

53.88 (4.75)*

-23.6#

5

Saline

55.21 (15.05)

66.23 (12.52)**

22.8

6

JB1

37.62 (19.87)

38.14 (22.27)ns

-2.1#

5

IGF1R expression

pIGF1R expression

pAkt expression

Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated
side by one-tailed paired t-test: *p< 0.05; **p<0.01; ns, non-significant. Significant
differences in percent increase between saline controls and JB1-injected mice by oneway ANOVA: #p<0.05.
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Table 13. Comparison of Non-Treated and Heat-Treated Expression of Markers for
IGF1 Activation in Hypertrophic Zone of Tibial Growth Plates in Saline and JB1Injected Mice.
Antibody in Hypertrophic Zone

Treatment

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

74.22 (9.94)

81.08 (2.95)ns

10.4

5

JB1

74.95 (15.10)

59.57 (13.78)*

-19.2#

6

Saline

82.13 (7.39)

90.07 (4.23)*

10.2

6

JB1

76.14 (12.74)

67.42 (10.13)ns

-10.1#

5

Saline

49.91 (14.15)

56.66 (17.93)ns

13.5

6

JB1

57.12 (25.83)

48.46 (29.78)*

-22.4#

5

IGF1R expression

pIGF1R expression

pAkt expression

Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated
side by one-tailed paired t-test: *p< 0.05; ns, non-significant. Significant differences in
percent increase between saline controls and JB1-injected mice by one-way ANOVA:
#p<0.05.
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A

B
IGF1R

C
pIGF1R

pAkt

SALINE
Heat-Treated

JB1
Heat-Treated

Figure 25. Expression of Markers of IGF1 Activation Decreases in Heat-Treated
Proximal Tibial Growth Plates when IGF1 is Inhibited
Comparison of heat-treated proximal tibial growth plates from a saline control and JB1injected mouse immunostained for (A) IGF1R (B) pIGF1R and (C) pAkt. A larger
quantity of positive staining, shown by dark brown nuclei, was counted in saline mice
compared to JB1 mice.
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Figure 26. Heat-Induced Effect on IGF1 Activity in the Tibial Growth Plate is
Evident in the PZ and HZ
(A) IGF1R expression in saline and JB1-injected mice. (a) Error bar plot shows percent
change in heat-treated limb compared to non-treated limb. IGF1R expression in the PZ
increased by 14.5% and decreased by 28% on heat-treated sides of saline and JB1injected mice. (b) IGF1R expression in the HZ increased by 10.4% and decreased by
19.2% in saline and JB1-injected mice. (B) pIGF1R expression in saline and JB1injected mice. (a) pIGF1R expression in the PZ increased by 7.7% and decreased by
23.6% in saline and JB1-injected mice. (b) pIGF1R expression in the HZ increased by
10.2% and decreased by 10.1% in saline and JB1-injected mice. Mean ± 1 standard
error plotted. *p< 0.05; **p<0.01, significance in left-right comparisons; #p<0.05
comparing % change in JB1-injected mice with saline controls.
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5.3.6 GHR-/- Growth Parameters
When levels of circulating IGF1 are low, femoral length (paired t=0.17, ns,
p=0.88) and tibial elongation rate (paired t=0.3, ns, p=0.80) did not differ on the heattreated sides of 5 week old GHR-/- mice treated for 14 days (Fig. 27, Table 14). In wildtype mice, femoral length and tibial elongation rate increased by 1.1% and 10.8%
respectively as seen in Chapter 3 (Table 5). The heat-induced increase in femoral
length (F(1,12)=29.2, p<0.001) and tibial elongation rate (F(1,12)=13.1, p<0.01) was
significantly greater from the equivalent left-right pairs measured in GHR-/- mice.
Humeral length (paired t=0.2, ns, p=0.87) did not differ as seen in wild-type mice.

137

Table 14. Comparison of Non-Treated and Heat-Treated Bone Parameters of 5Week Old Wild-Type and GHR-/- Mice.
Parameter

Genotype

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Wild-type

10.14 (0.11)

10.15 (0.13)ns

0.1

9

GHR-/-

7.51 (0.04)

7.51 (0.04)ns

0.0ns

5

Wild-type

12.86 (0.18)

13.00 (0.17)***

1.1

9

GHR-/-

9.32 (0.08)

9.32 (0.09)ns

0.0#

4

Wild-type

109.57 (11.18)

121.22 (10.70)***

10.8

8

GHR-/-

53.98 (12.59)

54.36 (12.23)ns

0.9#

5

Humeral Length (mm)

Femoral Length (mm)

Tibial Elongation Rate (µM/day)

Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated
side by one-tailed paired t-test: ***p<0.001; ns, non-significant. Significant differences
in percent increase between saline controls and JB1-injected mice by one-way ANOVA:
#p<0.05; ns, non-significant.
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Femoral Length
#

1

***
p<0.001

0

-1

WILD-TYPE
(N=9)

GENOTYPE

GHR-/(N=4)

% Increase on the Heat-Treated Side

% Increase on the Heat-Treated Side
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Figure 27. Extremities of Growth-Hormone Receptor Knockout (GHR-/-) Mice are
not Lengthened with Unilateral Heat-Treatment
(A) Error bar plots shows percent change in heat-treated limb compared to non-treated
limb. Femoral length increased by 1.1% on the heat-treated sides of wild-type mice
treated for 14 days from 3-5 weeks of age. Femoral length did not change with
treatment in GHR-/- mice. (B) Tibial elongation rate increased by 10.8% on the heattreated sides of wild-type mice, and GHR-/- mice had a minimal increase of 0.9% with
heat-treatment. Mean ± 1 standard error plotted. ***p<0.001, significance in left-right
comparisons; #p<0.05 comparing % change in wild-type and GHR-/- mice
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5.4 DISCUSSION
The goal of this study was to determine if the heat-enhanced bone elongation
observed after targeted limb heating is IGF1 dependent. The heat-treatment effect on
bone elongation is attenuated in growing mouse models exhibiting both locally blocked
IGF1 and low IGF1. Femoral length and tibial elongation rate was shown to increase by
over 1% and 7% respectively in heat-treated limbs of saline control mice after either 7 or
14 days of unilateral heating. In JB1-injected (blocked IGF1) and GHR-/- (low levels of
IGF1) mice, both femoral length and tibial elongation rate did not differ between the
heat-treated and non-treated contralateral sides. Our data supported the hypothesis that
with diminished IGF1 activity, heat-enhanced limb length is attenuated.
Although we were not able to perform immunostaining on GHR-/- mice the
results using our model and JB1 as an antagonist of IGF1 activity demonstrated that
heat-enhanced chondrocyte proliferation and hypertrophy in proximal tibial growth
plates was attenuated when IGF1 is blocked. Chondrocyte proliferation and hypertrophy
are common indicators of longitudinal growth as discussed in Chapter 3. There is a
positive relationship between rate of chondrocyte proliferation, size of chondrocyte
enlargement, and linear bone growth rate (Cooper et al., 2013; Hunziker, 1994b;
Kember, 1993; Rolian, 2008; Wilsman et al., 2008). According to the findings of this
study, the proliferative and hypertrophic zones of growth plates on non-injected sides of
saline control mice each made up 45% of the total growth plate height (the remaining
10% being the reserve zone). On the heat-treated side, there was a shift in zonal height
as the proliferative zone made up 41% of total growth plate height (Fig. 23C) while the
hypertrophic zone of chondrocytes took up 48% of total height (Fig. 23D). This observed
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shift in zones was absent in mice injected with the IGF1 blocking drug as the
proliferative and hypertrophic zone height made up 42% and 47% of total height
respectively on both non-treated and heat-treated sides. When evaluating proliferation
in the growth plate, expression of PCNA increased by 8.6% on the heat-treated side of
saline control mice but decreased by 12.1% when IGF1 was blocked (although not
statistically significant) (Fig. 24, Table 11). Results demonstrated that an increased rate
of proliferation with heat-treatment is dependent, in part, on IGF1 activity in the
proliferative zone of the growth plate.
To test for activation of IGF1 signaling, immunohistochemistry methods detected
expression of specific markers for IGF1 activity in tibial growth plates including IGF1R,
pIGF1R (activated receptor) and pAkt (downstream IGF1 activation). Measured
expression levels of these markers (as done in Chapter 4) suggest in this study that the
heat-enhanced increase in IGF1 activity is attenuated when IGF1 is blocked. On heattreated sides of the saline control mice, there was an increase in IGF1R, pIGF1R and
pAkt expression while levels decreased when IGF1 was blocked in JB1-injected mice
(Fig. 25, 26; Tables 12,13). Measured expression of signaling molecules as a result of
IGF1 activated receptors including pIGF1R and downstream pAkt increased on the
heat-treated sides of saline control mice by over 7%. Expression of pIGF1R and pAkt
decreased by over 10% and 2% respectively on the heat-treated sides when the
antagonist blocked IGF1 from binding to the receptor. This decrease in expression was
observed in both the proliferative and hypertrophic zones of the growth plate as
expected since IGF1 has been shown to increase cellular proliferation and
differentiation both in vitro and in vivo (Abbaspour et al., 2008; Choukair et al., 2014;
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Ciarmatori et al., 2007; Tahimic et al., 2013; Yakar & Isaksson, 2016). However, down
regulation of pAkt was more substantial in the hypertrophic zone (22.4% decrease)
compared to the proliferative zone (2.1% decrease). One plausible explanation for these
results could be rationalized by findings from Ciarmatori et al. (2007) and Kiepe,
Ciarmatori, Hoeflich, Wolf, & Tönshoff (2006) in growth plates of both cell lines and
whole animals demonstrating that IGF1-driven proliferation is regulated by both the PI-3
kinase and MAPK pathways, while the hypertrophic zone is regulated by only the PI-3
kinase pathway (Ciarmatori et al., 2007; Kiepe et al., 2006). Regulation pathways could
be compared in our model by analyzing expression levels of pAkt and important
downstream signaling molecules from the MAPK pathway such as ERK.
A surprising finding from this study was the significant decrease in IGF1R
expression in both the proliferative zone (28% decrease) and the hypertrophic zone
(19% decrease) from growth plates after treatment with the antagonist (Fig. 26A; Tables
12,13). It was expected that with targeted limb heating IGF1R expression would either
remain unchanged or increase in mice administered the IGF1 blocking drug since
binding of IGF1 to its receptor enhances activation and initiates internalization and
recycling of IGF1R (Chow et al., 1998; Yin, Guan, Liao, & Wei, 2009). Cell culture
studies modeling the growth plate have shown that other antagonists of IGF1 signaling
have reduced chondrocyte proliferation without impacting expression of IGF1R
(Choukair et al., 2014). While literature does not support our findings, it is possible that
the down regulation of IGF1R is a unique characteristic of IGF1 peptide analog JB1.
The obscure ligand-independent mechanisms of IGF1R internalization may be a
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potential mechanism of JB1-bound IGF1R down regulation (Morcavallo, Stefanello,
Iozzo, Belfiore, & Morrione, 2014; Reilly, Mizukoshi, & Maher, 2004).
Numerous studies have investigated the use of kinase inhibitors as a method for
IGF1 inhibition in various tissues (Li et al., 2009; Pillai & Ramalingam, 2013; Refolo et
al., 2017). However, blocking IGF1 activity by peptide analogs has been considered a
more specific method for inhibiting cellular proliferation (Brock et al., 2011; Huang et al.,
2000; Kleinridders, 2016; Pietrzkowski et al., 1992; Todd et al., 2007; Smith et al., 1999;
Wen et al., 2012). Besides their high specificity, IGF1 peptide analogues also have low
molecular weights and low toxicity (Pietrzkowski et al., 1992). Monoclonal antibodies,
such as αIR3, also have high specificity against IGF1R comparable to the peptide
analogues, but are over 100-fold larger in size (Huang et al., 2000). Small molecular
size is important for this study because the targeted growth plate is avascular and
solute transport occurs by means of surrounding vasculature (Brodin, 1955). In vivo
imaging studies have shown that molecules under 10kDa enter the growth plate from all
directions of surrounding vasculature, while molecules over 40kDa cannot enter to a
significant degree (Farnum et al., 2006). Aside from being commercially available, JB1
was chosen for this study at only 1.2kDa and therefore falls well in the range of
molecules capable of vascular transport into the cartilage growth plate. The small size
of JB1 may also explain why heat-induced decrease in expression levels of IGF1
signaling proteins were more prominent than the increase in expression seen in the
heat-treated saline control mice. It is possible that the smaller size of JB1 (1.2kDa)
allows for increased transport into the growth plate relative to IGF1 (7.6kDa).
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The use of localized heat-treatment, as explained in Chapter 2, has been
established as an effective method for enhancing limb elongation in growing mice
(Serrat et al., 2015). Research into the mechanism of action is important in the hopes of
translating our findings to develop a noninvasive alternative for treatment of bone
elongation disorders in children. The ultimate goal would be to target localized heat to
the site of the growth plate and increase limb elongation without impacting overall
growth. In this study, there were no significant differences in change of body mass
between saline controls and JB1-injected mice over the duration of heat-treatment and
did not impact overall growth. The similarity observed between the non-treated sides of
saline controls and JB1-injected mice is another indication that the effect of blocking
IGF1 was limited to the heat-treated side.
Limitations to this study include the small sample size of the GHR-/- mice.
Unilateral heating experiments were carried out previous to establishing a consistent
methodology as published (Serrat et al., 2015), and as described in the chapters of this
dissertation. Also, since expression levels of PCNA, IGF1R, pIGF1R, and pAkt were not
measured in the GHR-/- model, future studies will be essential to assay these important
variables. Expanding upon the findings in the GHR-/- mouse model, future studies may
be designed to understand the impact of heat-treatment on the GH-IGF1 axis at the
level of the epiphyseal growth plate. While the current study focused on local IGF1
activity in the growth plate, GH and related signaling molecules have yet to be studied in
targeted limb heating experiments. GH has both direct and indirect control on the
growth plate and has been shown to directly stimulate chondrogenesis and induce local
IGF1 activity (Isaksson et al., 1982, 1985; Ohlsson, 1992b, 1998; Schlechter et al.,
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1986). In hope of translating the limb-heating model to treat children with bone
lengthening disorders, including those with irregular GH-IGF1 regulation, it is important
to determine if mild heat impacts GH in regulating longitudinal growth. Since the
molecular size of GH (22 kDa) exceeds that of IGF1 (7.6 kDa) and the threshold of
heat-enhanced vascular delivery (10 kDa) to the growth plate (Serrat et al., 2014a), the
effects of heating would be expected to be at the level of local GH regulation. It is also
expected that if targeted limb heating increases GH activity, it would not be independent
of IGF1 since results from this study showed that when IGF1 activity was inhibited, and
GH regulation was normal, the heat-enhanced growth effect was attenuated.

5.5 CONCLUSION
In conclusion, with diminished IGF1 activity, heat-enhanced limb length is
attenuated. Bone lengthening effects of temperature in hindlimbs of growing mice, such
as increased femoral length and tibial elongation rate, were absent in GHR-/- mice (low
levels of IGF1), and in JB1-injected mice (IGF1 was locally blocked). When IGF1 activity
is blocked, the heat-induced increase in proliferation and height of hypertrophic zone is
also attenuated. The variation between saline and JB1-injected mice in left-right
differences of bone length, growth plate morphometry and IGF1 signaling despite both
exhibiting normal body growth indicates that JB1 locally blocked IGF1 activity on heattreated sides. Together these results support the hypothesis that in the absence of IGF1
activity, targeted limb heating cannot effectively increase bone elongation in growing
mice. Chapter 6 will test whether heat-enhanced limb length can be maintained after
treatment has ended into skeletal maturity.
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CHAPTER VI: DIFFERENTIAL LIMB LENGTH IS MAINTAINED THROUGHOUT
SKELETAL DEVELOPMENT AFTER END OF TREATMENT

6.1 INTRODUCTION
During the post-natal development, functional growth plate cartilage augments
bone elongation with a rapid period of growth during early life then undergoes a gradual
decline in growth velocity and eventually ceases during adolescence. This process has
been termed as growth plate senescence (Lui et al., 2011). Although the murine growth
plate does not completely close and form a bony union as it does in humans, both reach
a period of growth culmination over a similar time frame and by comparable cellular
kinetics (Dawson, 1925, 1935; Geiger et al., 2014; Walker & Kember, 1972). Once
skeletal maturity is reached, the growth plate ceases to contribute to linear growth. In
mice, skeletal maturity is reached by 12 weeks of age (Kilborn et al., 2002; Li et al.,
2017; Serrat et al., 2007; Stempel et al., 2011; Zoetis et al., 2003), while humans are
considered skeletally mature at puberty between 13-18 years of age (Kelly & Diméglio,
2008).
Current treatment for bone elongation disorders including the invasive surgical
procedures to correct limb length discrepancies, and the drug regimens for GH and
IGF1 occur before skeletal maturity. Often, there is only a partially effective outcome
after both surgical procedures (Gurney, 2002; Hasler & Krieg, 2012) and drug regimen
therapy (Backeljauw et al., 2013; Laron, 2001; Ranke et al., 1995b; Wu et al., 2013). A
goal of many therapies for bone elongation disorders is to maintain corrections past
skeletal maturity to avoid resulting problems in adulthood. In children, while treatment is
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most effective during early childhood when growth is most rapid (Kelly & Diméglio,
2008), therapy continues until growth ceases at the end of puberty.
The concept of using localized heat as a noninvasive alternative to surgical
treatment for bone elongation disorders in children has thus far been supported by data
demonstrating that targeted limb heating can effectively lengthen extremities during
rapid periods of growth. However, in hopes of translating the results of this study into
developing a noninvasive method for lengthening bones as a therapy for children, it is
important to determine if the heat-enhanced bone elongation can be maintained
throughout skeletal development. Studies have shown that femoral and tibial lengths
remain almost 1% longer on the heat-treated sides of 12-week-old mice (Serrat et al.,
2015). The objective of this project was to understand the ability for unilaterally
lengthened extremities to remain longer until skeletal maturity following both a 7 day
and 14 day unilateral heating regimen in conjunction with low dose IGF1 administration.
It is hypothesized that differential limb length will be maintained throughout
skeletal development after treatments have ended. It is also expected based on
findings from Chapter 4, that persistent limb length differences will be prominent in
IGF1-injected mice.

6.2 MATERIAL AND METHODS
6.2.1 Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=31) mice were
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 and 28 days weaning
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age. Mice were singly housed at 21°C in standard plastic caging, exposed to a 12 hour
light/dark cycle and provided with food and water ad libitum.
As described in the previous chapters and as indicated by the unilateral heating
methods schematic (Fig. 28), mice post-weaning were treated with daily unilateral heat
(40°C) under the same procedural conditions. Mice were treated for 7 days from 3-4
weeks of age and for 14 days from 3-5 weeks of age. Subcutaneous injections of either
saline solution (3:1, 1xPBS:dH2O) at a volume of 0.01mL/g, or IGF1 (2.5mg/kg;
Peptrotech), were administered to mice daily at the start of the light cycle one hour prior
to heat-treatment for 7 days and 14 days (N=6 per group). These experimental groups
have not yet been described in previous chapters as tissue collection occurred later in
development. A group of non-heated, non-injected 3-week-old mice (N=7) were also
kept under equivalent housing conditions as non-treated controls. Daily mass was
recorded during the duration of limb heating, and then weekly mass was measured until
euthanization.
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Figure 28. Unilateral Heating Schematic
Mice were injected subcutaneously (SQ) with either saline or IGF1 (2.5mg/kg) one hour
prior to treatment of 40°C unilateral heat for 40 minutes daily for 7 days from 3-4 weeks
of age and 14 days from 3-5 weeks of age. Euthanasia and tissue collection occurred at
12 weeks of age when mice were skeletally mature. Mouse illustration based on “mouse
clip art black and white” from clipartstockphotos.com.
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6.2.2 Tissue Collection and Long Bone Measurements
Long bones (femora and humeri) were collected and measured as described in
Chapter 3 (Sections 3.2.2 and 3.2.3) but all experimental mice (N=31) were euthanized
for tissue collection at 12-weeks of age at skeletal maturity. In this study tibiae were
collected for long bone measurements since no histology was done. Non-treated
controls (N=7) were also euthanized at the same endpoint to evaluate natural limb
length differences at skeletal maturity.

6.2.3 Statistical Analysis
Statistical analyses were performed using SPSS 25.0 software (IBM Corporation,
Armonk, NY) with p<0.05 as accepted significance and comparisons as described in
Chapter 4 (Section 4.2.4).

6.3 RESULTS
6.3.1 Unilateral Heating Parameters
At the start of 7 day unilateral heating, a group of 3-week-old female mice (N=17)
were partitioned out into the corresponding non-treated controls (N=5) and heat-treated
saline (N=6) and IGF1-injected mice (N=6). At the experimental start, all mice were
comparable in mass (F(2,16)=2.7, ns, p<0.12), weighing an average of 9.0g (Fig. 29A,
Table 15). At skeletal maturity, mice were also comparable in mass (F(2,18)=2.3, ns,
p=0.14), weighing an average of 23.0g. The overall gain in mass was therefore 14.0g
with no significant differences between non-treated controls, saline mice treated for 7
days, or IGF1-injected mice treated for 7 days, as determined by multiple comparison
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analysis using one-way ANOVA (Table 15). At the start of 14 days unilateral heating,
another group of 3-week-old female mice (N=12) were separated into heat-treated
saline (N=6) and IGF1-injected mice (N=6). At the experimental start, all mice were
comparable in mass (F(1,11)=0.1, ns, p=0.83), weighing an average of 10.0g (Fig. 29A,
Table 15). At skeletal maturity, mice were also similar in mass (F(1,11)=2.5, ns,
p=0.14), weighing an average of 22.5g. Although IGF1-injected mice (23.1g) overall
gained about 1.0g more than the saline controls (22.2g), this was not statistically
significant (F(1,11)=2.0, ns, p=0.19). Therefore, with either 7 days or 14 days of limb
heating, mass remained comparable between groups from the start at 3 weeks of age
until skeletal maturity at 12 weeks of age (Table 15).
The core temperature averaged 36°C during unilateral heating. While mice were
anesthetized, the average surface temperature of non-treated hindlimbs was 30°C and
the heat-treated hindlimbs were 40°C. These recorded temperatures were consistent
with parameters during the daily limb heating reported in previous chapters. As reported
in Chapter 4, the recovery time from anesthesia was longer in IGF1-injected mice
compared to saline controls in this study. At the end of each daily heat-treatment
(40mins), the average time for saline mice to recover from anesthesia after 7 days and
14 days of heating was 1.4±0.23mins and 1.1±0.04mins respectively. The average time
for IGF1-injected mice to recover from anesthesia was 2.6±0.50mins and 2.7±0.40mins,
which was significantly longer than the saline controls after both 7 days (F(1,11)=33.2,
p<0.001) and 14 days (F(1,11)=101.9, p<0.001) of unilateral heating.
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Table 15. Comparison of Mass Between Heat-Treatment Groups at the Start of
Treatment and at Skeletal Maturity
Length of Heat-Treatment

Injection

Mass at Start (g)
3-weeks old

Mass at End (g)
12-weeks old

Change in Mass (g)

N

None

8.6 (0.8)

22.7 (1.0)

14.0 (0.9)

5

Saline

9.3 (0.4)

23.6 (1.1)

14.3 (1.2)

6

IGF1

9.2 (0.3)

22.4 (0.8)

13.2 (1.0)

6

Saline

10.1 (0.7)

22.2 (0.9)

12.2 (1.3)

6

IGF1

10.0 (0.4)

23.1 (0.9)

13.1 (0.9)

6

None

7 days

14 days

Values are mean (standard deviation). Sample size (N) is number of mice weighed.
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Figure 29. Mass did not Differ Between Non-Treated Controls, Heat-Treated Saline
Control Mice, and Heat-Treated IGF1-Injected Mice at Either Duration of Limb
Heating
(A) Error bar plots comparing starting (open circles) (at 3 weeks of age) and ending
mass (gray circles) (at 12 weeks of age) of starting and ending mass from mice
separated for 7 days
of heating. (B)
Comparison IGF1
of starting and ending mass from mice
NONE
SALINE
separated for 14 days
of heating. Mean
(N=5)
(N=6) ± 1 standard
(N=6) error plotted.
Injection
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6.3.2 Length of Long Bones Following 7 days of Heating
In non-treated control mice (N=7) humeral (paired t=1.5, ns, p=0.19), femoral
(paired t=0.2, ns, p=0.84) and tibial length (paired t=0.95, ns, p=0.41) did not differ
between left-right non-heated sides at skeletal maturity when mice were 12 weeks old
(Fig. 30). Following 7 days of limb heating, there was no difference in humeral length at
skeletal maturity in saline (paired t=0.21, ns, p=0.84) and IGF1-injected mice (paired
t=0.42, ns, p=0.69) (Table 16). Femoral length was increased by 0.5% (paired t=2.1, ns,
p=0.09) and 1.0% (paired t=5.8, p<0.01) on the heat-treated sides of saline and IGF1injected mice respectively (Fig. 30A(a), Table 16). Tibial length was increased by 0.5%
(paired t=3.7, p<0.05) and 0.4% (paired t=2.5, ns, p=0.06) on the heat-treated sides of
saline and IGF1-injected mice respectively (Fig. 30A(b), Table 16). No significant
differences in humeral (p=0.91), femoral (p=0.16) and tibial length (p=0.96) were
determined between saline controls and IGF1-injected mice.
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Table 16. Comparison of Non-Treated and Heat-Treated Sides of Experimental
Mice Bone Parameters Following 7 Days of Limb Heating.
Parameter

Injection

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

11.89 (0.16)

11.89 (0.17)ns

0.0

6

IGF1

11.84 (0.16)

11.82 (0.12)ns

-0.1ns

6

Saline

15.46 (0.30)

15.53 (0.25)ns

0.5

6

IGF1

15.21 (0.18)

15.36 (0.18)**

1.0ns

6

Saline

17.55 (0.37)

17.63(0.33)*

0.5

5

IGF1

17.38 (0.20)

17.45 (0.17)ns

0.4ns

6

Humeral Length (mm)

Femoral Length (mm)

Tibial Length (mm)

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01;
ns, non-significant. Significant differences in percent increase between saline controls
and IGF1-injected mice by one-way ANOVA: ns, non-significant.
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Figure 30. Extremities Remained Longer on the Heat-Treated Sides at Skeletal
Maturity when Limb Heating was Coupled with IGF1 Administration
(A) Error bar plots show percent change in heat-treated limb compared to non-treated
limb compare in saline and IGF1-injected mice treated for 7 days. (a) Femoral length
was 0.5% and 1.0% longer on the heat-treated sides of saline and IGF1-injected mice
(b) Tibial length was 0.5% and 0.4% longer on the heat-treated sides of saline and
IGF1-injected mice. (B) Error bar plots compare % increase in bone length in saline and
IGF1-injected mice treated for 14 days. (a) Femoral length was 0.6% and 1.0% longer
on the heat-treated sides of saline and IGF1-injected mice (b) Tibial length was 0.1%
and 0.8% longer on heat-treated sides of saline and IGF1-injected mice. Mean ± 1
standard error plotted. *p< 0.05; **p<0.01; ***p<0.001, significance in left-right
comparisons; #p<0.05 comparing % change in IGF1-injected mice with saline controls.
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6.3.3 Length of Long Bones Following 14 Days of Heating
Following 14 days of limb heating, there was no difference in humeral length at
skeletal maturity in saline (paired t=0.95, ns, p=0.39) and IGF1-injected mice (paired
t=0.06, ns, p=0.95) (Table 17). Femoral length was increased by 0.6% (paired t=2.3, ns,
p=0.07) and 1.0% (paired t=6.7, p<0.001) on the heat-treated sides of saline and IGF1injected mice respectively (Fig. 30B(a), Table 17). The increase in femoral length on
heat-treated sides was comparable (F(1,11)=2.0, ns, p=0.19) between saline and IGF1injected mice. Tibial length increased by 0.1% (paired t=0.74, ns, p=0.49) and 0.8%
(paired t=7.3, p<0.001) on the heat-treated sides of saline and IGF1-injected mice
respectively (Fig. 30B(b), Table 17). No significant differences in humeral (p=0.89) and
femoral (p=0.28) lengths were determined between saline and IGF1-injected mice, but
the increase in tibial length on heat-treated sides of IGF1-injected mice was greater
than saline (p<0.01). Overall, results demonstrate that a degree of heat-enhanced bone
length is maintained into skeletal maturity when limb heating is coupled with
administration of IGF1 and particularly following 14 days of unilateral heat-treatment.
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Table 17. Comparison of Non-Treated and Heat-Treated Sides of Experimental
Mice Bone Parameters Following 14 days of Limb Heating.
Parameter

Injection

Non-Treated
(30C)

Heat-Treated
(40C)

Percent
Increase

N

Saline

11.73 (0.15)

11.74 (0.13)ns

0.1

6

IGF1

11.90 (0.20)

11.90 (0.16)ns

0.0ns

6

Saline

15.30 (0.08)

15.39 (0.15)ns

0.6

6

IGF1

15.41 (0.14)

15.56 (0.14)***

1.0ns

6

Saline

17.42 (0.17)

17.44 (0.18)ns

0.1

6

IGF1

17.49 (0.33)

17.63 (0.32)***

0.8#

6

Humeral Length (mm)

Femoral Length (mm)

Tibial Length (mm)

Values are mean (standard deviation). Sample size (N) is number of left-right pairs.
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01;
***p<0.001; ns, non-significant. Significant differences in percent increase between
saline controls and IGF1-injected mice by one-way ANOVA: #p<0.05; ns, nonsignificant.
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6.4 DISCUSSION
In this study, differences in long bone length were examined in skeletally mature
mice (12 weeks of age) to determine if the resulting heat-enhanced limb lengthening in
young mice (3-4 and 3-5 weeks of age) reported in previous chapters is sustained until
adulthood. IGF1 therapy has been shown to effectively increase skeletal growth and
when administered in conjunction with 14 days of unilateral heating augments heatenhanced limb elongation (Chapter 4). Therefore, this study examined the long-term
impact of IGF1 administration in conjunction with limb heating.
As reported in Chapter 4, immediately following treatment end points, femoral
lengths of saline mice treated for 7 days and 14 days were 1.7% and 1.1% longer on
heat-treated sides respectively. Femoral length of IGF1-injected mice treated for 7 days
and 14 days was 1.7% and 1.9% longer on heat-treated sides respectively. This study
reports significant increases in femoral length of IGF1-injected mice after 7 days (1.0%)
and 14 days (1.0%) of treatment, but less than significant increases in femoral length on
heat-treated sides of saline mice after 7 days (0.5%) and 14 days (0.6%) of treatment
(Fig. 30A(a), B(a); Tables 16, 17). Femoral length compared between sides of nontreated mice was equivalent. Data supported the hypothesis that differential limb length
was maintained throughout skeletal development after treatments have ended, and
more so when heating was coupled with IGF1 administration.
These results are not analogous to those reported by Serrat et al. (2015) in
another study comparing persistent left-right increases in femoral length at skeletal
maturity following 14 days of treatment. Serrat et al. (2015) reported a significant 1.0%
increase in femoral length in non-injected 12-week-old mice treated for 14 days.
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Discrepancy between studies may be explained by variations in methodology. It can be
speculated whether or not an augmented limb length differential at skeletal maturity
would have also been seen if that study were done in conjunction with IGF1
administration. It was also reported by Serrat et al. (2015) that femoral length was 1.3%
longer on heat-treated sides of mice treated for 14 days. Importantly, both studies show
that despite the significant increase in femoral length maintained into adulthood, length
differential was not sustained by the same extent at skeletal maturity as immediately
following treatment. The diminished differential in limb length at skeletal maturity may be
explained by similar mechanisms to those regulating the phenomenon of “catch-up”
growth. Typically, catch-up growth is explained as recovery in linear growth from
growth-inhibiting conditions (Lui et al., 2011; Reich et al., 2008). During catch-up
growth, growth plates increase activity. Further investigation would be needed to
determine if the heat-enhanced linear growth accelerates the onset of growth plate
senescence and the non-treated side thus partially “catches-up” to the heat-treated
side.
Since the growth plate at skeletal maturity no longer contributes to longitudinal
growth, tibial growth plates were not collected for growth rate and histological analysis
as in previous studies described thus far. Therefore, the tibia served as an additional
long bone for comparison of length. Tibial length was 0.5% and 0.1% on the heattreated sides of saline control mice after 7 days and 14 days of heating respectively
(Fig. 30A(b), B(b); Tables 16, 17). The IGF1-injected mice had an increase of 0.4% and
0.8% in tibial length on the heat-treated sides following 7 days and 14 days of heating
respectively. Based on tibial length, the IGF1-injected mice maintained a more
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substantial differential in length compared to saline controls, but only with 14 days of
heating. Similar to what was observed in femoral length, the non-treated control leftright tibial length was nearly equivalent. One limitation in this study is the possible
discrepancy in tibiae measurements from inconsistent disarticulation and cleaning of
bones from mice after the 7-day heat-treatment. Multiple personnel were responsible for
the process of obtaining clean tibiae for measurement and collecting whole tibiae for
long bone measurements was not as practiced and concise as those done for femora
and humeri. However, the same individual consistently collected all tibiae from the 14day experiments.

6.5 CONCLUSION
In conclusion, heat-enhanced limb length is maintained throughout skeletal
development after treatments have ended, and more so when heating was coupled with
IGF1 administration. Since other studies have shown that heat-alone can maintain limb
length differential, repeated studies are recommended to increase sample size and gain
a better understanding of the potential of limb length differences to be maintained into
adulthood. Nevertheless, in this study, IGF1 has a role in permanently sustaining heatenhanced bone growth. Future studies will investigate if heat-treatment elicits
permanent changes to the growth plate allowing for maintenance of the limb length
differential, such as permanent increases in vascular supply. It is important to determine
the full potential of unilateral heat-treatment in maintaining limb length differential in
order to translate these methods to treatment in children with bone growth disorders
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with the prospective of producing permanent changes to be upheld throughout
adolescence.
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CHAPTER VII: THERMAL IMAGING REVEALS TEMPERATURE RETENTION IN
HINDLIMBS OF MICE AFTER TARGETED INTERMITTENT LIMB HEATING

7.1 INTRODUCTION
The relationship between the vascular system (blood and vessels) and the
epiphyseal growth plate is a complicated one. While bone is a highly vascularized
tissue, growth plate cartilage is avascular and requires indirect vascular routes to supply
nutrients and hormones that are essential for longitudinal bone growth (Brodin, 1955;
Maes, 2013; Trueta, 1968). Temperature regulates vasculature (Serrat, 2014b). Heat
increases blood flow in the limbs (Barcroft & Edholm, 1943; Chiesa, Trangmar, &
González-Alonso, 2016) and exposure to warm temperature has also been shown to
increase transport into the growth plate (Serrat et al., 2009, 2010, 2014a). Therefore, it
is plausible that the heat-enhanced linear bone growth is enabled by changes in
vasculature.
Infrared thermal imaging is a technique that has been used to measure surface
limb temperature in both clinical and veterinary applications (Inagaki, Ohno, Histome,
Tanaka, & Takeshita, 1992; Jones, 1998; Soerensen & Pedersen, 2015; Turner, 2001)
as well as in experimental settings (Dezechache, Wilke, Richi, Neumann, &
Zuberbϋhler, 2017; McGreevy, Warren-Smith, Guisard, 2012; Tattersall & Milson, 2003;
Tattersall, 2016). Tattersall and Milson (2003) captured infrared thermal images of
golden-mantled ground squirrels to demonstrate a shift in blood flow to the periphery
associated with cooling in hypoxic conditions. The advantage to using thermal imaging
is methodology entails minimal stress to unanesthetized animals as a non-contact
approach of acquiring skin temperature. Studies have shown that blood flow positively
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correlates with skin temperature (Carter et al., 2014; Senay, Prokop, Cronau, &
Hertzman, 1963; Song, Chelstrom, Levitt, Haumschild, 1989; Turner, 2001). Therefore,
thermal imaging can be used to measure heat retention at the surface of the limb as an
indicator of the extent of increased blood flow. If targeted limb heating results in an
increase in blood flow as expected, it is hypothesized that skin temperature of heattreated limbs will remain elevated for an extended time following treatment.

7.2 MATERIAL AND METHODS
7.2.1 Infrared Thermal Imaging
As an extensive pilot study (IACUC approved) to determine the period of time in
which limb temperature remains elevated on the heat-treated side after each daily
regimen, female C57BL/6 (N=12) mice were obtained (Fig. 31). Experimental mice were
treated with daily unilateral heat (40°C) under the same procedural conditions as
described in previous chapters. Mice were treated for 7 days from 3-4 weeks of age
(N=6) and 14 days from 3-5 weeks of age (N=6). No injections were administered.
Infrared thermal images were captured at 320 X 240 resolution using a FLIR E8 infrared
camera (sensitivity <0.06C in temperature range of -20 to 250°C). Images were
captured 1 hour prior to limb heating and then 1, 4 and 8 hours post-heating. Imaging
times were chosen based on a pilot study conducted prior to experiments that
determined the optimal imaging settings. During the 7-day and 14-day heating regimen,
5 separate days (over a total of 14 days of treatment) were chosen for imaging.
Temperatures recorded over the 5 days (N=6 mice per day) were pooled at each time
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point (N=5 recordings per time point) for a total of N=30 temperature recordings per
time point.
When each mouse was removed from the cage for imaging, the sleeping position
was noted (if possible) to account for any positioning impact on surface temperature.
Imaging intervals were chosen to avoid excessive imaging that negatively impacted
daily gain in body mass. Mice were positioned consistently on a 4 inch cylindrical piece
of polyethylene foam mounted to a mouse cage lid on a customized imaging cart. The
camera was placed in a tailor-made stand at a 67.5° angle. Surface temperatures of the
heat-treated (right) and non-treated (left) hindlimbs were obtained from calibrated
images using the FLIR tools 2.1 software. Mean surface temperature was averaged
from three different points along the distal end of each limb approximately above the
tibia.
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30C

40C
3-week-old female mice treated daily
for 7 days or 14 days with 40°C
unilateral heat 40 min/day

Hind limbs imaged using FLIR E8
infrared thermal imaging camera

Start of 12-hour light cycle
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Limb Heating
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Figure 31. Infrared Thermal Imaging Schematic
Mice were treated with 40°C unilateral heat for 40 minutes daily for 7 days from 3-4
weeks of age or 14 days from 3-5 weeks of age. Thermal images of hind limbs were
captured using a FLIR E8 infrared thermal imaging camera (2008 © FLIR® Systems,
Inc) 1 hour prior to, and 1 hour, 4 hours, and 8 hours post-heating. Euthanasia and
tissue collection occurred 1 day after the last day of heat-treatment. Mouse illustration
based on “mouse clip art black and white” from clipartstockphotos.com.
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7.2.2 Statistical Analysis and Sample Size
Statistical analyses were performed using SPSS 25.0 software (IBM Corporation,
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side
comparisons for surface temperatures were done using one-tailed paired t-tests. The
one-way ANOVA with a Tukey post hoc test was used to determine significant
differences between multiple treatment days that infrared thermal images were captured
throughout the duration of limb heating. Data were reported as mean ± standard
deviation (SD) in tabular format and as mean ± standard error (SE) in graphical format.
Sample sizes for measurements that are documented as less than the size of the
experimental sample set were a result of failure to confidently obtain surface
temperatures from thermal images such as when the limbs were properly positioned.

7.3 RESULTS
7.3.1 Temperature Retention in Hindlimbs Post-Heating
Hindlimb surface temperature of female mice (N=6) was assessed using infrared
thermal imaging recorded over 5 days throughout the duration of limb heating. Data
were pooled at each time point (1hr prior to heating, and 1hr, 4hrs and 8hrs postheating) since no significant differences were observed between the multiple treatment
days that infrared thermal images were captured (F(1,29)=0.20, ns, p=0.94). Surface
limb temperature was 31.1±0.2°C on the non-treated side (left) and 30.8±0.2°C on the
intended heat-treated side (right), 1hr prior to treatment (Fig. 32A). The 0.8% difference
in temperature was not significant between contralateral sides (paired t=1.6, ns,
p=0.13). Surface limb temperature was 30.3±0.9°C and 30.4±0.9°C on the non-treated
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and heat-treated sides respectively, 1hr following treatment (Fig. 32A). The 0.4%
difference in limb temperature was not significant between contralateral sides (paired
t=0.7, ns, p=0.51). Surface limb temperature was 31.1±0.7°C and 31.5±0.8°C on the
non-treated and heat-treated sides respectively, 4hrs following treatment (Fig. 32A, B).
The 1.2% increase in limb temperature on the heat-treated side was significantly
warmer than the non-treated side (paired t=2.3, p<0.05). Surface limb temperature was
31.1±0.9°C and 30.9±0.7°C on the non-treated and heat-treated sides respectively, 8hrs
following treatment (Fig. 32A). The 0.4% difference in limb temperature was not
significant between contralateral sides (paired t=0.8, ns, p=0.40). Therefore, limb
temperature remained elevated on the heated side up to 4 hours after treatment.
If apparent at the onset of imaging, the sleeping position of the mouse was noted
to compare if the hindlimb surface temperature reflected the huddled position of the
mouse during sleep. Since mice have been shown to demonstrate a degree of
handedness (Biddle, Coffaro, Ziehr, & Eales, 1993), if they also displayed sleep position
preference (left versus right side sleeping) that may account for the measured limb
temperature differentials. However, while some positions were not obvious, the
positions that were observed did not relate to measured surface limb temperature of
individual mice. Therefore, sleeping position seemed to be independent of hindlimb
temperature.
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Figure 32. Thermal Imaging Shows Hindlimb Surface Temperature Remains
Elevated up to 4 Hours Post-Heating
(A) Error bar plot shows the difference in limb temperature between non-treated and
heat-treated limbs at each time point (N=30, N=6 left-right limb temperatures pooled
over N=5 days of heating). The heat-treated side was -0.8%, 0.4%, 1.2% and -0.4%
warmer than the contralateral non-treated sides. (B) Captured infrared thermal images 4
hours post-heating of non-treated (left) and heat-treated (right) hindlimbs. Image
analyzed in FLIR tools using the iron color pallet to distinguish thermal profiles between
23°C and 36°C. Warmer temperatures as seen by the lighter color profile, are observed
on the heat-treated side.
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7.4 DISCUSSION
Warm temperature increases blood flow in limbs (Barcroft & Edholm, 1943;
Chiesa et al., 2016) and measured skin temperature is positively correlated to blood
flow (Carter et al., 2014; Senay et al., 1963; Song et al., 1989; Turner, 2001). Thermal
imaging data revealed that temperature remained elevated (1.2% increase) on the
heated side up to 4 hours post-heating. Therefore, data support the hypothesis that skin
temperature of heat-treated limbs will remain elevated for an extended time following
treatment. Results indicate that targeted limb heating caused an increase of blood flow
in the limbs that is sustained up to 4 hrs after treatment ends. It is possible that this
retention in limb temperature is due to a heat-enhanced increase in blood flow that
facilitates bone lengthening.
Temperatures were nearly equivalent (0.4% difference) 1 hr following treatment
suggesting a systemic post-anesthesia thermoregulatory response. By 8 hrs postheating, limb temperatures were again similar (0.4% difference) reflecting increased
activity as mice approached the dark cycle. Another possible explanation for these
results are exemplified in a study by Song et al. (1989) measuring blood flow in heated
human forearms (40°C for 60 mins). They found that blood flow momentarily declined
before increasing for several minutes and then rapidly declining corresponding with
changes in volume and speed of red blood cells (Song et al., 1989). Comparable, this
study demonstrated a similar trend in changes in skin temperature but over a period of
hours instead of minutes. This time differential may be due to whole limb warming
versus only a localized portion of the limb, as well as a much smaller animal (mouse)
compared to humans.
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One important question at the start of this pilot study was whether or not heat
retention was additive with consecutive days of heat-treatment. After collection of
temperatures at various time points during different treatment days, no differences were
seen in the mean hindlimb temperature at each time point. While hindlimb surface
temperature remained elevated up to 4 hours after treatment, it was independent on the
day of heating. Comparable temperatures recorded between the days of treatment
indicated that temperature retention does not increase with additional days of heating,
and heat-enhanced temperature effects occur within the first 4 hours post-heating.
Results in this study suggest heat-enhanced linear growth is enabled by changes
in vasculature since blood flow positively correlates with skin temperature (Carter et al.,
2014; Senay et al., 1963; Song et al., 1989; Turner, 2001). However, the means by
which heat-induced changes in vasculature occur remain unknown. In addition to the
transport and delivery of essential nutrients and hormones, the vascular system also
has a role in the delivery of heat (Scholander, 1955; Serrat et al., 2008; Serrat, 2014b).
Therefore, vasculature has the potential to facilitate limb growth through the delivery of
warm blood to the growth plate and module temperature-sensitive genes and pathways.
During endochondral ossification, hypertrophic chondrocytes secrete angiogenic
factors that initiate vascular invasion and recruitment of bone absorbing and forming
cells that replace mineralized cartilage with bone (van der Eerden et al., 2003;
Filipowska et al., 2017; Gerber et al., 1999b; Horner et al., 1999; Hunziker, 1994b;
Maes et al., 2004; Zelzer & Olsen, 2005). The key regulator involved in this process of
endochondral ossification is vascular endothelial growth factor (VEGF) (Emons et al.,
2010; Gerber et al., 1999b). Other factors expressed in the growth plate, such as IGF1
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(Ahmed & Farquharson, 2010; Álvarez-García et al., 2010), have also been shown to
stimulate VEGF and induce vascular invasion.
One method for assessing heat-induced changes in vasculature at the site of the
growth plate is to study expression of angiogenic factors (VEGF and CD31) in
hypertrophic chondrocytes with heat-treatment. A preliminary study collected (nonquantitated) images of the proximal tibial growth plate from mice treated for 7 days from
3-4 weeks of age dual stained with fluorescent antibodies against VEGF (magenta) and
CD31 (yellow) (Fig. 31). Expression of angiogenic markers (CD31 and VEGF) appeared
to increase in the hypertrophic zone on heat-treated sides. However, a method for
standardizing and quantifying these images is necessary to determine significance.
Another methodology for studying vascular changes at the growth plate is by
multiphoton microscopy (MPM). MPM is a novel method of in vivo live animal imaging
(Zipfel et al., 2003) and can be used to fluorescently label and track transport of small
molecules into the growth plate (Serrat & Ion, 2017). Serrat et al. (2009, 2010, 2014a)
have already shown that temperature increases solute uptake into the growth plate. By
fluorescently labeling specific regulators or linear growth (such as IGF1 and VEGF), this
method could be used in future studies to determine if targeted limb heating increases
vascular transport of these molecules to the growth plate to promote heat-enhanced
limb elongation. Although vasculature stands out as a key player in facilitating the heatenhanced limb growth response, it is also possible that heat may modulate
temperature-sensitive genes and pathways through more direct mechanisms as an
alternate to, or in addition to, vascular transport.
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Figure 33. Expression of VEGF and CD31 Appeared to Increase in the Growth
Plate on the Heat-Treated Sides
Left-right comparison of proximal tibial growth plate from mice treated for 7 days from 34 weeks of age. A greater trend in positive immunofluorescent staining for VEGF
(magenta) and CD31 (yellow) was observed on the heat-treated sides. Sections were
stained using immunohistochemistry methods and primary antibodies were detected by
double immunofluorescence (IF). Mouse monoclonal antibody against VEGF (1:50,
ThermoFisher Scientific, MA1-16629) and rabbit polyclonal antibody against CD31(1:50,
abcam, ab28364) were detected by the VectaFluor Duet double labeling kit (Vector
Laboratories, DK-8818) using Dylight® 488 anti-rabbit IgG and Dylight® 594 anti-mouse
IgG. Since using a mouse primary antibody on mouse tissue, the Vector M.O.M. kit
(Vector Laboratories, MP-2400) was used to eliminate high background staining.
Imaged using the Leica DM2500 optical microscope and filters blue (DAPI), green
(CD31) and red (VEGF) to detect fluorescence. Exposure was adjusted uniformly for
both CD31 and VEGF, but DAPI was taken at a lower exposure (a great deal brighter in
comparison). The same section of sample was taken at 20X for each filter for
consistency when images were merged in ImageJ.
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7.5 CONCLUSION
While results from this extensive preliminary study support our hypothesis that
skin temperature of heat-treated limbs will remain elevated for an extended time
following treatment, future studies are necessary to further validate the connection
between increased blood flow and linear growth. These studies will be important for
determining if the duration of elevated skin temperature is associated with an increased
blood supply to the growth plate. The results from this chapter preface future studies
into possible mechanisms of the targeted heating-model, as it suggests a heat-induced
increase in blood flow that accelerates bone lengthening.
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CHAPTER VIII: CONCLUDING REMARKS AND FUTURE DIRECTIONS

Bone elongation disorders, whether congenital or acquired in origin, can lead to
painful musculoskeletal disabilities in adulthood (Gurney, 2002). Intervention is
recommended for children during critical stages of postnatal longitudinal bone growth.
Existing treatment options to correct left-right asymmetry in limb length involve invasive
surgery and/or drug regimens, which are often only partially effective (Gurney, 2002;
Hasler & Krieg, 2012; Niedzielski et al., 2016; Pendleton et al., 2013; Sabharwal et al.,
2015; Stevens, 2016). Therefore, it is important to find alternative, less invasive
treatment options for bone lengthening. Previous studies in weanling mice
demonstrated that after 14 days of targeted limb heating (40°C) on one side of the body,
femoral length (1.3%) and tibial elongation rate (>12%) increased on heat-treated sides
(Serrat et al., 2015). The goal of this dissertation was to build upon an established
method using targeted limb heating as a potential non-invasive alternative to enhance
bone lengthening.
The epiphyseal growth plate is the main site of longitudinal growth and the main
regulator of local cartilage growth is IGF1. Therefore, investigation focused on the
effects of temperature on chondrocyte morphology and IGF1 action in the growth plate.
It was hypothesized that exposure to warm temperature augments the actions of
IGF1 in the growth plate and permanently increases length of the extremities. The
central aims of the study were 1) determine if IGF1 enhances bone elongation in heattreated extremities and 2) determine potential vasculature modifications and long-term
extent of left-right limb length asymmetries resulting from unilateral heat-treatment.
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The application of the model for targeted limb heating (unilateral heating model)
and its functional impact is described in Chapter 2. X-ray and weight bearing data
indicated that even small discrepancies in limb length (nearly 1%) have a functional
impact on hindlimb weight distribution (nearly 20%) in young mice. These findings set
the foundation for following experiments using the unilateral heating model as a means
to test the overall hypothesis. The impact of heat-treatment on the cellular level of the
growth plate had previously been unexplored. Others have determined that the main
contributing factors to longitudinal growth include the rate of chondrocyte proliferation
and hypertrophy (Cooper et al., 2013; Farnum, 2007, Hunziker et al., 1987; Hunziker &
Schenk, 1989; Hunziker, 1994b; Kember, 1993; Rolian, 2008; Walker & Kember, 1972;
Wilsman et al., 1996a,b, 2008). It was expected that targeted limb heating would be
accompanied by an increase in bone elongation, chondrocyte proliferation (assessed by
PNCA expression in proliferative zone), hypertrophic zone height, and expression of
IGF1 signaling (IGF1R, pIGF1R, pAkt) in growth plate chondrocytes. Mice treated for 7
days from 3-4 weeks of age (determined in Chapter 2 and 3 to be an efficient age range
for heat-induced bone elongation), femoral length (1.7%), tibial elongation rate (7.7%),
hypertrophic zone height (8.6%) and chondrocyte proliferation (8.6%) increased on
heat-treated sides of saline-injected controls (Chapter 3). There was also an increase in
IGF1R (14.5%) and pIGF1R (7.7%) expression in the proliferative zone demonstrating
heat-enhanced IGF1 activity in the growth plate (Chapter 5). Left-right limb length
asymmetry, along with enhanced growth plate kinetics was also observed in mice
administered a low dose of IGF1 (2.5 mg/kg, once daily) in conjunction with targeted
limb heating. However, advanced bone elongation compared to heat alone (saline-
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injected controls) was only observed when IGF1 was administered with 14 days of heattreatment (Chapter 4).
There was no heat-induced increase in the parameters assessing linear bone
growth when IGF1 activity was blocked in JB1 injected mice and levels were low in
GHR-/- mice (Chapter 5). The overall gain in mass, one physiological outcome
subjective to changes in IGF1, did not differ between groups suggesting targeted limb
heating affects local regulation of IGF1 in growth plate chondrocytes. Future studies
may re-examine the potential differences between male and female mice that may be
observed with heat-enhanced IGF1 activity in the growth plate. While previous studies
showed no differences in heat-enhanced bone elongation between sexes (Serrat et al.,
2015) these mice were not administered IGF1.
In the preliminary investigation of heat-induced changes in vascular supply, skin
temperature was measured by infrared thermal imaging. Limb surface temperatures
were recorded prior to, and at various times following, unilateral heat-treatment. It was
concluded that limb surface temperature remained elevated (1.2%) on the heat-treated
sides up to 4 hrs post treatment (Chapter 7) but this heat-retention was not
accumulative after consecutive days of heating. These results suggest that the retention
in skin temperature may be due to an increase in blood flow that normalizes after 4
hours of heat-treatment. To verify if there is a true correlation between the observed
retention in limb temperature and increased blood flow, experiments to quantify blood
flow (such as the Doppler method) would need to be conducted in conjunction with
thermal imaging. In vivo multiphoton microcopy would also be useful to quantify if
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increased blood flow correlates to increased delivery of growth enhancing molecules to
the growth plate.
An additional study to determine heat-enhanced changes to vascular supply
observed angiogenic factors (VEGF and CD31) in hypertrophic chondrocytes by
immunohistochemistry (IHC) analysis. Images seem to indicate an increase in VEGF
and CD31 expression in hypertrophic chondrocytes signifying a heat-induced increase
in angiogenesis in the growth plate (Chapter 7). Future studies will be necessary to
quantify expression levels and to determine if increased expression of angiogenic
markers is a result of heat-induced increases in transport of signaling molecules, or a
result of temperature-sensitive genes and pathways (either directly or by indirect
delivery of warm-blood through the vasculature).
Long-term effects of heat-treatment were also assessed by the heat-induced leftright asymmetries in limb length sustained at skeletal maturity (12 weeks of age)
(Chapter 6). Femoral length was increased on heat-treated sides of saline (0.5%) and
IGF1-injected (1.0%) after 7 days of unilateral heat-treatment. Heat-treated femora were
also increased in saline (0.6%) and IGF-injected (1.0%) mice after 14 days of heating.
While femoral length differential was observed at skeletal maturity at both durations of
treatment, these differences were only statistically significant in mice administered IGF1
during heat-treatment. Tibial length increase on heat-treated sides (0.8%) was also
maintained in IGF1-injected mice at the 12 week of age endpoint, but only following 14
days of treatment. Further studies will need to be done to understand how IGF1
administration in conjunction with heating elicits a more permanent limb lengthening
effect compared to saline control mice. Next steps of this study will also be to collect x-
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ray images and weight bearing data (as described in Chapter 2) at skeletal maturity to
provide translation relevance.
The purpose of this study was to build upon the established method using
targeted limb heating. The findings reviewed in the chapters of this dissertation have
achieved this by determining that heat-enhanced growth is dependent on IGF1 and its
local regulation of growing cartilage, which may involve changes to vasculature supply.
While aware that other factors play a role in regulating longitudinal bone growth, IGF1
was the focus of these studies since it has been shown to be essential for normal linear
growth. Throughout this dissertation the role of IGF1, GH and VEGF have been
described in detail to regulate longitudinal bone growth in the growth plate (Fig. 34).
Both endocrine (GH and IGF1) and autocrine/paracrine (IGF1 and VEGF) actions of
these factors have shown to be important in regulating linear growth. However future
studies will be needed to determine how heat-treatment affects GH and VEGF, as well
as other factors that regulate chondrocytes of the growth plate, including the Ihh/PThrP
feedback loop (not demonstrated in Fig. 34).
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Figure 34. Diagram Summarizes the Action of Important Factors in the Different
Zones of the Growth Plate
(A) Demonstrates regions of the growth plate in which growth hormone receptor (GHR),
insulin-like growth factor 1 receptor (IGF1R), IGF1 and VEGF are expressed. (B)
Indicates the effects of GH, IGF1 and VEGF on growth plate chondrocytes. Illustration
focuses on main factors discussed in this dissertation and excludes other endocrine and
autocrine/paracrine factors that also regulate the growth plate. Illustration based on
Mackie et al. (2008).
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Filling gaps in these studies mentioned above would be beneficial for expanding
upon the unilateral limb-heating model in the mouse. However, further studies using a
larger animal model will be fundamental to advancing toward the ultimate goal of
translating these methods clinically to humans in the hopes to develop an alternative,
non-invasive treatment to enhance linear growth in children with bone lengthening
disorders. The next step would be to use the targeted limb heating approach using
larger animal models to work towards answering questions such as: how does 40°C
heat-treatment translate into a larger animal? Is 40-minutes long enough to warm the
entire limb and elicit lengthening effects (considering the threshold of heat-tolerance in
larger animals)? What is the optimal period of postnatal growth in larger animals for
heat-treatment (such as the comparable toddler to elementary school age in humans)?
What device can be used to administer localized heat (such as a heating cuff)? This
device would help control for uniform heating as an alternative to warming the entire
side of the body done in mice. Continuing these studies using the targeted heating
model may lead to new approaches to increase bone lengthening in children with linear
growth disorders that would otherwise cause painful, chronic musculoskeletal conditions
in adulthood. Summaries of the concluding remarks (Table 18) and future directions
(Table 19), for this dissertation are found on the following pages.
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Table 18. Summary of Concluding Remarks.

182

Table 19. Summary of Future Directions.
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APPENDIX B: LIST OF ABBREVIATIONS
ABC…avidin-biotin complex
ALS…acid labile subunit
BMP…bone morphogenic protein
BrdU…bromodeoxyuridine
CD31…cluster of differentiation 31
DAPI…4’,6-diamidino-2-phenylindole
EDTA…ethylenediaminetetraacetic acid
ERK…extracellular receptor kinase
FGF…fibroblast growth factor
GH…growth hormone
GHR-/-…growth hormone receptor knockout
GnRH…gonadotropin releasing hormone
GP…growth plate
H2O2…hydrogen peroxide
HSP…heat-shock protein
HZ…hypertrophic zone of growth plate cartilage
IF…immunofluorescence
IGF1…insulin-like growth factor 1
IGF1R…insulin-like growth factor 1 receptor
IGF2…insulin-like growth factor 2
IGFBP…insulin-like growth factor binding protein
IHC…immunohistochemistry
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Ihh…Indian hedgehog
LID…liver IGF1-deficient
LLD…limb length discrepancy
MAPK… mitogen-activated protein kinase
MPM…multiphoton microscopy
OTC…oxytetracycline
pAkt…phosphorylated Akt
PBS…phosphate buffered solution
PCNA…proliferating cell nuclear antigen
PECAM1 (CD31)…platelet endothelial cell adhesion molecule
PI-3…phosphatidylinositol-3
PI3K…phosphoinositide 3-kinase
pIGF1R…phosphorylated insulin-like growth factor 1 receptor
PTHrP…parathyroid hormone-related protein
PZ…proliferative zone of growth plate cartilage
RZ…reserve zone of growth plate cartilage
SD…standard deviation
SE…standard error
SQ…subcutaneous
T3…triiodothyronine
TKI…tyrosine kinase inhibitors
TRα1…thyroid hormone receptor alpha 1
TRβ…thyroid hormone receptor beta
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VEGF…vascular endothelial growth factor
WISP3…Wnt induced secreted protein 3
Wnt…wingless/integrated
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